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The bicyclic 4-nitroimidazoles PA-824 and OPC-67683 that are currently in Phase II clinical 
development represent a promising novel class of therapeutics for Tuberculosis (TB) 
(Mukherjee and Boshoff, 2011). Both compounds are pro-drugs that are reductively activated 
within Mycobacterium tuberculosis (Mtb), the causative organism of TB. PA-824 as a 
potential anti-TB agent has many attractive characteristics - most notably its novel 
mechanism of action, activity against aerobic replicating and hypoxic non-replicating 
mycobacterium, activity in vitro against drug-resistant clinical isolates, and activity as both a 
potent bactericidal and a sterilizing agent in mice.  While PA-824 was optimized for its 
aerobic cellular activity, its anaerobic activity correlated with the amount of nitric oxide (NO) 
generated when the pro-drug was reduced by an Mtb deazaflavin cofactor (F420) dependent 
nitroreductase (Ddn) (Singh et al., 2008). The physiological role of both F420 and the 
activating enzyme Ddn in Mtb is unknown. This thesis delves into two areas that are in line 
with the Novartis Institute of Tropical Diseases’ initiatives in developing drugs against latent 
TB and in unravelling novel Mtb ‘targets’ for discovery of therapeutics against drug resistant 
Mtb.   
(i) Biochemical and structural characterization of Ddn enzyme, to understand substrate / 
cofactor specificity of the enzyme and to support a programme that focused on rational 
optimization of bicyclic nitroimidazoles  
(ii) Evaluation of the physiological role of cofactor F420 and Ddn in Mtb pathogenesis as 




In order to further enhance current understanding of the mechanism of action of PA-824, Ddn 
activity was evaluated with PA-824 and a selected collection of chemically distinct 
nitroimidazole analogs substrates by investigating reoxidation of F420H2, production of NO 
and by determining binding constants of the analogs to the protein. A direct 
chemiluminescence-based NO detection assay to measure the kinetics of NO production by 
Ddn was developed. Binding affinity of PA-824 to Ddn was monitored through intrinsic 
fluorescence quenching of the protein facilitating an enzymatic turnover-independent 
assessment of affinity. The results from this research work suggest that the tail portion of the 
nitroimidazole determines the binding orientation of the head group, conferring 
stereospecificity in orientation of the molecule towards reduction (Cellitti et al., 
2012;Gurumurthy et al., 2012). The results presented elucidate structural features important 
for understanding substrate binding providing insight into the activation of bicyclic 4-
nitroimidazoles that could facilitate optimization of this class of compounds toward more 
efficient killing for improved TB treatment. 
F420 is a low redox potential (-360 mV), soluble 7, 8-didemethyl-8-hydroxy-5-deazariboflavin 
that is characteristic of methanogenic bacteria where it is involved in anaerobic respiration 
and energy metabolism. Several mycobacterial species, including M. leprae whose genome 
has undergone reductive evolution, retain both F420 biosynthetic machinery and an F420 
dependent glucose 6-phosphate dehydrogenase (G6PD), FGD1. FGD1 catalyses the 
oxidation of glucose 6-phosphate to phosphogluconolactone and in turn reduces F420 to 
F420H2. Several prior studies in M. smegmatis have suggested a role for FGD1/F420 in 
combating nitrosative and oxidative stress. In order to understand and further explore the role 
of F420 in Mtb, an F420 deficient MtbΔfbiC mutant was generated and characterized. The F420 
deficient mutant was hypersensitive to oxidative as well as nitrosative stress. Furthermore, 
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the quinone reductase activity of the F420H2 dependent reductase Ddn was identified. Here, a 
novel F420 dependent anti-oxidant mechanism that protects Mtb against oxidative stress and 
bactericidal agents has been established (Manuscript submitted to PLOS Pathogens). The 
findings of this thesis enhance current understanding of the complex mechanisms by which 
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1 Tuberculosis and Thesis: An Introduction 
 
1.1 Tuberculosis: The Global Burden  
In 2010, the number of people who fell ill with Tuberculosis (TB) dropped to 8.8 million (9.4 
million in 2009) with the global incidence rate falling to 128 cases per 100,000 population (139 in 
2009). The number of deaths due to TB fell to 1.4 million in 2010 (1.7 million in 2009) and this 
includes 350,000 people with the human immuno-deficiency virus (HIV). The overall TB death 
rate has fallen by 40% since 1990 with a constant decline in the number of deaths even (WHO, 
2011a). Despite the falling numbers, TB, an infectious disease, remains a global threat. Its 
etiologic agent, Mycobacterium tuberculosis (Mtb), is estimated to have infected almost a third of 
the world’s human population (WHO, 2011a). The World Health Organization (WHO) estimates 
that the largest number of new TB cases in 2008 occurred in the South-East Asia Region, which 
accounted for 35% of incident cases globally. However, the estimated incidence rate in sub-
Saharan Africa is nearly twice that of this region (~340 cases per 100 000 population) (Figure 
1.1A). Eighty percent of the world TB cases come from the 20-25 high burden countries, with 
more than one third in Indian and China (WHO, 2009a;Dye and Williams, 2010). Among these 
countries, China has made dramatic progress in showing a sustained decline in TB burden 
through domestic investment and various international collaborations on TB. On the other hand, 
case numbers have declined at a steady rate in western and central Europe, North and South 
America and the Middle East (WHO, 2011a). Disproportionate aggregation of cases in poorer 
nations has been a characteristic of TB for the past decade (Figure 1.1A); this indicates not only a 
critical need for efficient health systems of which the TB control programs form a part but also 
treatments and technology that are affordable to disease endemic nations.   
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1.2 TB Drug Development: Challenges Galore  
Despite ten compounds having progressed into clinical development, the global drug pipeline for 
TB is inadequate to address the various inherent and emerging challenges of treatment (Ma and 
Lienhardt, 2009) (Barry, III and Blanchard, 2010). The existing therapy for TB is a multi-drug 
regimen that lasts for six months – its effectiveness being compromised by the length of the 
treatment and therefore emergence of resistance issues due to lack of adherence - short and 
simple regimens that are effective, safe and robust are the need of the hour. Rifampicin (RIF) 
discovered 40 years ago, represents the last novel class of antibiotics introduced for the first-line 
treatment of TB. In the early 1990s, significant clinical resistance to isoniazid (INH) and RIF, the 
two most potent first-line TB drugs, began to emerge (Edlin et al., 1992). TB caused by Mtb that 
is resistant at least to INH and RIF, is referred to as multi-drug resistant TB (MDR TB). While 
MDR TB is becoming increasingly rampant (Figure 1.1B), another form of the disease, the 
extensively drug-resistant (XDR) TB is emerging. Drugs with novel mechanisms of action are 
necessary for the effective management of MDR and XDR TB (Gandhi et al., 2006). Co-infection 
of Mtb and HIV is yet another major roadblock in the control or eradication of TB – HIV 
infection increases the chances of developing TB and hence introduces an additional clause in the 
desirable traits for new anti-tuberculars i.e. drugs that do not interact with protease inhibitor-
based HIV regimens (Corbett et al., 2003). While treatment of active TB is challenging enough, 
Mtb presents another hurdle in the form of latency – i.e. an infection that is asymptomatic. 
Therefore drug development needs to address TB prophylaxis as well as develop combinations 
that eradicate various bacterial subpopulations (Ma and Lienhardt, 2009). In addition to 
developing a compound with all the desirable characteristics mentioned, drug development for 
TB requires novel regimens, improved global clinical trial capacity, better trial designs and most 






Figure 1.1 Epidemiological Maps of the Global Burden of TB 
 (A) Estimated TB incidence rates, 2010 (B) Distribution of proportion of MDR-TB among new TB 





1.3 TB: Matters of the Mycobacterium and its biology 
TB is an infectious disease caused by Mtb with humans being the only hosts for this pathogen. 
TB usually infects the lungs and is spread through the air. The infectious dose of TB is very low 
and inhaling fewer than ten bacteria can result in an infection. Most infections in humans result in 
an asymptomatic, latent manifestation; 5-10% of people who are infected with TB bacilli 
eventually progress to manifest active disease, which, if left untreated, kills more than 50% of 
such infected people. The classic symptoms of TB are chronic cough with blood-tinged sputum, 
fever, night sweats, and weight loss (Gengenbacher and Kaufmann, 2012). 
The genus Mycobacterium is currently known to comprise more than 100 species (Tortoli, 2006); 
only a minority of these are obligate human pathogens that cause diseases such as TB and 
leprosy. M. bovis Bacillus Calmette–Guérin (BCG) (attenuated form of M. bovis) and M. 
smegmatis are nonpathogenic and therefore common surrogates for Mtb in research.  
Mtb is an aerobic, nonmotile bacillus that is weakly gram-positive but can be identified by the 
acid-fast Ziehl-Neelsen staining; it is typically diagnosed by microscopy in the sputum of active 
TB patients. At 37 °C and under optimal availability of oxygen and nutrients, the Mtb bacillus has 
a generation time of 18–24 h and forms colonies on agar within 3–4 weeks. Mtb belongs to the 
actinobacteria family (GC-rich genomes) and is surrounded by an impermeable and thick cell 
wall/capsule that is made of peptidoglycans, polysaccharides, unusual glycolipids, and lipids 
mainly consisting of long-chain fatty acids, such as mycolic acid. Mtb has the capacity to become 
dormant – a non-replicating state characterized by low metabolic activity and phenotypic drug 
resistance – a phenomenon that is characteristic to a specific physiologic state and that is 
independent of genetic mutations.  
 The genome of the Mtb H37Rv strain was published in 1998; its size is about 4 million base pairs 
with approximately 4000 genes. With the development of molecular techniques, the ability to 
construct mutants and test individual gene products for specific functions has significantly 
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contributed to the understanding of the Mtb pathogenesis. The following subsections discussing 
the biology and pathophysiology of Mtb not only present the various challenges that the organism 
poses in the context of drug development but also highlight some of the key processes that can be 
targetted by therapeutics that are designed to combat the pathogen. Significant advancements in 
the understanding of  Mtb biology have resulted in the identification of numerous pathogen 
‘targets’ that are the focus of several drug discovery programmes. The research focus of this 
thesis (to be elaborated in section 1.6 of the Introduction) falls broadly under the umbrella of drug 
discovery against latent TB and the identification of novel Mtb ‘targets’ towards the same. An 
introduction to Mtb pathophysiology proves vital before expanding on the objectives of this 
thesis.  
1.3.1 Mtb Pathogenesis: Infection of alveolar macrophage and survival strategies  
Infection with Mtb is caused by the inhalation of minute aerosol droplets carrying a small number 
of bacteria (Raupach and Kaufmann, 2001). At the primary site of infection, the lung, Mtb bacilli 
are phagocytosed by alveolar macrophages, the primary line of defence against microbes (Nathan 
and Shiloh, 2000) (Deretic et al., 2009) (Liu and Modlin, 2008) and the site to which the entire 
repertoire of host defense is targeted (Rothman and Wieland, 1996). The success of Mtb as 
pathogen is largely dependent on the following aspects: (i) Mtb’s manipulation of host 
macrophages and its metabolic adaptation; (ii) survival strategies adopted to combat and resist 
acidic, nitrosative, oxidative stress within the macrophages (iii) formation of well-organized 
granulomas to create a confined environment in the lung (iv)  Mtb’s capability to shut down its 
central metabolism and enter into a non-replicating persistent state thereby resisting both host 
defense and drug impact (Gengenbacher and Kaufmann, 2012). 
Mtb survives inside macrophages by arresting the maturation of the phagosome, thereby 
restricting acidification and limiting both phagosome- lysosome fusion and the hostility of the 
intracellular environment (Armstrong and Hart, 1975;MacMicking et al., 2003;Russell et al., 
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2009). In the event of maturation of Mtb containing phagosomes into phagolysosomes upon IFNγ 
activation (MacMicking et al., 2003), Mtb has evolved several other mechanisms which to 
combat potential bactericidal chemistries (Rhee et al., 2005;Nathan and Shiloh, 2000). Genome-
wide microarray techniques to study Mtb's transcriptional response to this transition have 
suggested the phagosomal environment to be nitrosative, oxidative, hypoxic and limited in 
nutrients (Schnappinger et al., 2003). Although not as popular and well accepted as the 
phagosome maturation arrest, escape into the cytosol represents yet another possible survival 
strategy for Mtb.  Survival of Mtb is therefore facilitated by a variety of mechanisms that include 
but are not limited to manipulation of macrophages, metabolic adaptation to the intracellular 
environment and mechanisms that confer resistance to the hostile environment and stresses 
encountered by the bacteria within these host cells (Ehrt and Schnappinger, 2009a).  
1.3.2 Granulomas: The hallmark of TB infection 
Histological and molecular studies, carried out retrospectively, to understand TB infection in 
humans have lent significant insights into the progression of the disease. In vitro analyses of the 
responses of murine and human macrophages to Mtb infection indicate a robust pro-inflammatory 
response of the cells. Infected macrophages are stimulated to invade the lung epithelium (Ulrichs 
and Kaufmann, 2006;Flynn and Chan, 2005;Algood et al., 2005) and consequently there is a 
recruitment of several other components of the immune system that result in the remodelling of 
the infection site (Ulrichs and Kaufmann, 2006;Flynn and Chan, 2005). The result is the 
formation of the granuloma; a structure that is responsible for immune containment and therefore 
results in latent TB infection (LTBI) (Tully et al., 2005;Dheda et al., 2005). The solid granuloma 
is not only the site of Mtb containment during latency but also the source of tissue damage at the 
early stage of disease and is therefore the histological correlate of both protection and pathology 
(Reece and Kaufmann, 2012). In humans, the granuloma shows high plasticity and these different 
stages are not distinct entities but form a continuum (Gengenbacher and Kaufmann, 2012).  
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The heterogeneous granulomas present diverse and unfavorable microenvironments, such as 
nutrient limitation and hypoxia, to which the pathogen has to adapt and which trigger the 
metabolic downshift of sub-populations of Mtb to dormancy. While ‘latency’ is used to describe 
the state of the human asymptomatic disease or infection, ‘persistence’ or ‘dormancy’ is used in 
reference to Mtb’s physiology. Various in vitro models of dormancy have been developed to 
study non-replicating persistence of Mtb and altogether, these models suggest that stress-related 
genes and alternative pathways are upregulated during dormancy, while the genes of central 
metabolic routes, including glycolysis, TCA cycle, energy production and respiration, are 
downregulated (Gengenbacher and Kaufmann, 2012).  
1.3.3 Latency and Reactivation  
Mtb can persist in humans for years without causing disease, in a syndrome known as latent TB 
infection (LTBI). Evidence for coexistence of different Mtb stages in infected individuals is 
increasing; the equilibrium of dormant/replicating Mtb could possibly represent a distinguishing 
factor between LTBI and active TB (Gengenbacher and Kaufmann, 2012).  
In TB prophylaxis, INH has been used widely and successfully although it targets only replicating 
Mtb, suggesting that sometime during the 6-month preventive therapy, the bacteria transforms to 
become INH-susceptible (Fox et al., 1999). A more recent hypothesis that describes latent 
infection to be an active and dynamic process of constant reinfection could probably explain the 
efficacy of INH preventive therapy (Cardona, 2009).   
It is thought that the coexistence of both replicating and non-replicating Mtb could be an 
important factor determining the 6-month long treatment duration for TB as drugs in the current 
standard regimen primarily target metabolically active replicating Mtb. In contrast, the dormant 
pathogen does not contribute to active disease manifestation but is responsible for phenotypic 
drug resistance and serves as a reservoir of active Mtb to sustain pathology and disease.  
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People with LTBI are ‘reservoirs’ for reactivation of the bacilli (2-23% lifetime risk). However, 
this risk increases up to 10% annually if the immune system becomes suppressed, as is frequently 
observed in individuals co-infected with the HIV (Corbett et al., 2003;McShane, 2005). The 
synergy of TB and HIV is therefore deadly and TB kills more HIV-positive patients than any 
other opportunistic infection, accounting for about 30% of global AIDS deaths (McShane, 2005). 
Other factors associated with the likelihood of Mtb reactivation from latency are conditions 
known to compromise the immune system such as steroid therapy, age, and malnutrition.  
1.4 TB: Matters of the Clinic 
 
The previous section, 1.3, provided an insight into difficulties presented by Mtb and TB in the 
context of drug discovery. The numerous survival strategies adopted by the pathogen, the 
inaccessible granuloma structures formed during the progression of the disease and most 
importantly, the adoption of a non-replicating or dormant form by Mtb; all these present a series 
of complications in the development of therapeutics against the pathogen. Nevertheless, in order 
to truly appreciate the challenge around effective management of TB, one has to understand 
several other issues closely linked to the management of the disease – some examples being lack 
of an effective vaccine against TB or the unreliable nature of existing diagnostics. In the early 
1990s, the WHO, identifying TB as one of the top ten causes of disease and mortality, declared it 
as a global emergency (Onozaki and Raviglione, 2010). Despite the promotion of the Directly 
Observed Treatment and Short-course drug therapy (DOTS) to ensure adherence to the lengthy 
TB regimen, there has been an increase in the number of TB cases owing to the HIV epidemic, 




1.4.1 Preventive Measures against TB  
The TB vaccine M.bovis Bacille Calmette-Guerin (BCG) - an attenuated strain of M.bovis that 
underwent several passages - was first tested in humans in 1921. To date, it remains the only 
licensed TB vaccine and the oldest vaccine that is currently in use. However, its variable efficacy 
mandate case detection and treatment as parallel TB control strategies. Moreover, BCG is 
contraindicated in HIV infection (Hesseling et al., 2008). Therefore a novel TB vaccine or 
regimen is a key component of the STOP TB strategy. Ongoing clinical trials are evaluating 
several prophylactic TB vaccines that are either live mycobacterial vaccines designed to replace 
BCG or subunit vaccines that are designed to boost BCG (Rowland and McShane, 2011). 
Importantly, trials evaluating two therapeutic vaccines for TB are in progress. The most advanced 
candidate vaccines are in Phase IIb trials. Nevertheless, progression of TB vaccine candidates to 
advanced stages of evaluation will depend on validation of animal models, identification of 
biomarkers and most importantly, development of field sites in high-burden countries.  
1.4.2 HIV Co-infection  
TB is the leading cause of death among people living with HIV. Almost one in four deaths among 
people with HIV is due to TB. In 2010, 350,000 people died of HIV-associated TB. Although the 
number of HIV infected people who were screened for TB as part of ‘intensified case finding’ 
efforts have drastically increased - from 600,000 in 2007 to 2.3 million in 2010 -  this represents 
less than 7% of the 34 million people estimated to be living with HIV. Unfortunately, TB 
infection control measures are till date not implemented in several HIV service settings (WHO, 
2011b). In response to the TB/HIV crisis, the WHO, along with the TB/HIV Working Group is 
taking various measures in aspects of policy development and planning, capacity building, 




1.4.3 Diagnosis of Active, Latent and Drug-Resistant TB 
Chest X-rays  can be used to diagnose active pulmonary TB and the tuberculin or the Mantoux 
test, IFNγ release assays such as QuantiFERON-TB Gold In-Tube and T-SPOT.TB are used to 
diagnose latent TB depending on patient’s immunization status and affordability (Frieden and 
Driver, 2003;Ferrara et al., 2006;Nahid et al., 2006;Pai et al., 2009;Diel et al., 2011). 
A commercially available tool in late-stage development/ evaluation is the Xpert MTB/RIF assay 
(Cepheid, CA, USA), a nucleic acid amplification test (NAAT) for Mtb detection and MDR-TB 
screening. In contrast to the existing tests in clinic, it is rapid, fully automated and provides 
highly accurate diagnosis in a single test that identifies both the presence of TB and drug-resistant 
TB (WHO, 2009b). The Foundation for Innovative New Diagnostics (FIND) has negotiated a 
75% price reduction for the public sector and as of July 2011, 26 countries are implementing the 
Xpert MTB/RIF test (WHO, 2011a). Nevertheless, the 125 year-old sputum smear microscopy 
test is still the most widely used method to detect TB. It has a number of drawbacks including 
low sensitivity (particularly in HIV-positive patients and children) and inability to distinguish 
between drug-sensitive and drug-resistant TB. While culture-based methods (the current gold 
standard) that have been developed for diagnosis and drug susceptibility testing are highly 
sensitive, these methods are labor intensive, cumbersome and as a consequence of their 
limitations and the time taken for diagnosis, patients are inappropriately treated, drug-resistant 
strains continue to spread and resistance gets amplified. 
1.4.4 Treatment Regimens and Emergence of Resistance 
From the very first clinical trials, it was clear that monotherapy for TB with any agent led to the 
development of resistance (Tsukamura, 1978). TB chemotherapy therefore evolved to be a multi-
drug regimen a very long time back (Fox and Mitchison, 1976;Mitchison, 2005). The standard 
treatment regimen for TB consists of four first-line drugs –INH, RIF, pyrazinamide (PZA), and 
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ethambutol (EMB) for two months, then INH and RIF alone for a further four months (Blumberg 
et al., 2005).  
RIF inhibits the activity of the β-subunit of DNA-dependent RNA polymerase, which acts early 
in transcription (Campbell et al., 2001). RIF is the most efficient drug in terms of sterilizing 
activity since it is very effective against persistent bacilli in the continuation phase of treatment. 
INH is a prodrug and is activated by KatG, a catalase-peroxidase hemoprotein (Zhang et al., 
1992). INH inhibits InhA, a NADH-specific enoyl-acyl carrier protein reductase (Mdluli et al., 
1998). This process inhibits the synthesis of mycolic acids required for the mycobacterial cell 
wall. In humans, INH shows a high early bactericidal activity (EBA) that kills actively growing 
bacteria. For the first two weeks of treatment, INH causes rapid decrease in sputum bacilli. 
Afterwards, the decrease slows down for non-growing bacterial populations. PZA is only 
bactericidal against Mtb in an acidic environment (Zhang et al., 1999). It is a prodrug that is 
converted into its active form pyrazinoic acid by the enzyme pyrazinamidase which is only active 
in acidic conditions (Zhang and Mitchison, 2003). There are various hypotheses suggested for the 
mechanism of action of PZA – disruption of membrane potential and energy production, 
inhibition of Mtb FAS I (Ngo et al., 2007;Zimhony et al., 2007) or the inhibition of trans-
translation by the binding of pyrazinoic acid to the ribosomal protein S1 (RpsA), thereby 
explaining PZA’s ability to kill dormant mycobacteria (Shi et al., 2011). EMB blocks cell-wall 
biosynthesis by inhibiting arabinosyl transferases (Mikusova et al., 1995;Takayama and Kilburn, 
1989). This drug is effective against actively growing mycobacteria. It is used in combination 
with other first-line drugs in order to avoid the emergence of genetic resistance to the drugs.  
The initial 2-month intensive phase is designed to kill actively growing and semi-dormant bacilli. 
At least two bactericidal drugs, INH and RIF are necessary in this phase. PZA in the intensive 
phase enables the reduction of treatment duration from nine to six months. Addition of EMB 
benefits the regimen in the presence of initial drug-resistance or high burden of Mtb. The 
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continuation phase ensures killing of any residual dormant bacilli and RIF-resistant mutants that 
commence replication. At the end of the therapy regime, patients are considered ‘cured’ albeit 
with a possible relapse rate of 2-3%.   
For latent TB, the standard treatment is six to nine months of INH alone. Patients with MDR-TB 
are treated with the remaining first-line drugs to which Mtb is sensitive, in combination with 
second-line and other drugs used as TB therapeutics. ρ-aminosalicylic acid (PAS), cycloserine, 
fluoroquinolones (ciprofloxacin, moxifloxacin, ofloxacin), aminoglycosides (streptomycin, 
amikacin, kanamycin), polypeptides (capreomycin, viomycin) and thioamides (prothionamide, 
ethionamide) are the second-line drugs available against TB (Table 1.1).  
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Table 1.1 List of therapeutics against TB (First-line, Second-line and others) 
 
First-line  











































* Gene to which resistance is mapped to is indicated in brackets 
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In the last three decades, there has been no new drug specifically developed for TB that has been 
introduced into this regimen. XDR TB results from Mtb strains causing MDR-TB that have 
acquired additional resistance to a fluoroquinolone and to at least one of the three most potent 
injectables (kanamycin, amikacin and capreomycin) (Gandhi et al., 2006). Nearly 10% of MDR-
TB cases acquire such resistance to become XDR TB (Zignol et al., 2006). Recently, the 
emergence of totally-drug resistant (TDR) TB strains has been reported (Velayati et al., 2009). 
These are XDR TB strains that are resistant to all the tested additional second-line TB drugs 
(thioamides, cycloserine and salicylic acid derivatives). Like XDR TB, strains causing TDR TB 
emerge from MDR-TB strains. 
In 2009, WHO reported that 3.3% of the TB incident cases diagnosed worldwide was MDR-TB 
(WHO, 2010b). MDR-TB has been reported in nearly 90 countries and regions worldwide with 
especially high rates in India, China, Russia and other countries of the former Soviet Union. In 
2010 (WHO, 2011a), there was an estimated prevalence of 650,000 cases of MDR-TB worldwide 
(440,000 in 2008) and each year MDR-TB accounts for nearly 150,000 deaths (WHO, 
2010b;WHO, 2010a). MDR-TB is therefore a severe public health concern in both the developing 
and the developed world. Existing treatment for MDR-TB is not only longer and more extensive 
(up to two years) but is also more expensive. Despite the long treatment, MDR-TB is associated 
with higher mortality rates and the cure rates for range from 6-59% as opposed to 95% or above 
in the case of drug sensitive TB (Aziz et al., 2006). Moreover, second-line drugs used in the 
treatment of MDR-TB are not only less effective but are also often less tolerated with severe 






1.5 TB Drug Development: Global Initiatives   
In light of all that is discussed until now, it is no surprise that the development of new drugs for 
TB is lengthy, expensive and risky with expected revenues too small to justify commercial 
investment (Ma and Lienhardt, 2009). Few market incentives exist for the private sector to get 
involved in drug discovery and development activities in the context of TB. Nevertheless, in the 
last decade, ten compounds have progressed into the clinical development pipeline – four of these 
are existing drugs that are redeveloped for TB (gatifloxacin, moxifloxacin, rifapentine, linezolid) 
and six are new chemical entities specifically developed for TB (PA-824, OPC-67683, TMC-207, 
PNU-100480, AZD5847, SQ-109) (Ma and Lienhardt, 2009) (Figure 1.2). In addition to these, 
there are currently seven compounds in pre-clinical stage along with several others in the lead 
optimization phase (WHO, 2010a). The compounds in clinical development belong to six 
different classes - fluoroquinolones (gatifloxacin and moxifloxacin), rifamycins (rifapentine), 
diarylquinolines (TMC207), oxazolidinones (Linezolid, PNU-100480 and AZD5847), 
ethylenediamines (SQ-109) and bicyclic nitroimidazoles (PA-824 and OPC67683). Of these, 
compounds belonging to only two classes- bicyclic nitroimidazoles and diarylquinolines- offer 
new mechanisms of action against Mtb. Understaning the mechanism of action of bicyclic 
nitroimidazoles and the physiologic significance of their activating machinery in Mtb form the 
basis for the research work described in this thesis. Before detailing the objectives of the thesis in 








Figure 1.2 The Global Pipeline for anti-TB Therapeutics.  
(A) There are ten compounds in clinical development (Phase 1-III) with several other novel novel 
chemical entities in the lead optimization and preclinical development stages. Source: WHO 
Global Tuberculosis Control Report (2011) (B) Mode of Action of compounds in clinical 





DNA Gyrase Inhibitors: Gatifloxacin and moxifloxacin are members of the fluoroquinolone 
class which consists of broad-spectrum antimicrobial drugs that target DNA gyrase (Mitscher and 
Baker, 1998) and have been used as second-line drugs for the treatment of MDR TB (Moadebi et 
al., 2007).  These two fluoroquinolones have shown better in vitro activity against Mtb than 
ofloxacin and ciprofloxacin (Rodriguez et al., 2001). Results from studies in mice indicate that 
moxifloxacin-containing regimens have the potential to shorten treatment of drug-susceptible TB 
from 6 months to 4 months (Nuermberger et al., 2004). Phase II studies have shown that 
substitution of ethambutol or INH in the control regimen with moxifloxacin or gatifloxacin 
resulted in improved rates of sputum culture conversion (Burman et al., 2006;Rustomjee et al., 
2008b;Conde et al., 2009;Dorman et al., 2009). Currently, Phase III trials are in progress to 
evaluate the possibility of shortening treatment of drug-susceptible TB to four months by 
substitution of gatifloxacin for ethambutol, or moxifloxacin for ethambutol or INH (Clinical Trial 
Identifier: NCT00216385; www.remoxtb.org). The patient enrolment for the REMoxTB trial 
began in January 2008 and a total of 20-30 sites, including those in Asia (India, China and other 
countries), Africa and Latin America are being recruited into the study to reach enrolment targets 
(http://www.newtbdrugs.org/pipeline.php).   
RNA polymerase inhibitor: Three semisynthetic rifamycins— potent inhibitors of bacterial 
RNA polymerase – rifampicin, rifapentine, and rifabutin—have been introduced for the treatment 
of various microbial infections. Rifampicin is the key component of the first-line treatment for 
TB. Rifapentine, albeit a more potent analogue with a longer half-life than rifampicin, it suffers 
the same drawback as rifampicin owing to the induction of P450 enzymes (Keung et al., 1999;Li 
et al., 1997). Rifapentine is currently in Phase II / III trials; a Phase II clinical trial for treatment 
shortening of drug-susceptible TB treatment is designed to evaluate the antimicrobial activity and 
safety of an experimental intensive phase TB treatment regimen in which rifapentine is 
substituted for RIF and a randomized multicenter trial is designed to compare 12 once-weekly 
18 
 
doses of rifapentine 900 mg + INH 900 mg given by DOTS vs. 9-month of self-administered 
daily INH 300 mg in treatment of LTBI in persons at high risk 
(http://www.newtbdrugs.org/pipeline.php).  
ATP synthase inhibitor: TMC-207, a diarylquinoline is an ATP synthase inhibitor that was 
identified in M. smegmatis high-throughput screen (Andries et al., 2005). It is highly potent 
against drug-susceptible and drug-resistant strains of Mtb and the combination of TMC-207, 
rifapentine, and PZA administered once a week in mice was much more efficacious than was the 
standard HZR regimen given five times per week (Ibrahim et al., 2009;Veziris et al., 2011).  The 
delayed onset of EBA for TMC-207 (Rustomjee et al., 2008a) in comparison to standard drugs 
has been possibly attributed to the time required for depletion of ATP (Ma and Lienhardt, 2009). 
A phase II trial evaluating the safety, tolerability, and efficacy of TMC-207 when added to 
individualized treatment for newly diagnosed MDR TB is ongoing and is expected to be complete 
in 2013; results from the initial 2-month treatment phase show that the addition of TMC-207, 
compared with placebo, to standard treatment for MDR TB significantly reduced the time to 
sputum conversion and increased the proportion of patients that showed sputum conversion (48%  
vs. 9%) after 2 months of treatment (Diacon et al., 2009).  
Ribosome Inhibitors: Linezolid, an approved drug of the Oxazolidinone class, has low in-vitro 
activity against Mtb. Oxazolidinones inhibit protein synthesis by binding to the 70S ribosomal 
initiation complex and have a broad spectrum of activity against anaerobic and gram-positive 
aerobic bacteria, and mycobacteria (Diekema and Jones, 2001). Phase II studies evaluating the 
use of low dose linezolid for MDR-TB and pharmacokinetics of linezolid in MDR/XDR TB are 
currently ongoing (http://www.newtbdrugs.org/pipeline.php). PNU-100480 is an analogue of 
linezolid that is being developed for TB. It showed slightly better activity than linezolid against 
Mtb in vitro, but substantially improved activity in mouse models of TB (Cynamon et al., 1999). 
Murine studies have shown that a combination regimen of PNU-100480, moxifloxacin, and PZA 
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was more active than was the standard HRZ regimen (INH, RIF and PZA) indicating a potential 
for shortened treatment (Williams et al., 2009). PNU-100480 is being developed for the treatment 
of both drug resistant and sensitive TB. Phase 1 clinical trials evaluating pharmacokinetics and 
safety and an efficacy and safety study to assess the EBA of PNU-100480 in patients with drug-
sensitive pulmonary TB have been completed (http://www.newtbdrugs.org/pipeline.php). 
AZD5487 is a recently discovered oxazolidinone which is currently in phase I clinical 
development. 
Cell wall synthesis inhibitor: SQ-109, an Ethylenediamine, is a derivative of ethambutol, albeit 
with a seemingly different mode of action (Lee et al., 2003).  It interacts synergistically with INH 
and RIF (Chen et al., 2006) and more importantly, substitution of SQ-109 for ethambutol in the 
standard regimen improved activity in a mouse model of established Mtb infection (Nikonenko et 
al., 2009). SQ109 is currently being evaluated in an EBA study to determine safety, sputum 
clearance of mycobacteria and pharmacokinetics of multiple doses of SQ109 (alone or with RIF) 
in patients with smear-positive pulmonary TB (http://www.newtbdrugs.org/pipeline.php). 
Subsequent trials to evaluate safety, efficacy and pharmacokinetics of several dose ranges of 
SQ109 in combination with other anti-TB drugs in patients with drug-susceptible and drug-
resistant TB infection are being planned. 
Multiple target inhibitors: Two bicyclic nitroimidazoles are in clinical development. PA-824 is 
a member of the nitroimidazo-oxazine family (Stover et al., 2000) and OPC-67683 is a member 
of the nitroimidazo-oxazole family (Matsumoto et al., 2006). Both these bicyclic nitroimidazoles 
are antimycobacterial compounds that are equally active against drug-susceptible and drug-
resistant TB and are pro-drugs that exert their antimycobacterial activity through bioreduction of 
the nitroimidazole pharmacophore (Singh et al., 2008).  Another highlight of this class is its 
members are active against replicating and non-replicating bacilli highlighting their potential use 
in the treatment of latent infection. The subsequent section, 1.6, outlines some of the unique 
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features of PA-824, its mechanism of activation/action in Mtb and lays out the objectives and 
framework of this thesis.     
1.6 TB Drug Development: NITD’s Initiative and The genesis of this 
Thesis 
The Novartis Institute for Tropical Diseases (NITD) based in Singapore aims to discover novel 
treatments for major tropical diseases which will be made readily available, without profit, to 
patients in developing countries. In addition to establishing itself as a center for drug discovery in 
the areas of dengue, TB and malaria, NITD has undertaken an initiative to contribute to the 
education of students from the disease endemic countries. This PhD project is an outcome of such 
an initiative. In recognition of the urgent need to improve existing treatment for TB, NITD’s 
focus is to develop new therapeutics for MDR TB. Leveraging on the advancement in genomics 
and bioinformatics technologies, research carried out at the institute aims to unravel vulnerable 
parts of the pathogen (‘targets’) that can be targeted by small molecules. 
The bicyclic 4-nitroimidazoles, PA-824 and OPC-67683, are currently in Phase II /III clinical 
development and represent a promising novel class of therapeutics for TB (Mukherjee and 
Boshoff, 2011). Both compounds are pro-drugs that are bioreductively activated within Mtb. PA-
824 as a potential anti-TB agent has many attractive characteristics - most notably its novel 
mechanism of action, activity against aerobic replicating and hypoxic non-replicating Mtb, its 
activity in vitro against all tested drug-resistant clinical isolates, its narrow spectrum of activity 
and its activity as both a potent bactericidal and a sterilizing agent in mice.  While PA-824 was 
optimized for its aerobic cellular activity, its anaerobic activity correlated with the amount of 
nitric oxide (NO) generated when the pro-drug was reduced by an Mtb deazaflavin cofactor (F420) 
dependent nitroreductase (Ddn) (Figure 1.3) (Singh et al., 2008).  
21 
 
F420 is a soluble 7, 8-didemethyl-8-hydroxy-5-deazariboflavin with a ribosyl-phospholactyl 
moiety and polyglutamate chain (Jacobson and Walsh, 1984;Walsh, 1986) (Figure 1.3, Figure 
2.1C). It is present only in select groups of archaea and bacteria and is an obligate 2 electron 
(hydride) donor with a redox potential (-360 mV) more negative than nicotinamide cofactors 
(Bair et al., 2001a) (Graham and White, 2002). An F420 dependent glucose 6-phosphate 
dehydrogenase (G6PD), FGD1 catalyzes the oxidation of glucose 6-phosphate to 
phosphogluconolactone and in turn reduces F420 to F420H2. The oxidized form of the cofactor F420 
has a characteristic intense absorbance/fluorescence at 420 nm (emission 480 nm), which is redox 
dependent and is lost upon reduction of the cofactor.  F420H2 is the active form of the cofactor that 
is utilized by Ddn (Figure 1.3). The physiological role of both cofactor F420 and the activating 



























Figure 1.3 Mechanisms of Activation and Action of PA-824 
The cofactor F420 dependent G6PD, FGD1 reduces F420 to F420H2 which is inturn utilized by the 
deazaflavin dependent nitroreductase, Ddn in the bioreductive activation of PA-824. Reduction 
of PA-824 results in three major metabolites; the anaerobicidal activity of the drug is attributed 
to the NO generated along with the des-nitro metabolite. Source: Manjunatha et al. (2006) Proc. 




1.6.1 Objectives Overall 
This thesis delves into two areas that are in line with the NITD’s initiatives in developing drugs 
against latent TB and in unraveling novel Mtb ‘targets’ for discovery of therapeutics against 
MDR TB.  The two research topics that have been studied here are: 
(i) Biochemical and structural characterization of Ddn enzyme, to understand substrate / 
cofactor specificity of the enzyme and to support a programme at NITD that focused on rational 
optimization of bicyclic nitroimidazoles. Chapter 3 of the thesis provides an in-depth introduction 
to the development of nitroimidazoles as anti-tuberculars following which the results from this 
first research topic are discussed. 
(ii) Evaluation of the physiological role of cofactor F420 and Ddn in Mtb pathogenesis as a 
first step in assessing the suitability of cofactor F420 and its dependent pathways as targets for 
drug discovery. Results and Discussion of this section are presented in Chapter 4 along with a 
detailed literature review on cofactor F420’s physiochemical properties, its distribution across 
species, known F420 biosynthetic pathways, enzymes and processes known to utilize F420 and what 
is known so far of its role in Mycobacterium.  
The following chapter, Chapter 2, outlines the materials and methods used to carry out 
experiments towards the scientific results discussed in this thesis. 
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2 Materials and Methods 
 
2.1 Bacterial strains, media and culture conditions 
E.coli TOP10 strain (Invitrogen) used for plasmid amplification and E.coli Tuner (DE3) cells 
(Stratagene) used for protein expression were grown at 37 °C in Luria Broth (LB) medium or on 
LB agar. M. bovis BCG Pasteur strain (American Type Culture Collection (ATCC #35374) and 
Mtb H37Rv (ATCC #27294) strains were grown at 37 °C in Middlebrook 7H9 liquid medium 
(supplemented with 0.5% albumin, 0.2% dextrose 0.085% NaCl, 0.2% glycerol and 0.05 % 
Tween 80) or on Middlebrook 7H11 agar (supplemented with 10% oleic acid-dextrose albumin 
catalase (OADC) enrichment, 0.5% glycerol). All media were purchased from Difco. 
Experiments with Mtb H37Rv were all performed in a Biosafety Level 3 (BSL3) laboratory at 
NITD, Singapore. Mycobacterial culturing conditions such as logarithmic, aerated stationary, 
hypoxia induced dormancy and anaerobic shift down were adapted from established protocols 
(Boon and Dick, 2002). Generation of and culture conditions for Mtb mutants H37Rv-5A1-ΔfbiC 
and H37Rv-14A1-Δddn have been described previously (Manjunatha et al., 2006a). When 
required, antibiotics were added to the culture media at the following concentrations: kanamycin 
(kan) – 50 μg/ml for E.coli, 25 μg/ml for M.bovis BCG and Mtb H37Rv; hygromycin (hyg) – 150 
μg/ml for E.coli, 75 μg/ml for M.bovis BCG and Mtb H37Rv; ampicillin (amp) – 100 μg/ml for 






2.2 Drugs and Chemicals 
Metronidazole (Mtz), 1,4-Naphthaquinone, 2, 3- Dimethyl 1, 4-naphthoquinone (DMN), 
Menadione, Plumbagin, Benzoquinone and Coenzyme Q0-2 were all obtained from Sigma-
Aldrich. (S)-PA-824, (R)-PA-824 and Aza-PA-824 (Kim et al., 2009b) and OPC-67683 (Sasaki et 
al., 2006) were synthesized as described. Synthesis of (R) and (S) isomers of both CGI-17341 and 
a phenyl-oxazole derivative are described in the Appendix section (Appendix 1, 2). All 
compounds were dissolved in 90% DMSO either as 2, 10 or 50 mM stocks depending on 
solubility limits. 
2.3 F420 purification from M. smegmatis 
F420 was purified from M. smegmatis mc
2
155 cells using a modified version of a protocol 
described earlier (Isabelle et al., 2002a). Briefly, M. smegmatis was grown in large batches 
(Syngene Intl. Ltd.) in modified strullu-romand (MSR) medium in a fermentor, cells were 
harvested, resuspended in water and lysed by three rounds of autoclaving (10 min at 121 °C). The 
lysed cell extract was filtered and passed through a HiQ (Biorad) ion exchange 250 ml column 
chromatography followed by Florisil (Sigma) 250 ml column chromatography. F420 was further 
purified using reverse phase (Source RPC 30, GE Healthcare) chromatography (acetonitrile 
gradient, 400 nm) (Figure 2.1A). As expected, F420 showed an emission maximum at 470 nm 
when excited at 400 nm. Each of the peaks in the LC profile corresponded to one of the F420 
analogs (Figure 2.1B). As reported earlier (Bair et al., 2001b), F420 with 4-6 glutamate residues 
accounted for majority of F420 analogs in the purified sample.A final yield of 1.18 µmol/L culture 






















Figure 2.1 Purification of cofactor F420 from M. smegmatis 
(A) LCMS chromatograms at 280 nm (Top) and 400 nm (Bottom) showing the presence of various 
F420 species isolated from M.smegmatis. (B) Identification of F420 species corresponding to each 
peak by ESI-MS. (C) Structure of cofactor F420 with five glutamate residues (F420-5) - the most 
common form present in mycobacteria. The C-5 carbon of F420 (site of hydride reduction) is shown 
by an asterisk. 
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2.4  F420 reduction assay  
Reduction of purified F420 was carried out as described previously (Manjunatha PNAS) at 
ambient temperature in either a 100 mM potassium phosphate (pH 7.0) buffer or in a 100mM 
Tris-HCl buffer (pH 8.0). The reaction mixture typically contained 200 μM F420, 5 mM glucose-
6-phosphate (G6P) and an induced cytosol (at 25 °C, 100 μM IPTG) of an E.coli strain containing 
the pET30-FGD1 plasmid (Manjunatha et al., 2006a) at a 1:500 dilution. Reduction of F420 was 





. Cloning of the Mtb genomic DNA encoding FGD1 into the pET30b (+) vector has 
been described earlier (Manjunatha et al., 2006b). The induced cytosol from pET30-FGD1 had 
significant F420-reducing activity with no background from the host. Upon reduction for 30 min, 
the reaction mixture was heat inactivated at 65 °C for 15 min and was subject to ultra-filtration 
(Centricon 10 kDa). The resulting filtrate (F420H2) was used for all the enzymatic assays.  
2.5 Cloning, expression and purification of recombinant Ddn 
proteins  
The coding sequence for Ddn (Rv3547) was amplified by Polymerase Chain reaction (PCR) (Pfx 
polymerase, Invitrogen) from H37Rv genomic DNA using specific primers (Table 2.1, primer # 
23 and 24). PCR amplified fragments were cloned into BamHI and NotI sites of an entry vector 
of a Gateway expression system (Leder et al., 2007); further the gene was sub-cloned into various 
destination vectors. A construct (pMBPKan5-Ddn) coding for N-terminal MBP-His6-tagged Ddn 
was transformed into BL21 (DE3) Tuner cells and protein expression was induced with 0.1 mM 
IPTG for 20 h at 18 °C. Soluble recombinant MBP-His6-Ddn was purified on a nickel affinity 
binding column and the fusion protein was cleaved by PreScission protease (GE Healthcare). The 
digested protein was subjected to ion exchange chromatography (RESOURCE S, GE Healthcare) 
28 
 
and the elutant was passed through a second nickel affinity binding column to remove any 
remaining tagged protein and non-removed tags. The purified protein was stored at -80 °C in a 
buffer containing 20mM Tris-HCl pH 7.5, 100mM NaCl, 10% glycerol, 1mM DTT.  
A gene encoding Ddn but harboring genetic changes that result in mutation of Tyr65 to Lys65 
(Ddn::Y6L) was synthesized (GeneScript) for optimal codon usage in E. coli. Cloning, expression 
and purification of Ddn::Y65L was similar to that of the wildtype (WT) protein described above.  
2.6 Evaluation of Ddn enzyme activity 
 
2.6.1 Absorbance-based Methods 
Enzymatic activity was determined spectrophotometrically by monitoring F420H2 oxidation at 400 
nm (isosbestic point for oxidized F420) (Singh et al., 2008). F420H2 was prepared as described 
previously from F420 by FGD1 enzyme in the presence of glucose-6-phosphate as the substrate 




). Typically, the 
assay mixture to determine enzyme activity contained 50 μM PA-824, 100 μM F420H2 and 1 μM 
Ddn in a final volume of 100 μL unless specified otherwise. Control reactions without the 
enzyme and without PA-824 were included for each set of experiments. To determine the pH 
optimum for Ddn activity, F420H2 oxidation was monitored at ambient temperature at pH ranging 
from 6.0-8.0 (MES-OH [pH 6.0-6.5], Tris-HCl [pH 7.0-7.5], HEPES-NaOH [pH 8.0-8.5]). For 
temperature
 
optima, the reaction was carried out in an optimal buffer (referred to as Ddn buffer- 
200 mM Tris-HCl (pH 8.0) with 0.01% Triton X-100) at varying temperatures between 20-50 °C. 









(0-20 mM)], DMSO (0-10%), EDTA (0-20 mM) and reducing agent DTT (0-2 mM) 
on enzyme activity was evaluated by including them in the reaction mixture. To determine 
specificity of Ddn for F420H2, this component in the assay reaction was replaced with NADH and 
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NADPH. For Ddn kinetics experiments, the initial velocities of F420H2 oxidation were plotted 
against the substrate concentration (PA-824 and its analogs) and analyzed using non-linear 
regression to the Michaelis-Menten equation using GraphPad Prism 5 (GraphPad Software, Inc., 
La Jolla, California, USA). When nanomolar concentrations of Ddn was used in order to achieve 
steady state kinetics at lower concentrations of nitroimidazole substrates, detection of F420H2 
oxidation was not feasible since the rate of Ddn catalyzed F420H2 oxidation was comparable to the 
spontaneous re-oxidation of F420H2 in the absence of the enzyme. Therefore 1 μM of Ddn was 
used in all reactions and apparent kinetic constants Vmax, app, Km, app and kcat/Km, app for any given 
reaction were determined from the plotted data.  
Quinone reductase activity of Ddn was also determined spectrophotometrically by monitoring 
F420H2 oxidation at A400 nm in the Ddn buffer described above with varying concentrations of a 
quinone substrate. The reaction mixtures contained 100 μM F420H2, 0.1-1μM recombinant Ddn 
and varying concentrations of the quinone substrate (0-100 μM) in a total volume of 100μl. 
Control reactions with PA-824 as the substrate were included. For evaluation of menadione as a 
substrate, reaction was also monitored at 337 nm to determine menadione reduction specifically 
(Hasan et al., 2010). To determine cofactor specificity for the quinone reductase activity of Ddn, 
F420H2 in the assay was replaced with NADH or NADPH and the reaction was monitored for 
NAD(P)H oxidation. Initial velocities of F420H2 oxidation were plotted against the substrate 
concentration and analyzed using non-linear regression to the Michaelis-Menten equation using 
GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, California, USA). Kinetic constants Vmax, 






2.6.2 Mass Spectrometry (MS)-based Ddn enzyme activity 
High Performance Liquid Chromatography – Mass Spectrometry (HPLC-MS) reactions was 
carried out by our collaborator at the Tuberculosis Research Section, NIAID, NIH, USA. 
Analysis of the enzymatic reactions and controls were performed on Agilent 1100 LC-MS 
instrument using Luna (3 mm) C18(2) column (50 x 2 mm, Phenomenex). One method was used 
to analyze all reactions. Solution A contained water and 0.1% formic acid. Solution B contained 
acetonitrile and 0.1% formic acid. The column was equilibrated with 95% solution A for 1 min. 
The following gradient was used: 95% to 5% solution A from 0 to 11 min; 5% solution A from 
11 to 15 min; 5% to 95% solution A from 15 to 17 min; 95% solution A from 17 to 21.5 min. 
Flow rate was maintained at 0.3 ml/min and MS was recorder for 60 to 1000 mass range in the 
positive mode. This method allowed for the separation of PA-824 (10.3 min), menadione (10.0 
min) and menadiol (9.3 min). 
 
2.6.3 Fluorometry-based methods  
Ddn and its homologues in Mtb (Rv1261 and Rv1588) were all expressed and purified as MBP-
tagged proteins as described earlier (Singh et al., 2008) and their quinone reductase activities 
were evaluated with menadione as a substrate and by monitoring F420 specific fluorescence 
(Excitationλ 400 nm, Emissionλ 470 nm) of the reaction mixture over time. The reaction mixture 
consisted of menadione, F420H2 and respective enzyme at 103 µM, 47.3 µM and 0.09 µM 
respectively in a Ddn buffer. The steady state kinetic parameters for MBP-tagged Ddn, Rv1261c 
and Rv1558 were determined by monitoring the oxidation of reduced cofactor F420 by 
fluorescence measurement at 470 nm, after excitation at 400 nm with Optima multimode detector, 
equipped with appropriate filters. The rate of oxidation of F420H2 was monitored over 5 minutes 
for each concentration of the substrate. A calibration curve for F420 was plotted in order to 
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calculate the concentration of oxidized F420. All solutions were made in the Ddn buffer.  The Km 
for menadione and kcat for the oxidation of F420H2 by Ddn was determined by fitting the initial 
rates of oxidation of F420H2 against varying concentrations of menadione using non-linear 
regression to the Michaelis-Menten equation using GraphPad Prism 5 (GraphPad Software, Inc., 
La Jolla, California, USA). 
 
2.6.4 Ddn kinetics studies via NO release assay 
NO release was directly monitored using the Sievers Nitric Oxide Analyzer (NOA) 280i. The 
NOA consists of an ozone generator, a chemiluminescent reaction chamber and a red sensitive 
photomultiplier tube (PMT) (Figure 2.2). In an aqueous reaction buffer, reactive nitrogen species 
react with dissolved O2 to form nitrite, which is reduced to NO by sodium iodide (1%) in acetic 
acid. The chemiluminescence assay is based on a gas phase reaction between NO and ozone to 
generate electronically excited nitrogen dioxide (NO2
*
) which emits light in the red and near-
infrared and is detected by a thermoelectrically cooled, red sensitive PMT (Figure 2.2). The 
reaction chamber containing glacial acetic acid-NaI with 100 μL of 1x antifoaming agent was 
purged with nitrogen continuously. The reaction chamber was connected to the PMT and standard 
50 μL solutions of sodium nitrite (1 nM to 1 μM) were injected and a calibration curve was 
generated with nitrite concentration as a function of the PMT output (mV). Varying 
concentrations of nitroimidazole substrates or F420H2 were used with 1 μM of Ddn in a Ddn 
buffer. NO release profiles were monitored over a ten minute period injecting 50 μl of the 
reaction mixture at each time point.  Apparent kinetic constants Vmax, app, Km, app and kcat/Km, app for 
each substrate was determined by fitting the initial rate of NO release as a function of substrate 
concentration using non-linear regression fitted to the Michaelis-Menten equation. 
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Figure 2.2 The Nitric Oxide Analyzer (NOA) set up for measuring in vitro Ddn enzyme kinetics.  
The chemiluminescence assay is based on a gas phase reaction between NO and ozone to 
generate electronically excited nitrogen dioxide (NO2
*) which emits light in the red and near-





2.7 Ddn binding studies to PA-824, F420 and F420H2  
Fluorescence emission spectra of Ddn (excitation at 280 nm) in a 100 μL volume with or without 
ligand were recorded between 310 - 420 nm using a Tecan Infinite M1000 plate reader. 1 μM 
Ddn was incubated with increasing ligand concentrations for 30 min before fluorescence 
measurements. The extent of ligand binding to Ddn was determined by monitoring changes in 
maximal fluorescence emission at 334 nm. The dissociation constant Kd value ([ligand] at which 
50% of the protein’s intrinsic tryptophan fluorescence is quenched) was calculated by fitting the 
relative change in intrinsic fluorescence at 334 nm (1 – F/F0) of Ddn vs. ligand concentration to a 
one-site binding (hyperbolic model) using non-linear regression where F0 is the intrinsic intensity 
of fluorescence of 1 µM Ddn alone; F is the fluorescence at a given concentration of ligand; 
corrections were made to subtract ligand-associated fluorescence. 
2.8 Modeling of PA-824 at the binding pocket  
Modeling studies were carried out by our collaborator Dr. Yong Sok Lee at the Center for 
Molecular Modeling, Center for Information Technology, NIH, Bethesda, USA. Putative binding 
modes of both stereoisomers of PA-824 in the binding pocket of Ddn were investigated using 
high resolution co-crystal structures of F420 with Ddn and with a homolog from Nocardia 
(nfa33440) (Cellitti et al., 2012). The pseudo-equatorial conformer of (S)-PA-824 was 
constructed by replacing the methyl of 7R-methyl-PA-824 (Li et al., 2008) with a hydrogen, and 
then energy minimized in the gaseous phase with the density functional theory at the level of 
B3LYP/6-31G* (Frisch et al., 2009).  The geometry of (R)-PA-824 was obtained by inversion of 
(S)-PA-824 coordinates. Docking of both (S)-PA-824 and (R)-PA-824 to the binding pocket was 




2.9 Sequence Analysis 
The primary sequences of the genes were obtained from Tuberculist 
(http://genolist.pasteur.fr/TubercuList). Multiple sequence alignments were carried out using 
Vector NTI.  
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Table 2.1 Table of Strains, Plasmids and Primers used in this thesis 
 
Strain Description Source 
 
E.coli TOP 10 Used for routine molecular biology work Invitrogen 
E. coli BL21 (DE3) Strain used for T7 expression constructs Invitrogen 
Mtb H37Rv ATCC # 27294 Lab strain 
H37RvΔfbiC fbiC knockout in H37Rv; mutant incapable of 
synthesizing cofactor F420 
This study 
H37RvΔfbiC::fbiC H37RvΔfbiC strain complemented with fbiC 
gene via integration of the  pMV306-kan-fbiC 
vector 
This study 
M. bovis BCG ATCC # 35374 Lab strain 
BCGΔfbiC fbiC knockout in M.bovis BCG; mutant 
incapable of synthesizing cofactor F420 
This study 
BCGΔfbiC::fbiC BCGΔfbiC strain complemented with fbiC gene 
via integration of the  pMV306-kan-fbiC vector 
This study 












; pNAT83 encoding H37Rv Ddn::Y65L This study 
pMAL-c2x-Ddn Amp
r
; pMALc2x encoding N-terminal MBP 
tagged Ddn 
Singh et al. (2008) 
pMAL-c2x-Rv1261c Amp
r
; pMALc2x encoding N-terminal MBP 




; pMALc2x encoding N-terminal MBP 




; E.coli-Mycobacterium shuttle plasmid 
vector 
Bardarov et al. 
(2002) 
pGOAL17 Vector containing sacB-lacZ cassette flanked by 
PacI sites for secondary selection 
Parish and Stroker, 
2000 
pYUB5’-3’fbiC-PacI pYUB854 with (i) 1kb AflII-XbaI fragment 
containing 5’ upstream region of fbiC  (ii) 1kb 
HindIII-XhoI fragment containing 3’ 
downstream region of fbiC and (iii) 6kb PacI 





; integrates at att sites on mycobacterial 
genome 




; pMV306-hyg with 3.6kb HindIII-XbaI 
fragment containing fbiC coding sequence along 
with ~1kb  upstream promoter region 




; pMV306 –kan with 3.6kb HindIII-XbaI 





Primer (#) Description Source 
 
5’fbiC FP_AflII (1) 5’ gccttaagccgtactgcacccacggttc 3’ This study 
5’fbiC RP_XbaI (2) 5’ gctctagacctcatccacgttcagcgtg 3’ This study 
3’fbiC FP_HindIII (3) 5’ gcaagcttatggaggagaccatctcgcggatg 3’ This study 
3’fbiC RP_XhoI(4) 5’ atctcgagagctgctggcggtggacaacgta 3’ This study 
pYUBF (5) 5’ ggtctgacgctcagtcgaacgaa 3’ This study 
pYUBR (6) 5’ agtgaggcacctatctcagcgatc 3’ This study 
pMV306 F (7) 5’ gataaccgtattaccgcctt 3’ This study 
pMV306 R (8) 5’ ccagtctttcgactgagcct 3’ This study 
hyg –int-FP (9) 5’ gagagcctcgcgtcggagtc 3’ This study 
hyg –int- RP (10) 5’ gcagttgcaccaggctgtag 3’ This study 
fbiC- int- FP (11) 5’ cgccgaacctggtgtctggcgacgaa 3’ This study 
fbiC- int- RP (12) 5’ ctcgtcgtccaggatttccgcggcg 3’ This study 
fbiC5’ RC FP (13) 5’ gaagttgatctgcggtgcca 3’ This study 
fbiC 3’ RC RP (14) 5’ gggtgaactacgaacagatca 3’ This study 
hygF (15) 5’ cacgagcagacctcactagc 3’ This study 
hygR2 (16) 5’ acggttgctagcacgcgca 3’ This study 
Ddn-qRT-FP (17) 5’ ccgctcagcgacttctttat 3’ This study 
Ddn-qRT-RP (18) 5’ caggaagtagagcgggttga 3’ This study 
fbiC-qRT-FP (19) 5’ cagcctgtaggtcggaagtc 3’ This study 
fbiC-qRT-RP (20) 5’ gttcagcgtgacaccatctc 3’ This study 
sigA-qRT-FP (21) 5’ accgatgagccggtaaaac 3’ This study 
sigA-qRT-RP (22) 5’ ggtgctggtcgtagtgtcct 3’ This study 
Ddn FP_BamHI (23) 5′-caggatcccgaaatcaccgccgcggtt-3′ Gurumurthy et al., 2012 






2.10 Mycobacterial genomic DNA isolation 
Mycobacterial cells were grown till stationary phase (OD600 ~ 1.2) in 50 ml 7H9 medium and 
harvested by pelleting down at 3000 g for 10 min. Upon washing with 0.05% Tween 80, the 
pellets were resuspended in 600 μl of a buffer containing 3% SDS, 1 mM calcium chloride, 10 
mM Tris-HCl and 100 mM sodium chloride (NaCl). The resuspension was transferred to screw-
cap tubes containing 0.1 mm-diameter glass beads (BioSpec Products, Bartlesville, OK, USA) 
and heat inactivated at 85
o
C for 30 min. Upon addition of 20 μl of Proteinase-K (Invitrogen, 
Carlsbad, CA, USA), the bacilli were further incubated at 56 °C for 30 min. The cells were 
disrupted by three 1 min pulses using a bead beater (FastPrep FP220A) and cell debris was 
pelleted by centrifugation. To the supernatant, 0.5 M EDTA was added to a final concentration of 
2 mM. To this, an equal volume of phenol/chloroform/isoamylalcohol (49:49:2, vol/vol/vol) was 
added and the mixture was transferred to a phase-lock tube (Eppendorf, Hamburg, Germany). 
After centrifugation at 16,000 g for 5 min, the aqueous phase was extracted and to this aqueous 
phase, 0.1 volume of 3 M sodium acetate and 0.8 volume of isopropanol were added for DNA 
precipitation. DNA pellets obtained by centrifugation at 16,000 g for 15 min were washed with 
500 μl of 70% ethanol. The supernatant after wash was removed and the pellets were left to dry 
for 10 min. Genomic DNA isolated was resuspended in 100 μl of TE buffer and samples were 
stored at -20 °C for long term storage. 
2.11 Generation of genetic knockout mutants and complemented 
mycobacterial strains  
Knockout strains in both M.bovis BCG and Mtb H37Rv were generated using allelic exchange 
(homologous recombination) as described earlier (Bardarov et al., 2002). Briefly, a gene 
replacement cassette was constructed and transformed into the mycobacterial cell; a knockout 
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strain generated by homologous recombination was further selected as described and depicted in 
the following sections.  
2.11.1 Construction of knockout (gene replacement) cassette 
The 5’ upstream and 3’ downstream flanking fragments of the gene of interest (Rv1173, fbiC) 
were amplified from H37Rv genomic DNA by PCR using specific primers (Table 2.1 primers # 
1and2, 3and4) and cloned into the allelic exchange vector pYUB854 to flank a hygromycin 
resistance cassette. PCR was performed using a high fidelity Pfx polymerase according to the 
manufacturer’s protocol (Invitrogen). The PacI cassette containing the lacZ and sacB marker 
genes was excised from pGOAL17 plasmid and introduced into the pYUB854 vector containing 
the flanking sequences of the gene. The knockout plasmid was sequenced (Table 2.1 primer # 
5and6) before transformation. 
2.11.2 Construction of complementation vector  
For complementation, the coding sequence of the mycobacterial gene including a ~1kb upstream 
region was excised by restriction digest (HindIII-XbaI) from the previously described pMV306-
hyg-fbiC vector (Manjunatha et al., 2006b) and introduced into a pMV306-kan chromosomal 
integrating vector (Stover et al., 1991) to generate a pMV306-kan-fbiC complementation vector. 
The complementation plasmid was also sequenced (Table 2.1 primer # 7and8) before further use. 
2.11.3 Electroporation and selection of transformants 
Mid-log phase WT mycobacterial cultures (50 ml) grown in 7H9 medium were washed three 
times with equal volumes of 10% glycerol and 0.05% Tween 80 to prepare the cells for 
electroporation. Approximately 1 μg of the knockout plasmid was subject to UV exposure (70 
J/cm
2
) and was introduced into competent bacterial cells via electroporation at 2500 V in a Gene-
Pulser XCell machine (Bio-Rad, 61Hercules, CA, USA) in cuvettes with an electrode gap of 2 
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mm. Transformants (BCGΔfbiC or H37RvΔfbiC) were recovered for ~24 h and were then 
selected on 7H11 plates containing hyg and X-Gal. After an incubation of ~ 4 weeks, colonies 
were inoculated in 7H9 liquid medium and grown to a suitable turbidity for characterization. 
Similarly, according to the protocol described above, the complementation plasmid pMV306-kan-
fbiC was electroporated into competent cells generated from the knockout strains (BCGΔfbiC or 
H37RvΔfbiC). Transformants (BCGΔfbiC::fbiC or H37RvΔfbiC::fbiC), containing the 
complementation vector were selected on 7H11 plates containing both hyg and kan. 
2.12 Southern blot hybridization  
Genomic DNA (1 μg) isolated from WT and knockout strains was digested with BamHI 
restriction enzyme (New England Biolabs, Ipswich, MA, USA) at 37 °C for 3 h and the DNA 
samples were fractionated on a 1% agarose gel. Upon depurination of DNA by soaking the gel in 
several volumes of 0.2 N HCl and rinsing with deionised water, the gel was soaked for 15 min at 
ambient temperature in several volumes of alkaline transfer buffer (0.4 N NaOH and 1M NaCl) 
with constant gentle agitation. DNA was transferred from the agarose gel onto a positively 
charged nylon membrane that was wetted with deionised water and was immersed in the transfer 
buffer for at least 10 min before assembly of the transfer apparatus. Transfer of DNA onto the 
membrane was facilitated by weights in addition to the alkaline transfer buffer that results in 
covalent attachment of DNA to the positively charged membrane.  Upon overnight transfer, the 
membrane was soaked in a neutralization buffer (0.5 M Tris-HCl, pH 7.2 with 1 M NaCl) for 15 
min at ambient temperature following which it was pre-soaked in a commercially available 
hybridization buffer, DIG Easy Hyb (Roche, Mannheim, Germany) for an hour at 37 °C. 
Digoxigenin (DIG) labeled probes used for detecting specific regions on the genomic DNA were 
synthesized using the PCR DIG Probe Synthesis Kit (Roche, Mannheim, Germany) with specific 
primers (Table 2.1 primer # 1and2 for 5’ probe, 9and10 for hyg probe, 11and12 fbiC probe). PCR 
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products were denatured at 95 °C for 5 min to generate single stranded probes and were placed 
immediately on ice thereafter. The pre-soaked membrane was then left to incubate overnight at 42 
°C under gentle agitation in a hybridization solution that consisted of a probe added to the 
hybridization buffer at a final concentration of 2 μl/ml. Prior to detection of probe binding to the 
membrane, a series of stringency washes was performed with 0.1x – 2x Saline Sodium Citrate 
buffer (SSC, pH 7.0) that contained varying amounts of SDS (0.1-0.5%). Following this the 
membrane was washed and blocked with buffers available as part of the DIG Wash and Block 
Buffers (Roche, Mannheim, Germany) according to manufacturer’s instructions. For the detection 
of hybridized probes, α-DIG-alkaline phosphatase conjugated antibodies were used at 1:5,000 
dilution in the blocking solution and added to the membrane for 30 min at ambient temperature 
under gentle agitation following which the detection buffer containing 1:50 dilution of 
NBT/BCIP colorimetric reaction substrate was added. The reaction was sequestered with 
deionised water and images were captured by scanning the membranes. For re-hybridization with 
different probes, membranes were stripped in dimethylformamide (DMF) that was preheated to 
60 °C. Stripped membranes were washed in 0.2 N NaOH + 0.1% SDS at 37 °C under gentle 
agitation and equilibrated in 2x SSC prior to being pre-soaked in DIG Easy Hyb buffer for the 
next round of probing. 
2.13 Minimal inhibitory concentration determination (MIC99, MIC90) 
Drug sensitivity profiles of the various mycobacterial strains were determined by 7H9 broth 
dilution methods. MIC99 was determined by the pellet formation method (lowest drug concentration 
at which no visible mycobacterial pellet is seen) whereas MIC90 was determined by an absorbance-
based method (lowest drug concentration at which 90% reduction in visible growth as determined 
by OD600 is achieved). 50 μl of 7H9 complete medium was added to each well of a transparent U-
bottom 96-well microtitre plate (Nunc) and serial dilutions of the drugs (0-100 μM final 
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concentration for INH and PA-824; 0-10 μM final concentration for RIF) were made across each 
row. For the determination of MIC99, to the wells containing serially diluted drugs, 50 μl of 1 in 
2000 dilution of 0.5 OD600 mycobacterial culture was added and the plate was incubated at 37 °C 
for 10 days before visually recording the data for pellet formation. For MIC90 determination, 50 µl 
of 0.4 OD600 mycobacterial cells were added and the plate was incubated at 37 °C for 5 days before 
measuring absorbance values at 600 nm using a spectrophotometer (Tecan Safire
2
). 
2.14 Biochemical characterization of mycobacterial strains for 
detection of F420 levels  
Cofactor F420 levels in the various mycobacterial strains were determined by analyzing crude cell 
extracts for F420 specific fluorescence (λex/em 400/470 nm), modified from a protocol described 
previously (Guerra-Lopez et al., 2007).  Briefly, 50  ml of mid to late-log phase (OD600 0.5 -1.0) 
mycobacterial cultures were centrifuged at 4500 rpm for 15 min; the pellet was resuspended in an 
equal volume of 0.9% NaCl solution, centrifuged at 4500 rpm for 15 minutes and this step was 
repeated twice. After the washes, the pellet was resuspended in 3 ml of an extraction buffer 
(50mM disodium phosphate, 50mM potassium dihydrogen phosphate) and incubated in boiling 
water (100 °C) for 15 min, following which it was placed on ice for 10 min and was finally 
centrifuged at 47, 000 g for 20 min at 4 °C. To 2 ml of the supernatant, an equal volume of 
isopropanol was added; the mixture was vortexed and again centrifuged at 47, 000 g for 20 min. 
The supernatant of this final centrifugation step was then carefully removed and its fluorescence 
was measured in a quartz cuvette using a fluorimeter (Spectramax M2, Molecular Devices).  
2.15 In vivo NO release assay in M. bovis BCG cells 
Measurement of NO release in vivo was carried out as described previously (Singh et al., 2008). 
Briefly, early-log phase cultures of all 3 strains of M. bovis BCG were incubated with 10 μM of 
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the DAF-FM diacetate dye (Molecular Probes) for one hour at 37 °C. Labeled cells were then 
harvested by centrifugation, washed to remove any unbound probe and the pellets were finally 
resuspended in 7H9 medium. 100 μl of the resuspended cells were incubated with varying 
concentrations of PA-824 in a 96-well plate and fluorescence (495nm, 515nm) was measured at 
different time points using a BMG Labtech fluorimeter. 
2.16 Growth sensitivity assays 
2.16.1  Colony Forming Units Assay 
Mid-log phase cultures of the various mycobacterial strains were diluted in 7H9 medium to an 
OD600 of 0.02 and exposed to varying concentrations of redox cycling agent such as menadione (0-
100 μM) and plumbagin (0-50μM); bactericidal drugs such as INH, moxifloxacin (Mfx) (0-1.2 µM) 
and Clofazimine (Clof) (0-8 µM); bacteriostatic drugs such as ρ-aminosalicylic acid (PAS) (0-8 
µM) and nitrosative stress inducing acidified sodium nitrite (0-3mM) for a period of five to seven 
days. Serial dilutions of the bacteria were plated on 7H11 plates at various time points to determine 
colony forming units (CFUs). For nitrosative stress inducing conditions, bacteria were grown in 
acidic (pH 5.5) 7H9 medium (without the albumin supplement) as described earlier (Darwin et al., 
2003).  
2.16.2 Oxidative Stress Sensitivity Zone of Inhibition Assay 
Sensitivity of the various M. bovis BCG strains to oxidative stress inducing agents plumbagin, 
menadione and to drugs such as INH and moxifloxacin were determined by the zone of inhibition 
or disc diffusion assay as described previously (Hasan et al., 2010). In brief, 1 ml of bacterial 
cultures (OD600 0.2) were spread onto 7H11 plates to prepare a lawn of cells. Filter paper discs (7 
mm diameter) containing varying amounts of plumbagin (0-0.025 μmol), menadione (0-0.5 
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μmol), were placed on the lawns and the cells were grown for ~1 week. The diameters of clear 
zones were averaged from two independent experiments in duplicate.  
2.17 Macrophage infection and assay  
THP-1 cells were differentiated into macrophages with 5 μg/ul of PMF for 48 h. The differentiated 
cells were activated with 10μM of IFN-γ for 4 hours and infected with H37Rv, H37Rv∆fbiC, 
H37Rv∆fbiC::fbiC strains at 5 multiplicity of infection (MOI) ratio and incubated at 37 °C. 
Macrophage cells were lysed with Triton X-100 at 1, 3 and 5 days post infection and serial 
dilutions of the lysate were plated on 7H11 plates to determine CFUs/ml. 
2.18 Non-replicating persistence 
 
2.18.1 Gradual oxygen depletion (Wayne model) 
Hypoxic non-replicating bacilli were generated as described previously (Lim, 1999) from oxygen 
starved mycobacterial cultures. Mycobacteria were grown in Dubos liquid medium containing 
0.03% Tween 80 and 10% Dubos albumin in sealed glass tubes [2049 mm by 125 mm screw-cap 
flat bottom culture tubes (Wheaton, Millville, NJ, USA)] at final volume of 17 ml each from an 
initial OD600 of 0.005 and  were subject to slow withdrawal of oxygen as described (Wayne and 
Hayes, 1996). The Wayne cultures were sealed by tightly screwing down solid caps with latex 
liners, and stirred gently at 170 rpm on magnetic stirring platforms for ~30 days to allow the bacilli 
to enter into dormancy. Oxygen depletion in these cultures was monitored by the use of the oxygen 
indicator methylene blue as described previously (Wayne and Hayes, 1996). Growth and survival 
were monitored at various time points by enumeration of CFUs on Middlebrook 7H11 agar after 




2.18.2 Rapid oxygen depletion (Anaerobic shiftdown)  
Mid-log phase mycobacterial cultures grown in either 7H9 or Dubos medium were placed in an 
airtight container within an anaerobic condition generator and monitored for 14 days. A 
methylene blue strip used as an indicator was included. At different time points, varying dilutions 
were plated on 7H11 plates for determination of CFUs.  
2.19 Determination of [NADH] and [NAD+] Concentrations 
Mid-log phase (OD600~0.4-0.6) aerobic mycobacterial cultures were pre-incubated with 2 µg/ml, 
4 µg/ml and 10 µg/ml menadione for 3 h before extraction of [NAD
+
] and [NADH].  [NADH] 
and [NAD
+
] were extracted and quantified as described (Rao et al., 2008). Briefly, cells 
equivalent to OD600 2.5 were spun down and the pellets were resuspended in 0.2 ml of 0.2 M HCl 
(for NAD
+
 extraction) and in 0.2 ml of 0.2 M NaOH (for NADH extraction) and then incubated at 
55 °C for 10 min. Upon cooling to ambient temperature, the suspensions were neutralized with 
0.2 ml of 0.1 M NaOH (for NAD
+
 extraction) and 0.2 ml of 0.1 M HCl (for NADH extraction) 
and were centrifuged at 13,000 rpm for 5 min at 4 °C. The supernatants were used in a cycling 
assay that was used to measure the intracellular [NADH] and [NAD
+
] concentrations. A reaction 
mixture consisting of equal volumes of 1.0 M Bicine buffer (pH8.0),  absolute ethanol, 40mM 
EDTA (pH 8.0), 4.2 mM  MTS (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide), 
16.6 mM PMS (phenazine methosulfate), 2.5 volumes of milliQ water and 0.5 volume  of 100 
U/ml yeast ADHII (alcohol dehydrogenase) was prepared. 80 µl of this reaction mixture was 
added to 20 µl of the supernatants extracted and the absorbance at 490 nm was monitored at 
ambient temperature for 15 min. The rate of MTS reduction is proportional to the concentration 
of the nicotinamide cofactor. Standards of NAD or NADH from 0.3 µM to 10 µM were used to 




2.20 Quantification of Intracellular ATP 
Intracellular ATP was quantified by using the BacTiter-Glo Microbial Cell Viability Assay Kit 
(Promega) as described previously (Rao et al., 2008). Aliquots of 100 µl of bacteria were collected 
at various time points and immediately heat inactivated. 25 µl of cell lysates were transferred into 
96-well white plates and mixed with an equal volume of the BacTiter-Glo reagent (Promega) and 
incubated for 5 min in the dark. The emitted luminescence was detected by using a luminometer 
(Safire2, Tecan Instruments) and was expressed as relative luminescence units. ATP standards 
ranging from 0.1 to 100 nM were also included in all of the experiments as internal control. 
2.21 RNA isolation and quantitative reverse transcription (qRT) PCR 
Mid-log phase mycobacterial cultures were mixed with two volumes of RNA Protect bacteria 
reagent (QIAGEN, Venlo, Netherlands), incubated for 5 min at ambient temperature, and 
centrifuged at 3,000 g. Pelleted cells were resuspended in 100 μl of 8 mg/ml lysozyme and 
transferred to screw-cap tubes containing 0.1 mm-diameter glass beads (BioSpec Products, 
Bartlesville, OK, USA). Three 30 sec pulses using a bead beater (FastPrep FP220A) were used to 
disrupt cells and cell debris was pelleted by centrifugation. Total RNA was isolated from the 
supernatant with RNeasy mini kit (Qiagen, Venlo, Netherlands) according to the manufacturer’s 
protocol. Synthesis of complementary DNA (cDNA) and qRT-PCR to determine levels of Ddn 
and fbiC transcripts using gene specific primers (Table 2.1 primers # 17and18, 19and20) were 
carried out using an iScript One-Step RT-PCR kit according to manufacturer’s protocol (Biorad). 
Primers specific for sigA (Table 2.1 primers # 21and22) were used as an endogenous control to 
normalize the amount of DNA template added to each qRT-PCR sample. qRT-PCR reactions 
were carried out in triplicate using the iQ5 Real-Time PCR Detection System (Bio-Rad, Hercules, 
CA, USA). The comparative Ct method was used for relative quantification of gene expression. 
Control reactions that did not contain the reverse transcriptase or the template were included.  
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2.22 Protein extraction and Western Blotting 
Approximately 50 ml of mid-log phase (OD600 0.3-0.6) mycobacterial cultures were centrifuged at 
3000 rpm for 10 min at ambient temperature and the pellet was resuspended in 1 ml of a 200mM 
Tris-HCl pH 8.0 protein extraction buffer containing protease inhibitor cocktail (Roche).  The 
suspension was transferred into a 2 ml screw-cap tube containing glass beads and cells were 
disrupted using 4 cycles of 30s each beadbeating at the highest setting. Cell lysates were then 
centrifuged at 13,000 rpm for 10 min at 4 °C and the supernatant was used for protein 
quantitation and western blotting purposes. Protein lysate samples were separated on a NuPAGE 
4–12% polyacrylamide gel (Invitrogen) and Western blots were performed according to Kyhse-
Andersen (Kyhse-Andersen, 1984). Briefly, upon electrophoresis, proteins were transferred onto 
a PVDF membrane (Bio-Rad, Hercules, CA, USA) and after transfer the membrane was 
incubated in a blocking solution containing 5% bovine serum albumin in TBST (10 mM Tris-
HCl, 150 mM NaCl, 0.05% Tween 20, pH 8.0) for one hour at ambient temperature. After 
blocking, membranes were incubated for an hour with antibody solution that contained 1:500 
dilution of a polyclonal antibody that was raised in rabbits against the recombinant Ddn protein 
(described in section) in TBST buffer. Upon incubation with the primary antibody, the membrane 
was washed three times in TBST and incubated for an hour with anti-rabbit peroxidase-
conjugated secondary antibody. Blots were developed using the enhanced chemiluminescence 
method (Pierce). 
2.23 Mycobacterial membrane vesicle assay for ATP synthesis  
The protocol was developed and adapted from previously reported literature (Andries et al., 2005). 
Mid-log phase (OD600~0.4) cultures of WT M. smegmatis were centrifuged at 1, 500 x g for 10 min 
at 4 °C. For extracting membrane vesicles, 5 g (wet weight) of the pellet was resuspended in 10 ml 
of a membrane preparation buffer (50 mM MOPS-NaOH, pH 7.5 + 2 mM MgCl2) containing 
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complete EDTA-free protease inhibitor cocktail and 1.2  mg/ml lysozyme and the suspension was 
stirred at ambient temperature for 45 min. Upon addition of 150 µl of 1 M MgCl2 and 25 µl of 
DNAse I, the suspension was stirred for a further 15 min at ambient temperature following which 
all subsequent steps were carried out on ice. Cells were broken by 3 passages through a pre-cooled 
French Pressure cell (Thermo Electron) at 25,000 psi and the suspension was centrifuged at 4200 
xg at 4 °C for 20 min. The supernatant was then centrifuged at 45,000 xg at 4 °C for 1 h and the 
pellet from this centrifugation (containing membrane vesicles) was resuspended in 1 ml of the 
membrane preparation buffer and 15% v/v glycerol. The Pierce Bicinchoninic acid protein assay 
for used to determine protein concentration of the vesicle preparation as per manufacturer's 
instructions.  
For the control ATP synthesis assay, the final reaction mixture consisted of 5 µg/ml of the M. 
smegmatis membranes, diluted in an assay buffer (50mM MOPS-NaOH, pH 7.5 + 10mM MgCl2) 
along with  10 µM ADP, 250 µM Pi and 200 µM NADH. 10 µl of CellTiter-Glo (Promega) was 
added to an equal volume of the reaction mixture at various time-points (0 – 30 min) and ATP 




3 Biochemical and structural 
characterization of Ddn, the activating 
enzyme of bicyclic nitroimidazoles in Mtb 
  
Nitroimidazoles are commonly used antibiotics for anaerobic microbial infections in humans. 
They show better activity against obligate anaerobes than aerobic organisms because their 
bactericidal activity requires an oxygen-sensitive bioreduction of the aromatic nitro group (Lamp 
et al., 1999). Metronidazole is a widely used 5-nitroimidazole for the treatment of infections 
caused by anaerobic bacteria (Samuelson, 1999;Kokwaro et al., 1993). Mtb cultures become 
sensitive to metronidazole under low oxygen conditions. However, the compound has no activity 
against aerobically growing bacteria (Wayne and Sramek, 1994). Aerobic antitubercular activity 
of bicyclic nitroimidazoles was first reported from a series of 4- and 5-nitroimidazole [2, 1-b] 
oxazoles (Barry et al., 2004). A highly active lead compound, CGI-17341, showed activity in a 
murine infection model but was subsequently dropped (Nagarajan et al., 1989;Ashtekar et al., 
1993) because of in vitro mutagenic results in the Ames test, a biological assay that is used to 
assess the mutagenic potential of chemical compounds. Subsequent elaboration of the bicyclic 
nitroimidazole series resulted in the identification of Ames negative analogs PA-824 (Stover et 
al., 2000) and OPC-67683 (Matsumoto et al., 2006), two compounds that are currently in clinical 
development.  
3.1 The evolution of nitroimidazoles as anti-tuberculars 
Metronidazole, the first class of nitroimidazoles, evolved from azomycin (2-nitroimidazole) 
which was the active ingredient isolated from the extracts of streptomycete 6670 that showed 
activity against Trichomonas vaginalis (Voogd, 1981;Roe, 1977;Roe, 1999). While 
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metronidazole’s antiprotozoan activity was known to extend to Giardia lamblia and 
Trypanosoma cruzi (Schneider, 1961;Rodriques and de Castro, 2002), its antibacterial activity 
against Entamoeba histolytica was demonstrated only 5 years after its discovery (Roe, 1977). Mtz 
has been used in the treatment of diseases caused by anaerobic bacteria such as the gram-negative 
Bacteroides fragilis and gram-positive bacteria Clostridium difficile and Helicobacter pylori and 
features extensively in the treatment of abscesses, septicemias, pneumonia, endodermitis and 
bacterial vaginosis (Roe, 1999;Chiba et al., 2002).  Mtz’s bactericidal activity against dormant 
Mtb and its lack of activity against aerobic replicating Mtb reaffirmed its utility against 
anaerobically adapted bacteria (Wayne and Sramek, 1994). Since hypoxia is thought to be one of 
the key factors that maintain Mtb in its low metabolically active state in latently infected lungs 
(Via et al., 2008;Barry, III et al., 2009;Boshoff and Barry, III, 2005), Mtz’s activity against 
anaerobic non-replicating Mtb introduced the possibility of combination drugs that could treat 
non-replicating persistent Mtb, in addition to that active replicating ones (Young et al., 2008).  
The antimycobacterial property of the 2-nitroimidazole class was established as early as the 1970s 
(Cavalleri et al., 1973); however, redox potential properties (~150 mV higher than 5-
nitroimidazoles) made compounds of this class readily accessible for bioreduction; this meant that 
the 2-nitroimidazoles could not tap into the redox system of the pathogen selectively and were 
therefore toxic to the host due to non specific reduction (Schmid and Schmid, 1999). In 1989, the 
aerobic anti-tubercular activity of bicyclic nitroimidazoles (nitroimidazo [2, 1-b] oxazoles that 
were obtained during the development of radiosensitizers for cancer therapy (Agrawal et al., 
1979;Sehgal et al., 1981) was established (Nagarajan et al., 1989). While the lead compound 
CGI-17341 showed activity against drug-susceptible as well as MDR Mtb, its further 
development was stalled due its mutagenicity (Ashtekar et al., 1993).  
More than a decade later, two groups, overcoming the problem of mutagenicity, came out with 
their lead compounds that showed promising activity against Mtb; PA-824 was PathoGenesis’ 
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(now Novartis) lead compound from a series of nitroimidazooxazines (Stover et al., 2000) and 
OPC-67683 (also known as Delamanid) was Otsuka Pharmaceutical’s lead compound from a 
series of nitroimidazooxazoles (Matsumoto et al., 2006).  
3.2 PA-824 and OPC-67683  
PA-824 was found to be highly specific for the Mtb complex and had no activity against other 
mycobacteria such as M. avium, M. smegmatis, M. cheolonae, M. fortuitum (Stover et al., 2000). 
In addition to its efficacy against both replicating and non-replicating Mtb, PA-824 is active 
against MDR strains and clinical isolates. Pre-clinical studies demonstrated that PA-824 has 
potent bactericidal and sterilizing effects against drug-resistant and drug-susceptible TB. PA-
824’s MIC was found to be between 0.015 and 0.25 µg/ml for drug-sensitive strains and between 
0.03 and 0.53 µg/ml for drug-resistant strains (Stover et al., 2000).  
Several studies in mice have evaluated the replacement of standard anti-tubercular drugs by PA-
824 in the initial or continuation phases (Tyagi et al., 2005;Lenaerts et al., 2005;Nuermberger et 
al., 2008). These studies confirmed that while PA-824 could replace INH in the intensive as well 
as continuation phases of therapy, it could not do so for PZA. When combined with INH, PA-824 
prevented the selection of INH-resistant mutants (Tyagi et al., 2005).  PA-824 also demonstrated 
potent activity during the continuation phase of therapy, during which it eliminated bacteria that 
had survived the initial two-month intensive phase. This is likely because the bacteria that outlast 
the intensive phase treatment inhabit an anaerobic environment that facilitates bactericidal action 
by PA-824 (Lenaerts et al., 2005). Further extensive studies demonstrated that PA-824, in 
combination with PZA displayed synergistic bactericidal activity in the murine model of TB with 
comparable potency to the standard anti TB regimen of INH, RIF and PZA (also known as the 
HRZ regimen).  Studies have also demonstrated that PA-824, in combination with moxifloxacin 
and PZA, was able to cure faster than INH, RIF and PZA, thereby giving hope for a regimen that 
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would shorten the duration of chemotherapy. The novel combination of PA-824, moxifloxacin, 
and PZA cured mice more rapidly than the standard first-line regimen suggesting that PA-824 
may substitute well for RIF during intensive phase therapy (Nuermberger et al., 2008). 
Additionally, PA-824 may be particularly effective against latent TB bacteria when used in 
combination with moxifloxacin, as suggested by a 2005 study that examined the activity of 
various drug combinations against latent TB in a mouse model. The combination of PA-824 (100 
mg/kg) with moxifloxacin (100 mg/kg) was at least as active as the current treatment of INH 
therapy (Nuermberger et al., 2005).   
Pharmacokinetic studies of PA-824 in healthy individuals have shown that the drug is readily 
absorbed, orally bioavailable, safe and well tolerated, with no serious effects (Ginsberg et al., 
2009). In an EBA study carried out to evaluate the lowest efficacious dose of the drug for 
treatment of pulmonary TB, PA-824 showed substantial EBA at the lowest dose tested (200 mg 
per day for 14 days). This suggested that the plasma concentration had already surpassed the MIC 
at the lowest tested dose thereby necessitating extended EBA studies at lower doses (Diacon et 
al., 2010). The lack of difference in bactericidal activity between 200 mg and 1200 mg (highest 
dose tested) contradicted pre-clinical studies in mice, where the activity of PA-824 was dose-
dependent (Tyagi et al., 2005). This indicated that further studies were required to test lower 
doses of the drug. A recent study, based on in vitro and mice experiments, confirmed that a 200 
mg/day dose of PA-824 in humans could be sufficient to achieve maximum bactericidal effects 
and doses as low as 50 or 100 mg/day could be active against TB bacteria in humans. Based on 
pharmacokinetic results, researchers postulated that this could be because of PA-824’s longer 
half-life in humans (Ahmad et al., 2011).  
OPC-67683 has potent activity against drug-resistant and drug-susceptible TB in vitro and in 
mice. Results from both in vitro and mouse models demonstrated OPC-67683 to be of much 
higher potency in comparison with all the other first-line TB drugs. In vitro, OPC-67683 was 
52 
 
effective against drug-susceptible and MDR Mtb at a low concentration of 0.006-0.024 µg/ml. In 
mice, OPC-67683, in combination with RIF and PZA, eradicated Mtb and caused organ 
sterilization in 4 months in comparison to the current intensive phase regimen that does not cause 
complete sterilization even after 6 months of treatment. These early results strongly suggested 
that OPC-67683 could potentially shorten the duration of TB treatment (Matsumoto et al., 2006). 
Furthermore, its in vitro sterilizing activity was superior to INH and equal to RIF (Saliu et al., 
2007). OPC-67683 does not induce and is not metabolized by cytochrome P450 (CYP) enzymes, 
making it suitable for co-administration with antiretrovirals. OPC-67683’s ability to kill 
intracellular bacteria and its activity against anaerobic bacteria is believed to be an indication that 
it could be used in the treatment of latent TB (Matsumoto et al., 2006).  Similar to PA-824, OPC-
67683 was tolerated well by healthy volunteers and no serious side effects were reported (Shi and 
Sugawara, 2010). EBA studies revealed that activity was significant from the second day of 
treatment with the effectiveness of the medication hitting a plateau at 300 mg dose (Diacon et al., 
2011).   
The activity of both the bicyclic nitroimidazoles, PA-824 and OPC-67683, against bacteria in 
both aerobic and anaerobic states implies that it could potentially be used to treat both active and 
latent TB, and to shorten the duration of the standard treatment programme.  
3.3 Current Status: Clinical Development 
The TB Alliance is leading the development of PA-824 as a treatment for TB and the compound 
is currently in Phase II clinical trials with two of the four clinical studies already completed. 
While one of the completed studies (Clinical Trial Identifier: NCT00567840) evaluated the EBA 
of 14 consecutive days of oral administration of PA-824 at 200, 600, 1000 and 1200 mg per day 
in adult patients with newly diagnosed, uncomplicated, smear positive TB, the other was an EBA 
trial with lower doses of PA-824 (50, 100, 150 and 200mg once daily for 14 days).  The results 
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from the latter study demonstrate measurable dose-dependent bactericidal activity and aided in 
the dose selection for current and future combination trials containing PA-824 (Clinical Trial 
Identifier: NCT00944021). An EBA study aimed to evaluate PA-824 as part of a novel three-drug 
combination with PZA and moxifloxacin is currently ongoing (Clinical Trial Identifier: 
NCT01215851) and a study to assess the mycobactericidal activity of the same regimen 
(moxifloxacin, PA-824, PZA) after 8 weeks of treatment has been planned but has not yet started 
recruiting (Clinical Trial Identifier: NCT01498419). 
The development of OPC-67683 is sponsored by Otsuka Pharmaceutical Development and 
Commercialization, Inc and Otsuka Frankfurt Research Institute GmbH. Two Phase II studies 
evaluating the safety, efficacy and pharmacokinetics of the drug in patients with uncomplicated, 
smear-positive pulmonary TB and in patients with pulmonary sputum culture-positive, MDR TB 
have been completed (Clinical Trial Identifier: NCT00401271, NCT00685360). Another study 
that evaluates the safety, tolerability and pharmacokinetics of orally administered OPC-67683 to 
MDR TB patients refractory to treatment with an optimized background regimen (OBR) of anti-
TB medications in currently ongoing (Clinical Trial Identifier: NCT01131351).  Most recently, a 
phase III trial to evaluate the safety and efficacy of Delamanid administered orally as 200 mg 
total daily dose for six months in patients with pulmonary sputum culture-positive, MDR TB is 
ongoing and is currently recruiting (Clinical Trial Identifier:NCT01424670). This trial is 
multicenter, randomized, double-blind, stratified, placebo-controlled and is conducted globally in 
2 parallel groups at approximately 15 sites qualified to treat MDR TB. In addition, a sub trial 
comprised of HIV positive patients who will be on antiretrovirals during the trial and will be 
randomized to OBR plus placebo or OBR plus delamanid will be conducted at a limited number 
of these sites that have been prequalified as having an integrated approach to TB and HIV 
treatment and management and a sufficient population of MDR TB patients co-infected with HIV 
for enrollment.  
54 
 
Although early studies demonstrated OPC-67683 to be a potentially effective treatment for both 
drug-resistant and drug-susceptible TB, Otsuka Pharmaceutical has chosen to direct its initial 
focus on testing the drug as a treatment for MDR TB. Given that the current success rate for 
treating MDR TB is only about 70%, the drug will likely be licensed more quickly as a treatment 
for MDR TB.  
3.4 Mechanism of Activation and Action 
Nitroimidazoles are prodrugs that require bioreduction by a low redox potential electron transfer 
system for their activation that is essential for their cidal activity. The redox potentials of the 
electron transport system in microbes, especially of those under limiting-oxygen conditions are 
capable of reducing nitroimidazoles. While a single electron reduction that produces 
nitroimidazole species and radicals that cause DNA damage is responsible for the cidal activity of 
metronidazole (Edwards, 1993;Sisson et al., 2000;Yeung et al., 1984), the bicyclic 
nitroimidazoles require bioreductive activation by an obligate two electron transfer agent 
(Manjunatha et al., 2006a). 
Activated PA-824 inhibits lipid biosynthesis in a dose dependent manner without disrupting 
nucleic acid biosynthesis and the disruption of cell wall biosynthesis machinery is thought to be 
the main mechanism of PA-824’s aerobic activity (Stover et al., 2000). Transcriptional profiling 
analyses of PA-824 treated cells under aerobic conditions suggest that in addition to inhibition of 
cell wall biosynthesis, inhibition of respiration could contribute to the aerobic cidal activity of 
this compound (Manjunatha et al., 2009). Several studies have characterized spontaneously 
generated PA-824 resistant mutants as a means to identify the cellular machinery involved in its 
activation. The original observation that the F420 dependent G6PD, FGD1 was required for 
sensitivity (Stover et al., 2000) was followed by a series of papers describing resistance in 
isolates that had lost the ability to biosynthesize the deazaflavin cofactor F420 (Choi et al., 
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2001;Choi et al., 2002) and culminated in identification of a conserved hypothetical protein 
encoded by Rv3547, a deazaflavin dependent nitroreductase (Ddn) that was essential for 
susceptibility to the compound (Manjunatha et al., 2006a). Strains with disruptions in fgd1 and 
Rv3547 (ddn) could be made sensitive to PA-824 by complementation with intact copies of the 
respective genes (Stover et al., 2000;Manjunatha et al., 2006a).  Both FGD1 and Ddn are F420-
dependent enzymes, but only Ddn is capable of reducing PA-824 directly, while FGD1 recycles 
the cofactor to the reduced form.  
FGD1 catalyzes the oxidation of glucose 6-phosphate to phosphogluconolactone and in turn 
reduces F420 to F420H2. F420 is a soluble 7,8-didemethyl-8-hydroxy-5-deazariboflavin with a 
ribosyl-phospholactyl moiety and polyglutamate chain (Figure 2.1C) (Walsh, 1986). It is only 
present in select groups of archaea and bacteria and is an obligate 2 electron (hydride) donor with 
a redox potential more negative than nicotinamide cofactors (Bair et al., 2001b;Jacobson and 
Walsh, 1984).  F420H2 is the active form of the cofactor that is utilized by a Ddn. The 
physiological role of Ddn is unknown. Mtb proteomics studies have suggested that Ddn may be a 
peripheral membrane protein (Sinha et al., 2005;Gu et al., 2003), but its biological substrate and 
function remain unknown, and there is low levels of sequence identity/similarity to any protein of 
known cellular function (Singh et al., 2008).  Homologues do exist in several species, mostly 
within Actinobacteria, though not in M. leprae, the etiologic agent of human leprosy, which is 
resistant to PA-824 (Manjunatha et al., 2006c).   
In contrast to the reduction of metronidazole, PA-824 reduction occurs by a hydride transfer 
(Figure 3.1). The F420H2 dependent reduction of PA-824 by Ddn produces three stable metabolites 
resulting from reduction of the imidazole ring at C-3 (Singh et al., 2008). One of the major 
products formed is the des-nitro metabolite with subsequent release of nitrous acid which 
degrades to NO. Evaluation of several PA-824 analogs pointed to an observation that the amount 
of des-nitro metabolite formed (and the corresponding amount of NO generated) correlates well 
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with their anaerobicidal activity (Singh et al., 2008). Thus the anaerobic activity of PA-824 is 
attributed to the internal release of NO in Mtb which could react with cytochromes and hamper 
ATP homeostasis under hypoxic non replicating conditions (Manjunatha et al., 2009;Rao et al., 
2008;Boshoff and Barry, III, 2005). This killing mechanism mimicks the NO production by 
macrophages that is thought to be important in controlling TB in murine models and human 
macrophage cultures (MacMicking et al., 1995;Rich et al., 1997). However, the aerobicidal and 
anaerobicidal activities of PA-824 correlate poorly (Kim et al., 2009b;Kim et al., 2009a) and our 
mechanistic understanding of the reaction course leading to aerobic or anaerobic activity remains 
incomplete.  
OPC-67683, like PA-824 is a prodrug that appears to undergo similar reduction reactions with 
mutations conferring resistance to OPC-67683 mapping to ddn (Matsumoto et al., 2006;Maroz et 
al., 2010;Singh et al., 2008). However, in contrast to PA-824, only the des-nitro derivative of 
OPC-67683 was detected when M.bovis BCG was incubated with the compound. 
Macromolecular incorporation assays showed that OPC-67683 inhibits mycolic acid biosynthesis 
in M.bovis. Nevertheless, unlike INH, OPC-67683 did not inhibit total mycolic acid biosynthesis; 
it inhibited only that of methoxy- and keto-mycolates. The enzymatic target in fatty acid 
biosynthesis that results in the observed mycolate profiles has not yet been identified for either of 





























































































Figure 3.1 Reaction Mechanism of PA-824 Activation. 
The F420H2 dependent reduction of PA-824 by Ddn produces three stable metabolites resulting 
from reduction of the imidazole ring at C-3(Singh et al., 2008). One of the major products formed 
is the des-nitro metabolite with subsequent release of nitrous acid which degrades to nitric oxide 
(NO). Evaluation of several PA-824 analogs pointed to an observation that the amount of des-
nitro metabolite formed (and the corresponding amount of NO generated) correlates well with 
their anaerobicidal activity. Source: Singh et al. (2008) Science 322.  
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3.5 Objectives  
 
In order to further enhance our understanding of the mechanism of action of bicyclic 
nitroimidazoles in general and of PA-824 specifically, the F420H2 dependent nitroreductase 
activity of Ddn was studied using PA-824 and a selected collection of chemically distinct 
nitroimidazole analogs (Figure 3.2) by investigating reoxidation of F420H2, production of NO and 
by determining binding constants of the analogs to Ddn. In collaboration with the Genomics 
Institute of the Novartis Research Foundation (GNF), San Diego, USA and the National Institutes 
of Health (NIH), Bethesda, USA, the structure of a truncated version of Ddn in the presence and 
absence of F420 and the structures of two full length homologues from Nocardia farcinica, one of 
which is catalytically competent for PA-824 reduction in vitro, were solved (Cellitti et al., 2012).  
Structural and mutational studies with Ddn and the active homologue to identify key residues in 
the active site of this enzyme family were performed; results of experiments carried out at NITD, 
Singapore towards the structural work have been elaborated in this thesis while other aspects have 
been mentioned in brief. 
3.6 Summary of findings   
The biochemical properties of Ddn including optimal enzymatic turnover conditions and substrate 
specificity were determined. The preference of the enzyme for the (S) isomer of PA-824 over the 
(R) isomer is directed by the presence of a long hydrophobic tail. Nitroimidazoles bearing only 
short alkyl substituents at the C-7 position of the oxazole were reduced by Ddn without any 
stereochemical preference. However, with bulkier substitutions on the tail of the oxazole, Ddn 
displayed stereospecificity. Ddn mediated metabolism of PA-824 results in the release of reactive 
nitrogen species. A direct chemiluminescence-based NO detection assay to measure the kinetics 
of NO production by Ddn was established and has been described here. Comparison and analysis 
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of the structures of Ddn and of the homologues from Nocardia farcinica revealed regions of the 
enzyme that underwent changes upon cofactor binding and may be of potential significance in 
cofactor/substrate binding and in catalysis (Cellitti et al., 2012). The N-terminal 30 residues of 
Ddn were determined to be of functional importance but were flexible or accessed multiple 
conformations, preventing structural characterization of the full-length, enzymatically active 
protein. Nevertheless, the proposed orientation of the tail of PA-824 toward the N-terminus of 
Ddn was consistent with structure- activity relationship data. Binding affinity of cofactor F420 and 
PA-824 to Ddn was monitored through intrinsic fluorescence quenching of the protein facilitating 
an enzymatic turnover-independent assessment of affinity. (R)-PA-824, despite not being turned 
over by Ddn, bound to the enzyme with the same affinity as the active (S) isomer. This result, in 
combination with docking studies in the active site, suggested that the (R) isomer probably had a 
different binding mode than the (S) with the C-3 of the imidazole ring orienting in a non-
productive position with respect to the incoming hydride from F420. In summary, the results from 
both the biochemical and structural studies suggested that the tail portion of the nitroimidazole 
determined the binding orientation of the head group, conferring stereospecificity in orientation of 
the molecule towards reduction (Cellitti et al., 2012;Gurumurthy et al., 2012).The results 
presented elucidate structural features important for understanding substrate binding providing 
insight into the activation of bicyclic 4-nitroimidazoles that could facilitate optimization of this 
class of compounds toward more efficient killing in anaerobic and aerobic environments for 





Figure 3.2 Chemical Structures of Nitroimidazoles used in this study.  






3.7.1 Optimization of Ddn catalyzed PA-824 reduction  
Recombinant Ddn was expressed and purified as an MBP-His6 tagged protein in E.coli. The 
purified protein was a soluble aggregate and had a calculated size of ~17.5 kDa on SDS PAGE 
(Figure 3.3A) which corresponded to the predicted molecular weight. Protein concentration of 
3.03 μg/μL was obtained as determined by the standard Bradford assay (Bradford, 1976) and the 
final yield of the purified protein was about 30 mg per liter of culture. F420 was isolated from M. 
smegmatis and purified F420 was characterized by LC-ESI MS and fluorescence emission 
scanning. F420 was reduced to F420H2 as described in the Methods chapter. 
Enzymatic activity of Ddn was determined spectrophotometrically by monitoring F420H2 
oxidation at A400 nm. The enzyme activity of Ddn was determined between pH 6.0 to 8.0; the 
optimum pH for Ddn mediated F420H2 oxidation was 7.0-8.0 (Figure 3.3B). At pH 8.0, the 
enzyme was active at ambient temperature whereas its activity was compromised at 48 °C (Figure 








) had no 
effect on enzyme activity (data not shown). However, the presence of a detergent (0.01% Triton 
X-100) improved the enzyme activity significantly; thus the final buffer contained 200 mM Tris-
HCl (pH 8.0) with 0.01% Triton X-100 (Figure 3.3D). Addition of 10% DMSO, 2 mM DTT and 
20 mM EDTA to the Ddn buffer had no effect on enzyme activity (Figure 3.3E).   
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Figure 3.3 Purification of recombinant Ddn and optimization of enzyme activity. 
(A) SDS- PAGE showing expression and purification of recombinant Ddn enzyme   M- Marker;  
1-uncleaved MBP-His6-Ddn; 2-Cleaved Ddn; 3, 4, 5- flow through, wash and eluate from ion-
exchange column respectively. MBP-His-Ddn and cleaved Ddn proteins are denoted by arrows.  
(B, C) Effect of pH and Temperature on the activity of Ddn. (D, E) Effect of Triton X-100, EDTA, 
DTT and DMSO on Ddn activity  
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The F420H2 specificity of Ddn was investigated by monitoring Ddn catalyzed PA-824 reduction in 
the presence of various other redox active cofactors. The enzyme was not able to utilize NADH 
and NADPH in the reduction of PA-824 and was highly specific for F420H2 (data not shown). F420 
is present within cells as a series of poly-glutamylated forms containing 2-6 glutamates in the tail 
in a species-specific pattern. Both M. smegmatis and Mtb produce predominantly F420 species 
with 5-6 glutamate residues (Figure 2.1B) (Bair et al., 2001b). The ability of Ddn to utilize the 
F420 isolated from Methanobacterium thermoautotrophicum, which produces F420 with 2 
glutamates side chain (F420-2) (Eirich et al., 1978) was therefore evaluated. Ddn enzyme was able 
to utilize reduced F420-2 (Km, app 26 μM) as efficiently as F420-5 from M. smegmatis (Km, app 29 
μM).  
3.7.2 The lipophilic tail of nitroimidazole substrates determines reduction 
selectivity and efficiency  
In order to understand the effect of substrate structure on the enzyme kinetic parameters, first, the 
apparent steady state kinetic constants Km, app and   kcat/Km, app for the Ddn reaction with PA-824 in 
the presence of 100 μM F420H2 and 1 μM Ddn were determined (Figure 3.4 A,B). The Km, app for 




(Figure 3.4B, Table 3.1). To explore 
reduction selectivity, the  kinetic parameters of Ddn with a limited set of structurally diverse PA-
824 analogs including (R)-PA-824, des-nitro PA-824, Mtz, (R) and (S) stereoisomers of CGI-
17341 and (R) and (S) stereoisomers of a simple phenyloxazole series were further established 
(Figure 3.4B). Ddn was not able to oxidize F420H2 when using des-nitro PA-824 or (R)-PA-824 as 
substrates (Figure 3.4B), supporting the importance of the nitro group and the previously noted 
enantiomeric specificity for reduction of these nitroimidazo-oxazines (Singh et al., 2008). Ddn 
showed no biochemical activity using metronidazole, a monocyclic 5-nitroimidazole, as a 
substrate (Figure 3.4B) reinforcing the notion that metronidazole killing of anaerobic Mtb occurs 
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via a mechanism that is independent of F420 and Ddn. Aza-PA-824 was equally as good a 




(Figure 3.4B, Table 3.1 ).   
It has been shown previously that Mtb Ddn mutants were equally sensitive as WT Mtb to the 
nitroimidazo-oxazole analog CGI-17341 (Manjunatha et al., 2006b) suggesting involvement of 
other Ddn homologs in its activation. CGI-17341 is a racemic mixture that proved to be a modest 
substrate for Ddn (data not shown). In order to understand the enantiomeric specificity of 
nitroimidazooxazoles, the (R) and (S) stereoisomers of CGI-17341 were synthesized (Appendix 
1). Both (R) and (S) forms had highly potent Mtb cellular activity against WT H37Rv as well as 
against H37Rv-14A1-ΔDdn, suggesting a Ddn independent mode of activation. Nevertheless, 
activation was still F420 dependent as the H37Rv-5A1-ΔfbiC strain was resistant to both the 
stereoisomers (Table 3.1). These genetic studies suggest that while PA-824 is activated in Mtb 
exclusively by Ddn, activation of CGI-17341 is carried out by Ddn or other Ddn homologues 
(Rv1261c, Rv1558 and Rv3178, Figure 3.5). Although Ddn is not likely to be the only relevant 
reductase for activation of CGI-17341, these compounds nonetheless were Ddn substrates in 
vitro. Substrate dependent F420H2 oxidation was observed with both the (R) and (S) isomers of 
CGI-17341 at about half the maximal velocity achieved for PA-824 and there was no significant 
rate difference between the two enantiomers (Figure 3.4B, Table 3.1).  
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Figure 3.4 Ddn kinetics monitored via F420H2 oxidation.  
(A) Oxidation of F420H2 at varying PA-824 concentrations monitored by increase in absorbance at 
400 nm. (B) Michaelis-Menten plots for Ddn catalyzed reduction of PA-824, (R)-PA-824, des-nitro 
PA-824, metronidazole, Aza- PA-824, (R) and (S)-CGI-17341 and (R) and (S) phenyl oxazole 
derivatives at 100 μM F420H2. Each value represents the means ± standard deviations of initial 




Table 3.1 Characterization of various PA-824 analogs  
 
 






















PA-824  28.6±3.6 4.7±0.3 0.160±0.020 0.8 >100 >100 
(R) PA-824  ns ns ns >100 >100 >100 
(S) CGI-17341 207.2±70.8 2.4±0.6 0.011±0.002 0.5 >100 0.4 
(R) CGI-17341 123.2±20.1 2.2±0.2 0.020±0.005 0.25 >100 0.2-0.4 
(S) Phenyl-oxazole 67.8±37.5 1.7± 0.5 0.029±0.011 12.5 >100 12.5 
(R) Phenyl-
oxazole 
83.6±15.7 4.8±0.5 0.061±0.003 0.8 >100 0.8 
OPC-67683 † † † 0.01 >20 >20 
Aza-PA-824  12.9±3.4 1.6±0.1 0.117±0.015 0.8 >100 >100 
 




 not determined because of poor aqueous solubility of OPC-67683 (< 1 μM) 
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Earlier observations of PA-824 resistant Ddn mutants being partially resistant to 
nitroimidazooxazoles with longer hydrophobic substituents on the oxazole ring (Manjunatha et 
al., 2006b) led to a hypothesis that substrates with longer lipophilic tails would perhaps 
stereoselectively interact with Ddn. To probe into this further, (R) and (S) stereoisomers of a 
nitroimidazooxazole with a bulkier hydrophobic phenyl side-chain were synthesized (Appendix 
2). As postulated, the (R)-phenyloxazole was 15-fold more active in whole cell activity against 
WT H37Rv than its corresponding (S) enantiomer but similar activities of both isomers were 
observed when MICs were determined with a Ddn mutant (Table 3.1). Once again, this implicates 
the role of other homologs of Ddn in Mtb such as Rv1261c, Rv1558 and Rv3178 (Figure 3.5) in 
the cellular activation of simple nitroimidazooxazole analogs (Figure 3.5). When tested against 
purified Ddn, both (R) and (S)-phenyloxazole analogs were poor substrates for Ddn with kcat/Km, 








respectively (Table 3.1). Interestingly, the low 
specificity constants (kcat/Km, app) for all four tested nitroimidazooxazole analogues are largely 
driven by their high Km, app values. This is possibly because of the absence of the triflouromethoxy 
benzyl group which seems to be important for Ddn enzyme activity (Kim et al., 2009a). 
 Notably the maximal velocity of (R) isomer was nearly equal to that of PA-824 although the 
affinity was significantly lower (Km, app 84 µM). Thus it seems that Ddn displays stereospecificity 
with oxazole substrates with larger lipophilic tails but the stereo preference is the reverse of that 
















      R   G   G    G PLVLL T G KSG  R TPLMYL    D GRI IVAS GGAP NP WY NLKANP   VQIGTE    V AREL GD   ERA  W R V  VYP FADYQS T   R IPVVIL       Consensus (31)







------------------M EAIDWDQMNNQ IKEFRET-GGKAGGLFEGSPLVL HHTGAKSGKQRIAPL PLL---DGDRIYIFGSKGGADSHPDWYHNLVANPDTVVELGTETF-PVKARVLTGA---ERDEIYAKQVA-MSMEG_2850 (1)
-------MTDDSIDKEKLYSDTAALDDFNSK EEFRAN-GGKVGGPFENGTLLLLHTTG KSGQPRVSPLAYLP---VDGKILIVGSYAGGPKHPAWVHNLRANPNAHIEIGTEAY-DVVARELPDD---ERDATYPKIVE-MSMEG_3004 (1)
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-----------------------MVAVPEGYESLLERPLYGHLATVRPDGTPQVNAMWF WDGEVLRFTHTTKRQKYRNIKANPAVAMSVIDPDNPYRYLEVRGLVEDIVPDPTGAFYLKLNDRYDGPLTEPPADKADRVIIVMSMEG_3380 (1)
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N-terminus divergent sequence
 




Resistance to OPC-67683, (R) isomer of a bicyclic 4-nitroimidazooxazole with a hydrophobic tail 
on the oxazole ring, has also been mapped to Ddn (Matsumoto et al., 2006). OPC-67683 was 
highly active against Mtb H37Rv (MIC90 0.01 µM) whereas the Ddn mutant, as expected, was 
resistant to this compound, confirming that Ddn is the primary biological activator for this 
compound (Table 3.1). OPC-67683 showed substrate dependent F420H2 oxidation by Ddn (with an 
initial velocity of 63 nMmin
-1
 with 5 μM OPC-67683) (Figure 3.6A). However, owing to 
solubility limitations with this compound (< 1 µM in aqueous buffer), in vitro enzyme kinetics of 
Ddn with OPC-67683 could not be evaluated. Enzymatic formation of the des-nitro form of OPC-
67683 with Ddn was detected by LC-MS analysis (Figure 3.6B m/z 490 compared to 535 for the 










































































Figure 3.6 Ddn enzyme kinetics with OPC-67683 substrate 
(A) Oxidation of F420H2 monitored at 400 nm over time with 5 and 10 μM OPC-67683.  
(B) Ddn mediated in vitro metabolism of OPC-67683  
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3.7.3 Kinetic mechanism of Ddn catalysis 
The kinetic mechanism of Ddn was studied using preliminary two-substrate profile analyses 
(Figure 3.7A, B). The increase in the Vmax, app values with increasing concentrations of both PA-
824 and F420H2 suggest that reaction chemistry must occur through a ternary complex of Ddn: 
F420H2: PA-824 (Figure 3.7C). However, further analysis such as product inhibition studies are 
required to determine precise binding constants and to distinguish between a random versus an 






















































Ddn : F420H2 : PA-824
Ddn : PA-824





















Figure 3.7 Two-substrate profile analysis for Ddn.  
Michaelis-Menten plot of (A) initial velocity vs. [PA-824] and (B) initial velocity versus [F420H2] in 
the presence of 1 μM Ddn and varying concentrations of second substrate. Each value represents 
the means ± standard deviations of initial velocity of formation of oxidized F420 from a linear 
regression analysis. (C) Schematic representation of Ddn reaction mechanism: progression of 





3.7.4 The kinetics of NO generation by Ddn 
The Griess assay has been employed previously to study the in vitro release of reactive nitrogen 
intermediates produced from the Ddn-catalyzed PA-824 reaction (Singh et al., 2008). In this 
assay, a two-step diazotization reaction under acidic conditions results in the formation of an azo-
complex which can be monitored spectrophotometrically. Although a reliable end point assay for 
Ddn as reported, its low sensitivity (~ 1 µM) is of concern in the study of enzyme kinetics. In 
order to overcome this issue, an NO analyzer with a sensitivity of ~1 nM (1000-fold better) was 
employed to study in vitro Ddn kinetics and therefore an assay based on chemiluminescence 
detection was established. Steady state kinetics of Ddn with PA-824 and F420H2 in presence of the 
saturating concentrations of either substrate was investigated by monitoring NO generation 
(Figure 3.8A, B). The Km, app for PA-824 was 8 μM and for F420H2 was 22 μM with a kcat/Km, app 




. As expected, des-nitro PA-824 and (R)-PA-824 were not substrates for 
Ddn (Singh et al., 2008) and therefore did not show NO release (Figure 3.8A).   
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Figure 3.8 Monitoring Ddn kinetics using NO Analyzer.  
(A) Michaelis-Menten plots of reaction of PA-824, des-nitro PA-824 and (R)-PA-824 with 1 μM 
Ddn at 100 μM F420H2 (inset shows time-course NO release profiles at varying PA-824 
concentrations). (B) Michaelis-Menten plot of reaction of F420H2 with 1 μM Ddn at 50 μM PA-824. 
Each value represents the means ± standard deviations of initial velocity of formation of oxidized 





3.7.5 Ddn: Structural and Mutational studies 
These studies were carried out in collaboration with GNF, San Diego, USA and NIH, Bethesda, 
USA. Ddn could be expressed as a full-length soluble protein in E. coli only as an MBP fusion 
form (Kim et al., 2009a;Singh et al., 2008). Albeit being highly aggregated as determined by 
size-exclusion chromatography (data not shown), the MBP-fusion protein activates PA-824 in 
vitro. Nevertheless, the full-length aggregate was not able to produce crystals good enough for 
structure determination. Deletion of 30-40 residues from the N-terminus produced non-
aggregated monomeric protein that demonstrated tight binding of the cofactor, suggesting a 
physiologically relevant form (Cellitti et al., 2012). However, none of the N-terminally truncated 
soluble constructs were catalytically competent as assessed by monitoring oxidation of F420 in the 
presence of PA-824 (Figure 3.9B) suggesting that the N-terminus is important for substrate 
binding or catalysis. The N-terminus of Ddn is predicted to contain an amphipathic α-helix at 
residues 13 to 28 with a highly hydrophobic side that may be causing aggregation of full-length 
Ddn; while a series of mutants designed to disrupt this hydrophobic surface resulted in soluble 
monomeric protein, none of the mutant monomeric full-length proteins showed activity toward 
PA-824 (Cellitti et al., 2012).  
In total four structures of Ddn (N-terminal truncation mutants) were determined; two of the apo 
protein (NΔ30, NΔ33) and two of the holo protein (NΔ40) that was bound to cofactor F420 
(Cellitti et al., 2012).  As expected (Manjunatha et al., 2006b;Taylor et al., 2010), the backbone 
trace showed high similarity to proteins in the split barrel-like family of flavin binding proteins 
(Cellitti et al., 2012). The data from both holo crystals yielded clear difference electron density 
for F420 with two distinct tail glutamate residues.  Although the F420 preparation (from M. 
smegmatis) included larger poly-glutamate tail species, only two glutamates could be visualized 
(F420-2), consistent with the structure of FGD1 crystallized with a similar preparation (Bashiri et 
al., 2008).  Nevertheless, unlike in the case of FGD1, the Re-face of F420 is presented for reaction 
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with PA-824 in the case of Ddn (Cellitti et al., 2012). In order to confirm the binding pocket of 
F420 proposed by the crystal structures, mutation studies were carried out to determine F420 
binding residues. Mutations in Y133, Y65, A76 and K79, all of which are likely to play a role in 
stabilizing the F420 complex, uniformly resulted in loss of enzymatic activity (Cellitti et al., 2012). 
Furthermore, in an attempt to understand the structure of the full length Ddn protein including its 
N-terminus that is critical for catalysis, several Ddn homologues were expressed and purified; 
these proteins were tested for activity and put into crystallization trials to determine protein 
structures that could add to understanding the full-length Ddn enzyme for which only the core 
structure could be determined. A homologue from Nocardia farcinica,  nfa33440, sharing 42% 
sequence identity to Ddn (Figure 3.9A) and that was active in the PA-824 in vitro assay (Figure 
3.9B) was structurally characterized and the full-length structure of a second, inactive 
homologue, nfa18080 from the same organism was solved in the presence of F420 (Cellitti et al., 
2012).  The homologue structures were informative and provided insight into possible orientation 
of some conserved N-terminal residues in relation to the active site.  However, because low levels 
of sequence identity (Figure 3.9A; ~ 20% identity to Ddn residues 1-30) and potential flexibility 
of the N-terminal helix, these structures did not provide a reliable model for the N-terminus of 
































nfa18080    (1) --MPLTGEYEPSPSDWARKQVETYE------NSGGTEGTTLQGKPVVVLTTKGAKTGKLRKTPLMRVEHNGEYAVVA
nfa33440 (1) MRMSSTGEYVPSPSEWIGNQVAQYE------ASDGAEAGEFDGRPLVILTTVGRKTGALRKTPVMRVEHDGRYAVVA
Ddn (Rv3547) (1) MPKSPPRFLNSPLSDFFIKWMSRINTWMYRRNDGEGLGGTFQKIPVALLTTTGRKTGQPRVNPLYFLRDGGRVIVAA
Consensus    (1) M MS TGEY PSPSDW  KQVA YE      NSGGAEGGTFQGKPVVILTT GRKTG LRKTPLMRVEH GRYAVVA
78                                                                       153
nfa18080   (70) SLGGAPKHPVWYHNIKAEPHVELRDGTEVGDYTAREVTGEEKRVWWERAVEVWPDYAEYQTKTTREIPVFVLTPR-
nfa33440 (72) SQGGAPTHPAWYFNLVADPRAQLRDKDAVLSVVARELAGPERAEWWERAVRAYPTYQEYQDNTRRLIPVLLLEPGR
Ddn (Rv3547)   (78) SKGGAEKNPMWYLNLKANPKVQVQIKKEVLDLTARDATDEERAEYWPQLVTMYPSYQDYQSWTDRTIPIVVCEP--
Consensus   (78) S GGAPKHPMWY NLKADPKVQLRDK EVLDLTARELTGEERAEWWERAV MYPSYQEYQS T R IPVLVLEP  
B
 
Figure 3.9 Activity of Ddn constructs and homologues 
(A) Multiple Sequence Alignment of Nocardia farcinica homologues to Mtb Ddn  
(B)The activities of several N-terminal deletion constructs of Ddn measured by an increase in F420 
specific fluorescence. Homologous proteins from N. farcinica for which structures were 
determined were also tested for activity. 
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3.7.6 Ddn binding with PA-824 and F420 by fluorescence quenching 
Binding affinity of the substrates, PA-824 and F420, to Ddn was monitored through intrinsic 
fluorescence quenching of the protein facilitating an enzymatic turnover-independent assessment 
of affinity. Fluorescence emission spectra of 1 μM Ddn in the presence of increasing 
concentrations of PA-824 revealed that PA-824 efficiently quenched a significant fraction of the 
intrinsic fluorescence of this protein upon binding (Figure 3.10A). Ddn contains five Trp residues 
(positions 20, 27, 88, 123 and 139). In contrast to the full length protein, the N∆30 Ddn construct 
showed negligible intrinsic fluorescence suggesting that residues W20 and W27 are largely 
responsible for the observed signal (Figure 3.13B). Furthermore, docking studies (to be 
elaborated in the following section, Figure3.13A) indicated that W20 could be a critical residue 
involved in binding the hydrophobic tail of PA-824 highlighting that affinity studies based on 
fluorescence quenching of the full length protein may prove an apt way to evaluate binding 
changes to the protein. The extent of ligand binding to Ddn was determined by monitoring 
changes in maximal fluorescence emission at 334 nm. At saturating concentrations of PA-824, 
69.6% of the intrinsic Ddn fluorescence was quenched with no significant change in the 
maximum emission wavelength. To further explore the role of stereochemistry in determining 
substrate binding, the inactive (R)-PA-824 was also explored in this assay, which was incapable 
of turnover by Ddn. Surprisingly (R)-PA-824 was able to bind to the enzyme causing a reduction 
in intrinsic fluorescence by 78% at saturating concentrations (Figure 3.10B). However, under 
similar conditions, des-nitro PA-824 failed to bind Ddn (Figure 3.10C). The relative change in 
intrinsic fluorescence 1-F/Fo was plotted against the ligand concentration to generate saturation 
isotherms (Figure 3.10D). In the absence of F420H2, Ddn was able to bind PA-824 and (R)-PA-824 
































































PA-824 des-nitro PA-824 (R)-PA-824
PA-824 Kd: 13.95  3.47 M









































Figure 3.10 Binding of nitroimidazole substrates to Ddn evaluated by intrinsic tryptophan 
fluorescence quenching studies. 
Emission spectra in relative fluorescence units (RFUs) of 1 μM of Ddn protein (excitation at 
280nm) in the presence of increasing concentrations of (A) PA-824, (B) R-PA-824, (C) des-nitro 
PA-824. Arrows indicate quenching of fluorescence signal at the wavelength of maximum 
emission with increasing concentrations of ligand. Emission spectra of NΔ30 construct of Ddn 
(excitation at 280 nm) in the absence of any ligand is also included in (A).  
(D) Saturation isotherms for Ddn binding to the substrates. Kd values are indicated in the graphs. 
The experiments were carried-out at least three independent times and one such representative 
profile is shown.  
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Binding to the oxidized or reduced F420 was evaluated in a similar manner (Figure 3.11A, B). Ddn 
displayed extremely tight binding to oxidized F420 with Kd of 0.30 μM in contrast to the reduced 
form that showed a Kd of 3 μM (Figure 3.11D). Moreover, binding of F420-2 purified from 
Methanobacterium thermoautotrophicum to Ddn, as monitored by the same method, was 
comparable to that of F420-5 from M. smegmatis suggesting that the extended polyglutamate tail 



































































   F420 Kd : 0.31  0.12 M







































Figure 3.11 Binding of F420 to Ddn evaluated by intrinsic tryptophan fluorescence quenching 
studies. 
Emission spectra, in relative fluorescence units (RFUs) of 1 μM of Ddn protein (excitation at 280 
nm) in the presence of increasing concentrations of (A) F420 from M.smegmatis (B) F420H2 
(reduced F420 from M. smegmatis) (C) F420-2 from Methanobacterium thermoauotrophicum. 
Arrows indicate quenching of fluorescence signal at the wavelength of maximum emission with 
increasing concentrations of ligand. (D) Saturation isotherms for Ddn binding to the cofactors. Kd 
values are indicated in the graphs. The experiments were carried-out at least three independent 




In order to obtain further understanding of how the inactive (R)-form of PA-824 still bound to 
Ddn despite lack of turnover, potential binding modes of both forms to the co-crystal structures 
with F420 were examined (Cellitti et al., 2012). Since the full length Ddn protein structure was not 
solved, high resolution co-crystal structure of F420 with the active homologue from Nocardia as 
well as information from mutagenesis studies were used to support a structural model of the 
active site. This model was used to manually dock both isomers of PA-824 to arrive at putative 
binding modes. In both cases, a water molecule H-bonded to Ser72 was used as a docking point 
for the nitro group. Figure 3.12A depicts that the C-3 of the nitroimidazole of the (S) isomer is 
directly positioned above the C-5 of F420H2 (shown by asterisk in Figure 2.1C), and this allows a 
favorable hydride transfer from the C-5 of F420H2. However, the C-3 of the (R) isomer docked in a 
flipped orientation (Figure 3.12B) and is skewed away from the C-5 of F420H2 and this makes the 
hydride transfer very unlikely.  In both cases, the aromatic tail portion is aligned well with Trp16 
for aromatic-aromatic interactions that is consistent with the fluorescence quenching experiments. 
While not conclusive, this docking provides a plausible explanation for the observed stereo-
selectivity of the (S) isomer of PA-824 over the (R) isomer by Ddn as well as their comparable 



























Figure 3.12 Proposed docking modes of (S) and (R) isomers of PA-824.  
Binding modes of (A) catalytically active (S)-PA-824 and (B) catalytically inactive (R)-PA-824 to 
F420 bound Nocardia Ddn homolog, nfa33440 (Top panels). The respective bottom panels show 
the orientation of the geometry optimized enantiomers (in yellow) docked into the active site of 
a Nocardia Ddn homolog complexed with F420 with a few important residues in the binding 
pocket labeled. Bottom panel, (A) One of the oxygen atoms of NO2 of (S)-PA-824 was placed onto 
the crystal water molecule to H-bond with Ser72 of the Nocardia homologue. In this orientation, 
the C-3 of the imidazole is 4.1 Å away from the C-5 of F420, and also properly positioned for the 
incoming hydride transfer in terms of the angle of C-5-(H)-C-3;   note that the hydride (H) of C-5 is 
not seen in the X-ray structure.  Atoms represented by colors are as follows: green, carbon; blue, 
nitrogen; red, oxygen. Bottom panel, (B) The enantiomer, (R)-PA-824 was docked in a flipped 
orientation resulting in the C-3 of the imidazole at a distance of 4.3 Å away from the C-5 of F420 




3.7.7 Mutagenesis and characterization of the N-terminus of Ddn 
The loss of PA-824 activity in all truncated constructs of Ddn suggested the importance of the N-
terminus. Since the structure of a ternary complex of either Ddn or a homologue with F420 and 
PA-824 were not determined, modeling was used to visualize PA-824 binding to Ddn (Cellitti et 
al., 2012). The imidazole group of PA-824 was placed at an appropriate distance from the C-5 of 
the deazaflavin ring for hydride transfer (based on observations of other flavin-binding proteins 
(Fraaije and Mattevi, 2000)). In the lowest energy model, the nitroimidazole group of PA-824 
was located near the Re face of F420 and the nitro group of PA-824 was H-bonded with the side-
chains of S78, Y130 and Y136 (Figure 3.13A, (Cellitti et al., 2012)); mutations in each of these 
residues resulted in the loss of enzyme activity supporting the accuracy of the model (Cellitti et 
al., 2012). The proposed binding mode of PA-824 orients the hydrophobic tail toward the 
expected location of the N-terminus of Ddn.  Analogues of PA-824 clearly show a preference for 
monoaryl or biaryl tails (Kim et al., 2009b) (Palmer et al., 2010) and suggest the possibility that 
hydrophobic aromatic residues within the N-terminus play a critical role in substrate binding. In 
addition, results obtained in this research work with the nitroimidazooxazoles further validated 
this possibility. Ddn F16, F17, and W20 point mutants were used to test this hypothesis (Cellitti 
et al., 2012).  Single mutations F16L, F16V, or F16A reduced activity of the enzyme toward PA-
824 by 60% while mutations of F17 or W20 resulted in more variable effects, with loss of 15-
50% of activity as measured in terms of kcat/Km (Cellitti et al., 2012).  Because the apparent 
flexibility of this region of the protein might allow PA-824 to interact with more than one of these 
residues, double and triple mutations were studied.  The F16A/F17A mutant still possessed 40% 
of the activity of the WT enzyme (Cellitti et al., 2012), but the triple mutant, F16A/F17A/W20A, 
had only about 13% activity (Figure 3.13D).  Analysis of PA-824 and F420 binding by 
fluorescence spectroscopy showed that both the W20 single mutants and the triple mutant have 
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decreased affinity to PA-824, while additional loss of activity in the triple mutant is likely due to 


























Kd F420  
(μM)
Relative kcat/Km
Ddn WT 31.02 ± 5.56 0.9829 ± 0.2023 100
W20A 99.89 ± 39.90 5.157 ± 2.536 80
W20F 161.6 ± 88.78 1.601 ± 0.7685 87





Figure 3.13 Binding of PA-824 to Ddn and its mutants. 
(A) Putative binding mode of PA-824 Source: Cellitti et al. (2012) Structure 20. Schematic 
showing residues implicated in PA-824 bindng and catalysis. F16, F17 and W20 were not present 
in the Ddn X-ray crystal structures – these residues are included based on mutation data, in order 
to depict their potential interactions with the hydrophobic tail group of PA-824. (B) Titration of 
PA-824 in saturation binding analyis with MBP fusion of Ddn WT and mutants monitored at 330 
nm. The magnitude of fluorescence differences (1-F/Fo) was used for Kd calculation. (C) Values 
determined for MBP-Ddn mutants. Asterisks indicate the triple mutant which, even at saturating 
concentration of PA-824, showed less than 40% quenching. 
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3.8 Discussion  
 
The possibility of emergence of drug resistance warrants further study and optimization of second 
generation nitroimidazoles as anti-tuberculars (Kim et al., 2009b;Kim et al., 2009a;Kmentova et 
al., 2010;Palmer et al., 2010). The kinetic properties of analogs of this class as substrates for Ddn 
are important determinants of their activity against the whole organism. Therefore a more detailed 
biochemical and structural characterization of the activating mechanism and enzyme is important 
to support a deeper understanding of the structure activity relationship (SAR) in this series and to 
guide optimization efforts.  
Ddn enzyme activity was unaffected by the inclusion of monovalent or divalent cations. Also, the 
lack of any effect upon addition of a metal chelating reagent EDTA suggests that the enzyme 
activity is metal ion independent. Ddn is a 151 amino acid protein with only one cysteine residue 
at position 149 (Figure 3.5), implying that only intermolecular disulphide bonds may exist, if at 
all. DTT, up to 2 mM, had no effect on the activity of Ddn suggesting the lack of any structurally 
or functionally important intermolecular disulphide bonds. Addition of Triton X-100 improved 
the enzyme activity significantly; the presence of a surfactant possibly stabilizes Ddn, therefore 
contributing to improvement in activity. 
Consistent with the F420 bound crystal structure of the core enzyme lacking the N-terminus 
(Cellitti et al., 2012), Ddn was highly specific to F420H2 and was not able to utilize several other 
cofactors which exhibit similar reduction potentials (nicotinamide based cofactors) or resemble 
F420 structurally (flavins) (Eirich et al., 1978). Ddn could utilize reduced F420-2 as efficiently as 
the reduced F420-5 from M. smegmatis. Therefore, although the polyglutamate chain of F420 seems 
to be important for Ddn activity, the number of glutamate residues (ranging from 2-6) did not 
seem to contribute to nitroimidazole conversion.  
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Ddn was able to metabolize neither the (R) stereo-isomer nor the des-nitro derivative of PA-824. 
Tryptophan quenching studies indicated that Ddn was able to bind PA-824 and (R)-PA-824 with 
similar affinity. These results demonstrate that the physical binding of Ddn to PA-824 is not 
affected by the stereochemistry of the compound; however, the complete loss of activity of the 
enzyme with the (R) stereoisomer suggest that (R)-PA-824 may bind to Ddn non-productively 
and interfere with the catalysis of the enzyme likely due to the incorrect positioning of C-3 of the 
nitroimidazole ring to C-5 of the F420H2 from which the hydride transfer takes place. Molecular 
docking studies of (R)-PA-824 with active Ddn homologue strengthen this hypothesis (Figure 
3.12). Although there is some preliminary evidence that (R)-PA-824 is a competitive inhibitor of 
Ddn mediated reduction of (S)-PA-824 (data not shown), the very poor solubility of this 
compound precluded full characterization of the inhibition. These results suggest, however, that 
clinical development of a racemic mixture would not be advisable. The des-nitro derivative 
showed negligible binding to Ddn supporting the lack of enzyme activity with des-nitro PA-824 
as a substrate, suggesting a critical role for the nitro group in binding. Binding studies of Ddn 
with the F420 indicated higher affinity for F420 (Kd 0.3 μM) than F420H2 (Kd 3 μM). This binding of 
oxidized F420 in the active site could prevent the entry of a reduced F420 into the active site 
possibly explaining the low turn-over of the enzyme. However, the low binding constant for the 
product might change in presence of the nitroimidazole substrate which requires further 
investigation. 
The structure of the Ddn protein core with coenzyme F420 bound confirms that this protein adopts 
a split barrel-like fold common among flavin-binding proteins while the N-terminus appears to 
mediate aggregation that prevented study of the full-length WT protein.  The co-structures of Ddn 
and its homologues with the cofactor are the first examples of F420 bound to this protein fold 
(Cellitti et al., 2012).  Interestingly, all other F420-dependent enzymes studied so far, including 
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FGD1, catalyze reactions at the Si-face of F420 (Aufhammer et al., 2005;Aufhammer et al., 
2004;Bashiri et al., 2008;Ceh et al., 2009;Klein et al., 1996;Warkentin et al., 2001;Johnson and 
Mukhopadhyay, 2005).  The binding orientation of this cofactor to Ddn, however, is similar to 
that seen in split barrel-like FMN-binding proteins (Suto et al., 2000), aligning the Re-face of the 
flavins towards the substrate and implying a possible shared evolutionary origin of Ddn proteins 
with conventional flavoproteins.  This binding mode was supported by the loss of activity of 
mutants of Y133, Y65, A76 and K79; residues thought to anchor the cofactor based on the 
structure (Cellitti et al., 2012). 
Details of cofactor binding and subsequent mutagenesis experiments identified key residues for 
substrate binding and positioning in the active site. The loss of activity toward PA-824 upon N-
terminal truncation of Ddn implies that the N-terminus is important for full enzymatic function.  
The variability of the N-termini among homologous proteins of the same protein fold also 
suggests a role in the specificity of cellular functions.  NMR observations (Cellitti et al., 2012) 
and the fact that a defined structure for the N-terminus is only observed in crystals of Ddn 
homologues with F420 present support the assignment of the N-terminus as a flexible helix near 
the active site.  The proposed substrate orientation places the hydrophobic tail region of PA-824 
towards the area occupied N-terminus of Ddn which is likely to contribute to substrate affinity as 
well as solvent exclusion.  Extensive mutagenesis studies of the N-terminus of the full-length 
protein verified that while removing F16, F17 or W20 did impair the enzyme; mutation of all 
three residues in combination was required to eliminate the majority of enzymatic activity 
(Cellitti et al., 2012).  A flexible N-terminus that can interact with the pro-drug using any of these 
three aromatic residues is consistent with the previous synthetic work and quantitative structure-
activity relationship (3D QSAR) modeling using PA-824 and its analogues that have suggested 
that the tail region of these molecules interacts with one or two hydrophobic aromatic features in 
Ddn (Kim et al., 2009b;Kim et al., 2009a;Palmer et al., 2010). The importance of these 
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interactions is further supported by observations presented here of the effect of stereochemistry of 
the hydrophobic tail of analogs such as CGI-17341 and phenyl-oxazoles with Ddn.  
A binding mode for PA-824 that involves anchoring the nitroimidazole head group near S78, with 
Y130 and Y136 participating to position the substrate for reduction has been postulated (Figure 
3.13A, (Cellitti et al., 2012)). The identification of these residues and the lack of classic catalytic 
residues in the active site suggest that Ddn functions primarily by precisely orienting PA-824 for 
efficient direct hydride transfer from F420 and potentially through additional transition state 
stabilization.  Similar mechanisms in which the protein does not directly participate in hydride 
transfer have been suggested for both an F420-utilizing enzyme (Ceh et al., 2009) and an FMN-
associated enzyme of the split barrel-like fold family (Di Salvo et al., 2003) for which ternary 
donor/acceptor/protein structures are available.  This mechanism is also consistent with previous 
studies of the products of PA-824 reduction that suggested a hydride transfer from F420 to the 
imidazole ring of PA-824 (Singh et al., 2008). 
The F420H2 dependent reduction of PA-824 by Ddn produces three stable metabolites. As 
proposed earlier (Singh et al., 2008), the first hydride transfer from the C-5 of F420H2 to the C-3 
of PA-824 results in a nitronic acid intermediate of PA-824 from which all of the three 
metabolites arise. The des-nitro derivative of PA-824 (a major metabolite) is formed by 
elimination reaction with the release of nitrous acid, which in turn disproportionates to release 
NO and other reactive nitrogen species. Further chemical transformations and F420H2 mediated 
reduction result in the formation of exocyclic ketone and exocyclic imine. The chemistry 
involving reduction of C=C bond by F420H2 through the formation of Meisenheimer complex is 
well precedented in enzymes of the bacterial old yellow enzyme  (OYE) family involved in 
bioremediation of 2,4,6-trinitrotoluene and at least one of these enzymes has been shown to be 
F420 dependent (Toogood et al., 2010;Ju and Parales, 2010). The deazaflavin cofactor F420 is 
unique in that under normal conditions it is an obligate two electron or hydride ion donor (Walsh, 
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1986). However, the precise role of the low redox potential of the 5-deaza-cofactor (F420H2) in the 
mechanism of bicyclic nitroimidazole reduction is yet to be understood. 
A highly sensitive and robust method for examining in vitro Ddn enzyme kinetics based on NO 
detection using an NO analyzer has been described here. The anaerobicidal activity of bicyclic 4-
nitroimidazoles correlated with the formation of des-nitro species and release of reactive nitrogen 
intermediates (Singh et al., 2008). Although the two nitroimidazole clinical candidates for TB in 
phase II trials, PA-824 and OPC-67683, have modest anaerobic activity, they have been 
optimized only for aerobic whole cell activity. An assay that determines the release of NO will 
therefore facilitate target-based selection of PA-824 analogs that have improved anaerobic 




 which is 10 
times lower than what is observed in F420 oxidation assay. The efficiency of NO generation or 
detection seems to be reduced possibly due to quenching of NO in solution under the conditions 
tested or the non-enzymatic reaction between NO and F420H2 (Purwantini and Mukhopadhyay, 
2009). Consequently the utility of this assay needs to be reconfirmed after careful analysis of 
detection of various reactive nitrogen intermediates and reaction conditions. However, in the 
presence of saturating concentrations of F420H2 (100 μM) and with 4 μM PA-824, 1.12 μM NO 
was produced in 2 hours along with 7.2 μM of oxidized F420 (implying 155 nM of NO produced 
per μM F420 oxidized); in Mtb cells, release of micromolar concentrations of intracellular NO by 
Ddn would have a significant effect on cell viability.  
The physiological role of Ddn is currently unknown. Sequence homologs primarily exist in 
actinobacteria; however, there is little information on their potential cellular functions. Ddn was 
first experimentally detected in a study that identified membrane proteins in Mtb suggesting that 
Ddn might be a membrane associated protein (Sinha et al., 2005). Rv1261c, Rv1558 and Rv3178 
are the three homologs of Ddn in Mtb that have other orthologues in other mycobacterial species. 
Ddn and its homologs form a class of previously uncharacterized F420H2 dependent 
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nitroreductases with no identified physiological substrate. A recent bioinformatics study that 
carried out phylogenetic profiling of 1451 bacterial and archaeal genomes based on F420 
biosynthesis nominated three dominant families, one of which was the Ddn family (Selengut and 
Haft, 2010). The study indicates that the Ddn family is restricted to F420 producing bacteria. 
Another study that identified F420H2 dependent reductases in the degradation of aflatoxins showed 
that a Ddn homolog in M. smegmatis, Msmeg_5998, utilized F420H2 in the reduction of the 
unsaturated ester moiety of aflatoxins, thereby activating them for spontaneous hydrolysis (Taylor 
et al., 2010;Graham, 2010). Both the degradation of aflatoxin and reduction of PA-824 by Ddn 
seem to share a common mechanism in which hydride is transferred from the low redox-potential 
deazaflavin to the electron deficient ring systems of the substrates. The apo-structure of a 
distantly related protein, Msmeg_3356, an F420-dependent aflatoxin reductase from M. smegmatis 
that was reported in the same study (Taylor et al., 2010) aligns well to the Ddn core (rmsd is 1.3 
Å over 109 aligned Cα atoms to Holo-1) and contains an N-terminal helix similar to the 
homologue structures in our study.  Although the physiological functions of these proteins are 
currently unknown, F420-dependent redox biochemistry appears to be widespread in 
Actinobacteria, and therefore may be important for many pathogenic species. 
The structural characterization of Ddn, its biochemistry described here with PA-824 and other 
analogs, and the methods developed will prove useful in future attempts to characterize additional 
members of the Ddn enzyme family. Ddn is likely to be only one of a class of enzymes that is 
important for activation of nitroimidazole pro-drugs, and a more detailed understanding of the 
mechanisms of activation and specificity of these enzymes are certain to be important for 
developing not just PA-824 but other candidates in the anti-TB drug portfolio.  Knockout of F420 
biosynthesis or of FGD1, but not of Ddn, resulted in resistance to CGI-17341, a nitroimidazo-
oxazole (Manjunatha et al., 2006b).  However, this preference of Ddn for PA-824-like 
nitroimidazo-oxazines may not be complete as the ddn gene is also reported to be disrupted in an 
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OPC-67683 (nitroimidazo-oxazole) resistant strain (Matsumoto et al., 2006). Results from our 
study point out that it is infact the lipophilic tail of nitroimidazole substrates determines reduction 
selectivity and efficiency.  Recent SAR modeling also suggests that 4-nitro and 5-nitro 
compounds have different targets (Kim et al., 2009a).  While these data suggest that developing 
nitroimidazole compounds will be a complex process, the success of metronidazole and others in 
this class should be encouraging for the current candidates (Barry et al., 2004).  Since Ddn 
appears to be capable of rigorous structure-based specificity, characterizing this protein for its 
binding to the various nitroimidazole analogs will certainly prove to be beneficial to optimize a 
backup clinical candidate for PA-824. 
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4 Evaluation of the physiological role of 
cofactor F420 in Mtb pathogenesis 
 
 
F420 is a low redox potential (-360 mV), soluble 7, 8-didemethyl-8-hydroxy-5-deazariboflavin 
with a ribosyl-phospholactyl moiety and polyglutamate chain (Jacobson and Walsh, 1984) 
(Walsh, 1986). The cofactor derives its name from its intrinsic absorption at 420 nm, contributed 
by FO, the cofactor’s deazaflavin catalytic subunit. F420 is characteristic of methanogenic bacteria 
where it is involved in anaerobic respiration and energy metabolism. In other non-methanogenic 
archaea and in some actinobacteria, F420 dependent enzymes are involved in various other 
processes such as oxygen detoxification, sulfite reduction, antibiotic synthesis and DNA repair 
(Seedorf et al., 2004). A variety of mycobacterial species, including M. leprae whose genome has 
undergone reductive evolution (Cole et al., 2001a), contain F420 and a unique F420 dependent 
G6PD, FGD1 (Purwantini and Daniels, 1996a;Purwantini and Daniels, 1998). This suggests that 
F420 is important in some way to mycobacteria, including when it is involved in an actual 
infection. FGD1 catalyzes the oxidation of glucose 6-phosphate to phosphogluconolactone and in 
turn reduces F420 to F420H2. Interest in F420 in Mtb was accelerated after its incidental involvement 
in the activation of bicyclic 4-nitroimidazoles such as PA-824 and OPC-67683 that are currently 
in a phase II clinical development (Mukherjee and Boshoff, 2011).  F420H2 is utilized by a 
deazaflavin dependent nitroreductase (Ddn), a 151 amino acid protein encoded by Rv3547, in the 





4.1 Cofactors and drug targets 
A fundamental role of proteins is to act as enzyme-catalysts that increase the rate of chemical 
reactions within cells. Enzymes, in addition to binding to their substrates, bind to other small 
molecules called ‘cofactors’ that participate in and are essential for enzyme catalysis. Cofactors 
can either be inorganic entities such as heme, iron-sulfur clusters, metal ions such as iron, 
molybdenum, zinc etc. or small organic non-protein molecules such as the nicotinamides - NAD 
and NADP, flavins - FAD and FMN, biotin, coenzyme A and so on. Most of these cofactors are 
found in a huge variety of species, and some are universal to all forms of life. An exception to 
this wide distribution is a group of unique cofactors that evolved in methanogens, which are 
restricted to this group of archaea (Cheeseman et al., 1972). Owing to their critical role in several 
important enzymatic functions, inhibition of cofactor synthesis impacts an array of metabolic 
pathways making biosynthetic pathways of cofactors attractive drug target candidates (Begley, 
2006;Mack and Grill, 2006;Mdluli and Spigelman, 2006). Several efforts in TB drug 
development have involved cofactor biosynthetic pathway components as targets: NAD (Boshoff 
et al., 2008), pantothenate (Sambandamurthy et al., 2002), folates (Huovinen et al., 1995) and 
biotin (Dey et al., 2010). Folate derivatives are cofactors utilized in the biosynthesis of essential 
molecules including purines, pyrimidines, and amino acids. While bacteria synthesize folate de 
novo, mammals must assimilate preformed folate derivatives through an active transport system 
(Mdluli and Spigelman, 2006). Dihydrofolate reductase, which catalyses the reduction of 
dihydrofolate to tetrahydrofolate, a key enzyme in folate utilization whose inhibition may affect 
the growth of Mtb (Gerum et al., 2002), and dehydropteroate synthase are validated targets of the 
widely used antibacterial sulfonamide, trimethoprim (Huovinen et al., 1995). Two enzymes 
involved in the de novo biosynthesis of NAD that affects the NADH/NAD
+
 ratio upon which Mtb 
is dependent, have been studied as possible drug targets. Genomic analysis studies have 
suggested that the riboflavin biosynthesis pathway is essential in Mtb (Morgunova et al., 2005) 
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and the lumazine synthase pathway has been validated as a target for anti-TB drug discovery. 
Apart from these ubiquitous cofactors, Mtb also synthesizes a unique deazaflavin cofactor called 
F420 that has limited distribution among euryarchaea, halobacteria (Lin and White, 1986), some 
cyanobacteria (Eker et al., 1990) and in Gram-positive bacteria with high G+C content (Bair et 
al., 2001b). 
4.2 Cofactor F420:  Properties, Distribution and functions 
The redox-active cofactor F420 was first isolated and identified chemically from 
Methanobacterium str. M.o.H. based on the oxidized cofactor’s intense absorbance peak at 420 
nm and its blue-green fluorescence (Cheeseman et al., 1972). Prior to this, a compound with 
similar characteristics was described in the mycobacterial species M. smegmatis (COUSINS, 
1960) and in M. phlei as a ‘greenish-yellow coenzyme’ that converts glucose-6-phosphate to 6-
phosphogluconolactone in the presence of a partially purified enzyme mixture (Sutton, 1964). 
While F420 is known to have a wide distribution among archaea (Gorris and Van der Drift, 1994), 
it has a limited distribution among the high G + C gram-positive bacteria (Daniels et al., 1985). 
F420 is named on the basis of its intense absorbance/fluorescence at 420 nm (emission 480 nm), 
which is redox dependent and is lost upon reduction of the cofactor.  
The chromophore of F420 is a 7, 8-didemethyl-8-hydroxy-5-deazariboflavin which is linked to 
ribityl sugar at its N-10 position to form FO (7, 8-didemethyl-8-hydroxy-5-deazariboflavin 
ribitol) (Figure 2.1C). FO is covalently linked to phospholactate through a hydroxyl group on 
ribose sugar to form F420-0. To this structure, glutamate residues are added and mature F420 in 
different organisms differs in the number of glutamate residues. F420 has unique chemical and 
biological characteristics; while structurally the isoalloxazine chromophore of F420 is very similar 
to that of the flavins (FMN and FAD), functionally it is similar to the nicotinamides (NAD(P)). 
F420 is an obligate two–electron carrier involved in hydride transfer reactions (Walsh, 1986) and 
97 
 
the redox potential of F420H2/F420 + 2e
-
 (-360 mV) is lower than those of the classical hydrogen 
carriers NAD(P)H/NAD(P) + 2e
- 
(-320 mV) and FADH2/FAD + 2e
-
 (-219 mV) (Walsh, 1986). 
Therefore, despite its structural resemblance to flavin analogues, chemical and biochemical 
properties of F420 are more similar to nicotinamide cofactors. The reduced form of the cofactor 
(F420H2) is stable, participates in most instances in two-electron transfer reactions and reacts 
rapidly with flavins (Walsh, 1986). 
Unlike other cofactors such as NAD, NADP and flavins, F420 is not ubiquitous and has a unique 
distribution. It is present in some members of three distantly related groups of prokaryotes 
(methanogenic and non-methanogenic archaea, actinobacteria and cyanobacteria) and in some 
eukaryotes. In methanogenic archaea, F420 is required for several steps in the methane 
biosynthesis pathway (Jones et al., 1987). In methanogenic archaea, till date twelve enzymes are 
known to be F420-specific: (1) F420-reducing hydrogenase (Fox et al., 1987;Michel et al., 1995); 
(2) F420-dependent formate dehydrogenase (Schauer and Ferry, 1986); (3) F420-dependent 
methylenetetrahydromethanopterin dehydrogenase (Kunow et al., 1993;Klein and Thauer, 
1995;Hagemeier et al., 2003); (4) F420-dependent methylenetetrahydromethanopterin reductase 
(Kunow et al., 1993;Shima et al., 2000;Shima and Thauer, 2001); (5) F420H2 dehydrogenase 
complex (Kunow et al., 1994a;Kunow et al., 1994b); (6) F420H2: NADP oxidoreductase (Elias et 
al., 2000;Warkentin et al., 2001); (7) F420-dependent secondary alcohol dehydrogenase (Klein et 
al., 1996;Aufhammer et al., 2004); (8) F420-dependent DNA photolyase (Kiener et al., 
1989;Yasui et al., 1988); (9) coenzyme F390 synthetase (Vermeij et al., 1994;Vermeij et al., 
1996);  (10) coenzyme F390 hydrolase (Kengen et al., 1991;Vermeij et al., 1995); (11) F420H2 
oxidase (Seedorf et al., 2004) and (12) sulfite reductase (Johnson and Mukhopadhyay, 
2008;Johnson and Mukhopadhyay, 2005). In non-methanogenic archaea, F420 is found in 
Halobacterium, Thermoplasma, Sulfolobus and Archaeoglobus species (Lin and White, 1986) 
and is involved in quinone oxidoreductase reactions (Jacobson et al., 1982;Hartzell et al., 
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1985;Ma and Thauer, 1990;Kunow et al., 1994a). The cyanobacteria Synechococcus sp. 
(previouslyknown as Anacystis nidulans) and Synechocystis sp., and the green alga Scenedesmus 
acutus use F420 in their photolyase (Eker et al., 1990;Yasui et al., 1988;Ng et al., 2000). 
Among eubacteria, F420 is present in the G+C rich gram positive actinobacteria, to which 
Mycobacterium belongs. In Streptomyces and Mycobacteria, F420 is also involved in the 
biosynthesis of several antibiotics and in nitrophenol biodegradation (Ebert et al., 1999). F420 
and/or its biosynthetic precursor and chromophore FO is used by Streptomyces species for 
synthesis of antibiotics (Ikeno et al., 2006) (Coats et al., 1989) (Mccormick and Morton, 1982) 
such as tetracycline and lincomycin and may be in that of mitomycin C biosynthesis (Mao et al., 
1999).  
4.3 F420 and Mycobacteria 
As mentioned in the previous section, long before the discovery of F420 in methanogens, an 
electron transfer component was reported in M. smegmatis (COUSINS, 1960) and in M. phlei 
(Sutton, 1964) whose description and properties suggest that it is likely to have been F420. 
Following the identification of F420’s presence in M. avium (Naraoka et al., 1984) and Mtb 
(Daniels et al., 1985), efforts were undertaken to evaluate the role of F420 in mycobacteria and its 
distribution among different mycobacterial species or strains. All mycobacterial species examined 
(M. smegmatis, Mtb Ra and Rv, M. avium-M. intracellulare, M. gordonae, M. fortuitum, M. 
kansasii, M. scrofulaceum, and M. leprae) thus far contain detectable levels of F420 (Purwantini 
and Daniels, 1996a). The levels of F420 in Mycobacterium species (0.006 to 0.044 nmol/mg of 
protein) are very similar to the range of F420 levels (0.0015 to 0.05 nmol/mg of protein) found in 
Streptomyces species  but are lower than those found in methanogens (0.2 to 3.4 nmol/mg of 
protein) (Daniels, 1992).  
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In Mycobacterium and Nocardia, F420 is involved in the oxidation of glucoase-6-phosphate by an 
F420-dependent G6PD, FGD1 and is in turn reduced to F420H2 (Purwantini and Daniels, 
1996a;Purwantini et al., 1997). As elaborated in the Chapter 3, FGD1 has shown to be required 
for the activation of the pro-drugs from the bicyclic nitroimidazole class of anti-TB therapeutics. 
For the activation of this nitroimidazole class, both the ability to produce F420 and subsequently 
reduce this deazaflavin with FGD1 is essential. Ddn, the F420H2 dependent nitroreductase 
bioreductively activates this class of compounds releasing reactive nitrogen species in the process 
(Manjunatha et al., 2006b;Singh et al., 2008). However, the physiological role of F420, FGD1 and 
Ddn in Mycobacterium is unknown.  
Mtb is unusual in having four open reading frames annotated as encoding G6P dehydrogenase 
enzymes, two of which require NADPH  as an electron donor (zwf1, zwf2) and two of which are 
F420-dependent (fgd1, fgd2). The two F420-dependent enzymes share 36% sequence identity over 
363 residues, although FGD2 has an additional N-terminal extension. The F420 binding residues 
identified in FGD1 are also present in FGD2, but there are differences in the substrate binding 
site such as the loss of phosphate binding residues Lys198, Lys259, and Arg283 (Bashiri et al., 2008). 
This suggests that whereas both FGD1 and FGD2 could reduce F420, they may use different 
substrates (Bashiri et al., 2008). The reaction catalyzed by FGD1 is equivalent to the first step in 
the pentose phosphate pathway, which normally provides NADPH for reductive biosynthetic 
reactions and maintenance of the cellular redox state. It has been suggested that the maintenance 
of both F420-and NADPH dependent G6PDs in Mtb may be essential for providing the redox 
flexibility that enables the bacterium to switch to the persistent state following phagocytosis 
(Bashiri et al., 2008).  
The gene coding for FGD1 shows homology with F420-dependent N5,N10-methylene-
tetrahydromethanopterin reductase (MER) from methanogenic archaea and with several 
hypothetical proteins from Mtb and Archaeoglobus fulgidus, but not with NADP-dependent 
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G6PDs (Purwantini and Daniels, 1998). Multiple sequence alignment of FGD1 and MER proteins 
revealed four conserved consensus sequences, portions of which were also revealed in alignment 
of FGD1 with the hypothetical proteins (Purwantini and Daniels, 1998).  
Not all F420-containing organisms possess FGD1; so far, the enzyme has been found only in 
Mycobacterium and Nocardia species and in Gordona amarae (Purwantini et al., 1997). FGD1 
has not been described in methanogens, streptomycetes, or any other organism. FGD1 is a unique 
G6PD in that it uses only F420 as an electron acceptor while a variety of bacterial and eukaryotic 
G6PDs use NADP, NAD, or in some cases both nicotinamides as electron acceptors. In addition 
to glucose-6-phosphate, the physiological substrates known to exchange electrons with F420 are 
rather limited in number: NADP (Eker et al., 1989;Kunow et al., 1994b); methenyl-, methylene-, 
and methyltetrahydromethanopterin (Kunow et al., 1993;Ma and Thauer, 1990); H2 (Jacobson et 
al., 1982); formate (Schauer and Ferry, 1982); the coenzyme M-heptanolyl threonine phosphate 
heterodimer (Deppenmeier et al., 1990); some alcohols (Bleicher and Winter, 1991); 
intermediates in the biosynthesis of tetracyclines (McCormick and Morton, 1982) and lincomycin 
(Coats et al., 1989;Kuo et al., 1989); O2 (Seedorf et al., 2004), sulfite reductase (Johnson and 
Mukhopadhyay, 2008;Johnson and Mukhopadhyay, 2005).  
The presence of an NADP-dependent glucose-6-phosphate dehydrogenase in Mtb and M. 
smegmatis crude extracts (Bai et al., 1976;Bai et al., 1975) has previously been reported and 
verified later (Purwantini and Daniels, 1998;Purwantini et al., 1997). The pentose phosphate 
pathway (in which G6PD is a key enzyme) is present in both the mycobacterial species and the 
Entner-Doudoroff pathway (which also uses G6PD) is not present in glycerol-grown Mtb (Bai et 
al., 1975) but functions at low levels in glucose-grown M. smegmatis (Bai et al., 1976). While it 
is still unclear if both the F420 dependent and NADP-dependent G6PDs play a role in these 
pathways, studies suggest that given the likely importance of these biosynthetic and energy-
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generating pathways, it would not be unreasonable to further investigate the F420-dependent 
enzyme as a target for antimycobacterial agents (Purwantini et al., 1997). 
Recently, nine M. smegmatis enzymes have been identified that utilize F420H2 to catalyse the 
reduction of the, β-unsaturated ester moiety of aflatoxins, activating the molecules for 
spontaneous hydrolysis and detoxification (Taylor et al., 2010). These enzymes belong to two 
previously uncharacterized F420H2 dependent reductase (FDR-A and -B) families that are distantly 
related to the flavin mononucleotide (FMN) dependent pyridoxamine 5'-phosphate oxidases 
(PNPOxs) (Di Salvo et al., 2003).  
4.4 Structural characterization of F420 dependent enzymes 
Reduction of the F420 coenzyme is achieved by hydride transfer from a substrate molecule to C5 
of the 5'-deazaflavin (Walsh, 1986). Crystal structures are available for a small number of 
archaeal F420-dependent enzymes, of which the mode of F420 binding has been defined for three 
proteins; secondary alcohol dehydrogenase (Adf), methylene-tetrahydromethanopterin reductase 
(Mer), and F420H2: NADP
+ 
oxidoreductase (Fno) (Aufhammer et al., 2005;Aufhammer et al., 
2004;Warkentin et al., 2001;Warkentin et al., 2005). Adf and Mer belong to the bacterial 
luciferase family of proteins and share a common mode of F420 binding. Sequence similarities 
between the archaeal Mer enzymes and mycobacterial FGD1 (23–28% identity) suggested that 
FGD1 might also belong to this family and exhibit the common binding mode (Purwantini and 
Daniels, 1998). The three-dimensional structure of Mtb FGD1 has been determined with and 
without bound F420 and in the presence of a bound citrate ion, which is shown to be a competitive 
inhibitor of substrate binding (Bashiri et al., 2008). Interestingly, most of the F420-dependent 
enzymes studied so far, including FGD1, catalyze reactions at the Si face of F420 (Bashiri et al., 
2008;Aufhammer et al., 2004;Ceh et al., 2009;Klein et al., 1996;Warkentin et al., 2005).   
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As described in detail in the previous chapter, the co-structures of F420 with Ddn are the first 
examples of F420 bound to a split barrel protein fold (Cellitti et al., 2012). In addition, the binding 
orientation of F420 to Ddn is similar to that seen in split barrel-like FMN-binding proteins (Suto et 
al., 2000), aligning the Re face toward the substrate and implying a possible shared evolutionary 
origin of Ddn proteins with conventional flavoproteins. The apo structures of two M. smegmatis 
proteins which are F420H2-dependent aflatoxin reductases (FDRs) have been reported, of which 
one protein is distantly related to Ddn (Taylor et al., 2010). While the FDRs adopt a split barrel 
protein fold like the PNPOxs, they possess an extended and highly charged F420H2 binding groove 
(Taylor et al., 2010). 
4.5 Biosynthesis of F420  
4.5.1 Structures of F420 in various species 
The structure of cofactor F420 (Figure 2.1C) from Methanobacterium thermoautotrophicum (F420-
2) contains a FO chromophore (7, 8-didemethyl-8-hydroxy-5-deazariboflavin). The side chain 
attached at the N-10 position contains ribityl, phosphate, and lactyl groups in sequence (forming 
F420-0 along with the FO chromophore), terminating with two L-glutamate groups connected with 
a γ-glutamyl linkage (F420-2). FO, a biosynthetic intermediate that lacks the phosphate-to-
glutamate portion of the side chain, is found in cells and media of methanogens and 
actinomycetes (Kuo et al., 1989) (McCormick and Morton 1982). As in the case of 
Methanobacterium thermoautotrophicum, in many other methanogenic bacteria, F420 
predominantly exists with two glutamate residues bound to F420-0 with the γ-peptide bond. 
However, exceptions do exist in the form of F420 present in Methanococcus jannaschii that 
contains three glutamates; two as residues with the γ-peptide bond, which is capped with a third 
α- glutamate arm (Graupner and White, 2003) (Nocek et al., 2007) and Methanosarcina barkeri 
that has F420 with four and five γ-linked glutamate groups (F420-4 and F420-5) (Gorris and Van der 
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Drift, 1994). Studies specifically attributed to determining the structure of Streptomyces 5’-
deazaflavins are limited to FO (Kuo et al., 1989) (McCormick and Morton, 1982). Nevertheless, 
thin-layer electrophoresis of Streptomyces griseus F420 suggests the presence of more than two 
glutamate residues (Eker et al., 1980). Similarly, F420 isolated from Sulfolobus, Thermoplasma, 
and halobacteria is reported to contain two or more glutamate groups (Lin and White, 1986). 
The structures of coenzyme F420 in M. smegmatis, as determined via proton NMR, amino acid 
analysis and HPLC revealed the presence of two major F420 structures that were composed of a 
chromophore identical to that of F420 from Methanobacterium thermoautotrophicum, with a side 
chain of a ribityl residue, a lactyl residue and five or six glutamate groups (F420–5 and F420–6) 
(Bair et al., 2001b). Peptidase treatment studies suggested that the L-glutamate groups in the 
cofactor are linked by γ-glutamyl bonds in the side chain. HPLC analysis indicated that Mtb, M. 
bovis BCG and M. fortuitum have F420–5 and F420–6 as the predominant structures, whereas M. 
avium, unlike the monoglutamate structure proposed earlier (Naraoka et al. 1984), contains F420–
5, F420–6 and F420–7 in significant amounts (Bair et al., 2001b). 
4.5.2 F420 biosynthetic pathway 
The assembly of F420 from 7, 8-didemethyl-8-hydroxy-5-deazariboflavin (FO), lactate, and 
glutamate requires at least six steps which are outlined in Figure 4.1/ Table 4.1. 
14
C labeling 
experiments in Methanobacterium thermoautotrophicum have shown that the deazaflavin ring of 
F420 is synthesized from the riboflavin precursor, pyrimidinedione (Jaenchen et al., 1984;Reuke et 
al., 1992). In methanococcus, condensation of pyrimidinedione with hydroxyphenylpyruvate is 
carried out by two enzymes that are annotated as cofG and cofH. In M. bovis BCG, transposon 
studies using PA-824 as a selective agent that generated mutants that could not synthesize the F420 
precursor FO identified  fbiC as the mycobacterial gene encoding an FO synthase (BCG1236 in 


















































































































































Figure 4.1 The proposed biosynthetic pathway of cofactor F420 in Mtb.  
The reaction catalysed by the product of the fbiC gene is highlighted. 
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Homologues of fbiC are found in all 11 microorganisms that have been fully sequenced and that 
are known to make F420. Four of these, from aerobic actinomycetes, coded for proteins 
homologous over the entire length of the M. bovis FbiC, but in seven microorganisms two 
separate genes were found to code for proteins homologous with either the N-terminal or C-
terminal portions of the M. bovis FbiC. Mtb, M. bovis, M. avium, M. leprae, Nocardia farcinica, 
Streptomyces coelicolor, S. avermatilis, Thermobifida fusca, and Rubrobacter xylanophilus have 
proteins that are homologous over the full length of FbiC. However, in Archaeoglobus fulgidus, 
Methanobacterium thermoautotrophicum, Methanococcus jannaschii, Halobacterium sp., 
Synechocystis sp., and Nostoc sp. all have two polypeptides (located adjacent or non-adjacent) 
that share homology with the N-terminal and C-terminal domains respectively of the FO 
synthases from mycobacterium (Choi et al., 2002). A molecular phylogeny of the paralogous 
cofG and cofH genes is consistent with the genes being vertically inherited within the 
euryarchaeal, cyanobacterial, and actinomycetal lineages. Ancestors of the cyanobacteria and 
actinomycetes must have acquired the two genes, which subsequently fused in actinomycetes.  
 
One of the early steps in the biosynthesis of F420 for the generation of its side-chain requires 
generation of 2-phospho-L-lactate, which is formed by the phosphorylation of L-lactate. In 
Methanococcus janaschii it has been shown that the L-lactate is not derived from pyruvate and is 
instead formed by the NAD
+
 dependent oxidation of L-lactaldehyde by CofA (Grochowski et al., 
2008). The lactaldehyde, in turn, was found to be generated either by the NAD(P)H reduction of 
methylglyoxal or by the aldol cleavage of fuculose-1-phosphate by fuculose-1-phosphate 
aldolase. In mycobacterium, the origin of the L-lactate is currently unknown. The biochemical 
route for the formation of the phosphodiester bond in F420 has been established in 
Methanosarcina thermophila and Methanococcus jannaschii. The first step in the formation of 
this portion of the F420 structure is the GTP-dependent phosphorylation of L-lactate to 2-phospho-
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L-lactate and GDP. The identity of the kinase that is responsible for the formation of 2-phospho-
L-lactate from L-lactate is currently not known in any of the F420 producers. The following step in 
the biosynthesis of F420 involves the coupling of 2-phospho-L-lactate to the chromophore, FO. 
This condensation requires an initial activation of 2-phospho-L-lactate through a pyrophosphate 
linkage to GMP to form lactyl (2)diphospho-(5’)guanosine (LPPG) and pyrophosphate (Graupner 
and White, 2001). In Methanococcus janaschii, a protein (CofC) that has domain similarity with 
other known nucleotidyl transferases such as GTP:adenosylcobinamide-phosphate 
guanylyltransferase (CobY), molybdopterin-guanine dinucleotide biosynthesis protein A (MobA), 
and N-acetylglucosamine-1-phosphate uridyltransferase (GlmU) encodes for this 2-phospho-L-
lactate guanylyltransferase function (Grochowski et al., 2008). A homologue of cofC in M. 
smegmatis was identified as part of a transposon mutagenesis study aimed to identify genes 
involved in the decolorization of triphenylmethane dyes (Guerra-Lopez et al., 2007). The 
transposon mutant disrupted in the M. smegmatis homologue of CofC (MSMEG_2392 in M. 
smegmatis, Rv2983 in Mtb) was unable to produce F420 and had accumulated increased levels of 
FO in comparison to the WT.  
F420-0 is formed from the condensation of lactyl-phosphate (from LPPG) with FO by 2-phospho-
L-lactate transferase (CofD) (Graupner et al., 2002). The transfer of the nonnucleotide portion of 
the LPPG to an acceptor places this reaction among a limited group of similar reactions such as 
those catalyzed by cobalamin synthase (cobS) involved in adenosylcobalamin biosynthesis, DNA 
ligase in the second step of a ligase reaction and CDP-choline:1,2-diacylglycerol phosphocholine 
transferase and CDP ethanolamine:1,2-diacylglycerol phosphoethanolamine transferase 
(Graupner et al., 2002). Similarly, phosphophatidylinositol synthase, glycerophosphate 
phosphatidyltransferase, and phosphotidylserine synthase in yeasts or bacteria catalyze the 
transfer of the 1,2-diacylglycerol phosphate portion of CDP-diacylglycerol to the respective 
107 
 
acceptor (Graupner et al., 2002). All of these enzymes have been grouped into a superfamily on 
the basis of their sequence similarities (Graupner et al., 2002).  
In Methonococcus janaschii, following the formation of F420-0, cofactor biosynthesis proceeds 
through the addition of two γ-linked glutamate residues by CofE, forming F420-2 (Li et al., 
2003a). Prior to fbiC identification, fbiA and fbiB (BCG3290 and BCG3291 in M.bovis BCG, 
Rv3261 andRv3262 in Mtb H37Rv) were identified in M. bovis BCG transposon studies using 
PA-824 as a selective agent (Choi et al., 2001); two mutants that could not make F420-5,6 but 
which made the biosynthesis intermediate FO contained transposons inserted in two adjacent 
genes fbiA and fbiB. Reverse transcription-PCR data demonstrated that fbiA and fbiB constitute an 
operon. It was therefore confirmed that fbiAB genes were involved in biosynthesis of F420 from its 
precursor FO, which encompasses addition of a phospho-lactate group and condensation of 
glutamate on FO (Choi et al., 2001). CofE from Methanococcus janaschii is homologous to FbiB 
(Li et al., 2003a). Therefore FbiA is likely to participate in the conversion of FO to F420-0 while 
FbiB plays a role in the addition of glutamates. This is consistent with the accumulation of an 
intermediate in the M. bovis BCG fbiB mutant and a lack of it in the fbiA mutant. 
 
The previous section discussing the diversity of F420 structures across species highlighted that F420 
present in Methanococcus jannaschii contains three glutamates; two as residues with the γ-
peptide bond, which is capped with a third α- glutamate arm (Graupner and White, 2003;Nocek et 
al., 2007). In Methanococcus janaschii, CofF encodes a γ-F420-2: α-L-glutamate ligase and 
catalyzes the ligation of a final α-linked glutamate residue to the terminal γ-linked glutamate to 
generate F420-3 (Li et al., 2003b). As in glutathione biosynthesis, two unrelated amino acid ligases 





The only enzyme involved in the F420 biosynthetic pathway that is yet to be identified in any of 
the F420 producers is the lactate kinase  (cofB) that potentially converts lactate to phospholactate. 
In mycobacterium, three genes (fbiA, B, C) have so far been identified as components of the F420 
biosynthetic pathway and their functions have been characterized based on genetic studies and 
bioinformatics analyses. T. fusca is the only organism we have found where these three 
functionally related genes (fbiABC) are clustered. It is possible that such an arrangement is seen 
among some other actinomycetes, but in S.coelicolor, and in the mycobacterium species for 
which genome sequences are available; these three genes are not adjacent. Based on evidence in 
literature, the proposed F420 biosynthesis scheme in mycobacteria is described in (Figure 4.1). 
Table 4.1 outlines F420 biosynthetic pathway components in M.janaschii, the organism in which 
most of the studies outlining the cofactor biosynthesis have been carried out. In addition to 
presenting homologues of the M. janaschii genes in Mtb, the table highlights the presence of 
these genes/enzymes in M. leprae highlighting the conservation of such massive biosynthetic 
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4.5.3 F420 isolation and production 
Due to the commercial unavailability of F420, research focused on this cofactor and cofactor 
dependent proteins requires in-house preparation (synthesis or isolation and purification) of F420. 
F420 has been purified from various microorganisms including archaea (Methanobacterium, 
Methanococcus and Methanosarcina species) and actinomycetes (Actinomadura, Actinoplanes, 
Streptomyces, Rhodococcus, Nocardia and Mycobacteria species), with differing yields (Isabelle 
et al., 2002a). F420 purification essentially follows the following steps: precipitation of cellular 
proteins using heat or an organic solvent, followed by separation of F420 from remaining cellular 
components based on its acidic nature (DiMarco et al., 1990) and finally its purification by 
chromatographic procedures such as ion exchange, adsorption, HPLC and gel filtration 
chromatography (Bashiri et al., 2010) (Isabelle et al., 2002b;Eirich et al., 1978). An improved 
chromatography system using rapidly flowing quaternary aminoethyl ion-exchange material and 
Florisil was able to purify F420 more easily than methods that existed previously and resulted in 
the production of 1 to 3 μmol of intracellular F420 per liter of M. smegmatis culture (Isabelle et al., 
2002a). Based on ease of growth and factors such as cost and safety, M. smegmatis has been 
designated as the best source for the cofactor (F420-5, 6) production given that there is no specific 
requirement for the cofactor with a certain number of glutamate residues in its tail portion 
(Isabelle et al., 2002a).  
Recently, Bashiri et al. have shown that an M. smegmatis strain over-expressing the Mtb FGD1 
enzyme could produce higher levels of F420 compared to the WT strain (Bashiri et al., 2010). 
Further, they investigated the effects of over-expression of other proteins known to be involved in 
mycobacterial F420 biosynthesis / metabolism on F420 production and showed that increased levels 
of F420 could be obtained by co–expressing some of these enzymes and manipulating growth 
conditions (Bashiri et al., 2010). With the growing recognition that F420 plays a crucial role in 
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mycobacteria and other organisms, the authors are right in claiming that a readily available source 
of the cofactor will be useful for evaluating its physiological and biochemical functions. 
4.6 F420’s role in Mycobacteria: Clues from Bioinformatics and 
Literature 
Comparative genomics-based investigations and phylogenetic profiling based on F420 biosynthesis 
have nominated several proteins in actinobacteria as candidate F420-dependent enzymes (Selengut 
and Haft, 2010). Of the three dominant families (luciferase-like monooxygenases (LLM), 
pyridoxamine 5'-phosphate oxidases (PPOX), and the deazaflavin-dependent nitroreductases 
(DDN)), the DDN family was determined to be limited to F420-producing species alone. While the 
LLM and PPOX families were observed in F420-producing species as well as species lacking F420, 
they were found particularly in higher numbers in many actinobacterial species including Mtb 
(Selengut and Haft, 2010). Identification of F420-correlated subsequences highlighted  that Mtb 
encodes at least 28 separate F420-dependent enzymes, most of unknown function; this and a 
paucity of FMN dependent proteins in the three dominant families suggest that Mtb  relies heavily 
on cofactor F420 for its redox reactions (Selengut and Haft, 2010). Interestingly, the closely related 
pathogen, M. smegmatis, not only displays a greater number of genes from each of the F420-
utilizing protein families, a much higher proportion of these genes appear to be FMN-dependent 
reinforcing the hypothesis that Mtb  has committed, to a larger extent, to an F420-dominated 
lifestyle for its oxidation needs (Selengut and Haft, 2010). Other than FGD1’s role as an F420 
dependent G6PD, little else is currently known about the biological role of the other enzymes in 
actinobacteria nominated to be F420 dependent. The LLM-family protein Rv2951c however bears 
exception as it has shown to be a key ketoreductase in the biosynthesis of the mycobacterial 
diacyl phthiocerol virulence factors (Onwueme et al., 2005;Simeone et al., 2007) opening up 
possibilities for cofactor F420 dependent reactions in mycobacterial PDIM biosynthesis.  
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F420 or F420 dependent pathway(s) do not seem to be essential for mycobacterial growth and 
survival under normal aerobic 7H9 medium growth conditions (Choi et al., 2002). However, an 
insertional inactivation of fbiC, an essential gene for the synthesis of the deazaflavin 
chromophore or catalytic unit of F420 has been shown to render Mtb hypersusceptible to acidified 
nitrite (Darwin et al., 2003). This in vitro treatment simulates an environment inside the 
phagosomes of an infected-activated macrophage, which produces NO by the action of inducible 
nitric oxide synthase (iNOS or NOS2) (MacMicking et al., 1995). Similarly, the role of F420H2 in 
direct non-enzymatic reduction of nitrogen dioxide (NO2) to NO has also been described 
(Purwantini and Mukhopadhyay, 2009) and mutant strains of M. smegmatis, a non-pathogenic 
relative of Mtb, which either did not produce (fbiC mutant) or could not reduce F420 (fgd mutant), 
were more sensitive to both NO2 generated nitrosative stress (Purwantini and Mukhopadhyay, 
2009) and redox-cycling agents generated oxidative stress (Hasan et al., 2010;Guerra-Lopez et 
al., 2007) than the wild-type strain.  
These observations suggest that the F420-FGD1 system plays an important role in detoxification of 
reactive nitrogen/oxygen intermediates and that mycobacteria could use F420H2 to combat 
nitrosative and oxidative stress generated by the activated macrophages. The following section 
provides a literature review of the various survival strategies adopted by Mtb in its defence 
against host induced stresses. 
4.7 Survival strategies in the phagosome: Mtb’s defence against stress 
The phagosomal defense repertoire of an activated macrophage against a pathogen includes, but 
is not limited to, oxidative and nitrosative stress imposed by reactive oxygen and nitrogen species 
(ROS and RNS) that are generated by the phagosomal enzymes NADPH phagocyte oxidase 
(NOX2) and iNOS. Apart from the ROS and the RNS, a number of other entities such as cationic 
antibacterial peptides, lysozyme, ubiquitin derived peptides and conditions such as acidity have 
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been shown to kill mycobacteria effectively. Upon macrophage activation, mycobacteira no 
longer block phagosome maturation and are therefore exposed to very unfavourable environment 
including the aforementioned products and conditions. NOX2 catalyzes the NADPH dependent 
reduction of phagosomal oxygen to form superoxide anions that dismutate into hydrogen 
peroxide and finally produce toxic hydroxyl radicals (Bedard and Krause, 2007). In monocytes 
and neutrophils, chlorination further adds to the toxicity of ROS. Nitrite ion, generated by iNOS, 
reacts at low pH to form nitrous acid that in turn results in the production of NO and nitrogen 
dioxide, two highly reactive radicals (Nathan and Shiloh, 2000). The two highly reactive 
molecules, NO and superoxide form the toxic peroxynitrite and all the mentioned reactive species 
damage captured microorganisms by modification of their DNA, lipids, thiols, tyrosine side 
chains, and active centers of metal-dependent proteins (Fang et al., 2004).  
To avert toxicity caused by ROS and RNS, Mtb follows a dual strategy of detoxification and 
damage repair (Figure 4.2). Several works have shown the requirement of genes involved in 
detoxification of reactive oxygen and nitrogen intermediates in the virulence of Mtb (Ehrt and 
Schnappinger, 2009a). The mycobacterial enzyme catalase peroxidase encoded by katG converts 
hydrogen peroxide into water and oxygen. Accordingly, a katG loss-of-function Mtb mutant 
showed hypersensitivity to hydrogen peroxide in vitro (Ng et al., 2004). sodA and sodC, both 
encoding a superoxide dismutase (Sassetti and Rubin, 2003), secA2, part of an accessory export 
system (Rigel and Braunstein, 2008), mshA, required for mycothiol biosynthesis (Vilcheze et al., 
2008), cysH, involved in sulfur assimilation (Senaratne et al., 2006), ahpC, ahpD, dalT, lpd, 
encoding the multifunctional NADH-dependent peroxidase and peroxynitrite reductase (Shi and 
Ehrt, 2006;Bryk et al., 2008) are all implicated in the detoxification of various reactive oxygen 
and nitrogen intermediates.  
The second principal strategy to oppose the effects of highly reactive intermediates includes 
repair of the damage caused or degradation of affected biomolecules and their rapid de novo 
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synthesis. The, proteasome-mediated protein turnover is shown to be critical during RNS-related 
stress (Darwin et al., 2003). Mutations in genes coding for proteins associated with proteasome 
function/machinery increased the sensitivity of the Mtb to in vitro generated RNS; disruption of 





mice (Darwin et al., 2003). Conditional silencing of the essential genes prcA 
and prcB, which encode proteolytic core proteins of the proteasome, not only conferred 
sensitivity to RNS but also impaired the survival of Mtb during chronic infection in mice 
(Gandotra et al., 2007).  
Interestingly, mutants that were hypersensitive to in vitro generated RNS revealed mutations in 
the nucleotide excision repair gene uvrB (Darwin et al., 2003) and mice infected with this mutant 
survived longer than those infected with WT Mtb. The significance of DNA repair mechanisms in 
combating host defenses is highlighted by the compromised virulence of an Mtb dnaE2 mutant 
during chronic mouse infection (Boshoff et al., 2003). The protein encoded by this gene, a DNA 
polymerase, is dispensable for growth in vitro but is essential for resistance to UV light. A 
histone-like protein, Lsr2, is thought to shield Mtb chromosomal DNA from ROI-mediated 
damage and is therefore implicated in Mtb virulence based on studies in both M. smegmatis and 
Mtb (Colangeli et al., 2009). Not surprisingly, in the case of Mtb, an interdependency of ROS and 
RNS defence is observed as these resistance mechanisms are likely to have coevolved against 





Figure 4.2 Mycobacterial mechanisms of sensing/countering endogenous and exogenous 
stress 





Mtb survives hostile conditions and has made a host out of human alveolar macrophages, cells 
that contribute to the first line of defense. Partial containment of Mtb infection is accomplished by 
formation of a highly organized, multicellular granuloma within which anti-bacterial properties 
such as acidity, nutrient-starvation, hypoxia, reactive oxygen and nitrogen species contain, but do 
not kill the invading microbe (Via et al., 2008;Barry, III et al., 2009). As discussed in the 
previous sections, several prior studies in M. smegmatis have suggested a role for F420H2 in 
combating both oxidative and nitrosative stress generated by various redox-cycling and NO 
releasing agents. In Mtb, the physiological significance and intracellular fate of neither F420 nor 
the F420H2 dependent enzyme Ddn are known. Ddn and its homologs in Mtb form a class of 
previously uncharacterized F420H2 dependent reductases with no identified physiological 
substrate. The overall objective of the research work describes in this chapter was to evaluate the 
physiological role of cofactor F420 and Ddn in Mtb pathogenesis as a first step in assessing 
cofactor F420’s suitability as a target for drug discovery.  
In order to understand the role of F420 or F420 dependent pathway in the pathogenesis of Mtb, an 
F420 deficient mutant in Mtb and M. bovis BCG was generated and characterized. Based on the 
proposed F420 biosynthesis scheme (Figure 4.1), the fbiC gene (Rv1173 in Mtb; Mb1236 in M. 
bovis BCG) was determined as the gene of interest to generate a knockout mutant that resulted in 
an F420 deficient strain; fbiC encodes an 856-amino acid FO synthase that is responsible for the 
condensation of pyrimidinedione with hydroxyphenyl pyruvate that is likely to be the first 
committed step in the F420 biosynthetic pathway. This mutant strain, which was devoid of 
cofactor synthesis, was used as a tool for further experimentation that helped to understand the 
function of cofactor F420 in physiological relevant settings. While most microbiological 
experiments were done both in Mtb as well as in M. bovis BCG, results of the Mtb experiments 
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are presented here. For some experiments which could not be performed in the BSL3 facility with 
Mtb, results in M.bovis BCG are presented. In addition, attempts were undertaken to determine 
the physiological substrate of Ddn in hope that this would also shed light on the importance of 
F420 dependent reactions in mycobacteria. 
4.9 Summary of findings 
Deletion of fbiC gene in the Mtb H37Rv and M bovis BCG knockout mutants were confirmed 
genetically and inhibition of cofactor F420 biosynthesis/production was confirmed biochemically 
via a fluorescence-based assay and PA-824 sensitivity assay. The F420 deficient mutants were 
hypersensitive to in vitro induced nitrosative and oxidative stress as and exhibited an enhanced 
reduction in NADH/NAD
+
 ratios upon treatment with redox-cyclic agent. In addition, these 
mutants showed survival defect under in vitro hypoxic dormancy models. Furthermore, in 
agreement with the recent hypothesis on a common pathway for bactericidal agents leading to 
bacterial cell death through oxidative stress (Kohanski et al., 2007), F420
 
deficient mutants were 
hypersensitive to mycobactericidal agents like INH and moxifloxacin.  
In order to gain insight into the physiological reaction catalyzed by Ddn, various different classes 
of compounds were tested for substrates in a Ddn mediated F420H2 oxidation assay that led to the 
identification of the redox cycling agent menadione, a 2-methyl-1, 4-napthoquinone and an 
analogue of menaquinone which is the sole quinone present in Mtb, as a substrate for reduction by 
F420H2 catalyzed by Ddn. Evaluation of activity with several other analogues indicated that 
quinones were much better substrates than PA-824 and that the quinone reductase activity of Ddn 
was F420H2 specific. In addition to Ddn, two other Mtb homologues Rv1261c and Rv1558 also 
encode for F420H2 dependent quinone reductase (Fqr) function and at the expense of F420H2, use 
quinones as efficient substrates resulting in the formation of dihydro-quinones. The Fqr enzymes 
catalyze an F420H2 specific obligate two electron reduction of quinones and thereby compete with 
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the harmful one electron reduction pathways which contribute to the formation of cytotoxic 
semiquinones. Fqr thus emerges as a new class of proteins that protect mycobacteria against 
oxidative stress thereby contributing towards intrinsic resistance against bactericidal agents. These 
results highlight a novel F420 dependent anti-oxidant mechanism that protects mycobacterium 
against oxidative stress and bactericidal agents (Manuscript in preparation). Further, the results 
described here open up an avenue for the inhibition of cofactor biosynthesis or the activity of the 
Fqr class to potentiate the action of bactericidal agents or to use F420 deficient mutants as a 
screening tool in drug discovery to identify cidal compounds.  
4.10 Results 
 
4.10.1  fbiC knockout mutants are compromised for the production of F420 
Generation of an F420 deficient strain by deletion of a chromosomal copy of fbiC gene (Choi et al., 
2002) proved an important tool in evaluating the role of F420 under different physiologically 
relevant conditions. An H37Rv∆fbiC knockout mutant was generated by homologous 
recombination and replacement of the fbiC gene by hygromycin resistance cassette (Figure 4.3A). 
PCR analysis of the genomic DNA isolated from the WT, knockout (H37RvΔfbiC) and 
complemented strains (H37RvΔfbiC::fbiC) using primers (Table 2.1) to amplify parts of fbiC 
(primer # 11and12), hygromycin resistance cassette (9and10) and 5’ upstream/ 3’ downstream of 
hygromycin resistance cassette (13and16, 15and14) was used to confirm knockout and 
complementation of the fbiC gene in the respective strains. The genotype of H37Rv∆fbiC strain 
was confirmed by PCR (Figure 4.3B), southern blotting (Figure 4.3C) and genomic DNA 
sequencing. H37Rv∆fbiC strain was complemented with pMV306::fbiC where the fbiC gene was 
under its native promoter. After genetic confirmation of the knockout, F420 levels in the 
H37Rv∆fbiC and its complemented strain were confirmed by measuring fluorescence intensity 
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(λex/em 400/470 nm) of crude cell extracts (Guerra-Lopez et al., 2007).  The knockout exhibited a 
significantly lower fluorescence than the WT (Figure 4.3D). The complemented strain showed 
restored fluorescence levels indicating that the cofactor biosynthesis had been reinstated when a 
copy of the Mtb fbiC gene under its native promoter was introduced into the knockout strain 
(Figure 4.3D). Ddn is an F420H2 dependent reductase which bio-activates the TB 
chemotherapeutic bicyclic nitroimidazole PA-824 (Gurumurthy et al., 2012;Singh et al., 2008). 
As expected, the H37Rv∆fbiC mutant was resistant to PA-824 and the complemented strain had 
restored sensitivity to PA-824 (Figure 4.3E). All three strains were equally sensitive to RIF and 
INH, drugs that have an F420
 
independent mode of action, establishing an F420 specific phenotype 
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Figure 4.3 Generation and characterization of H37Rv fbiC deletion strain.  
(A) fbiC locus in the H37Rv-WT and H37Rv∆fbiC strains. Numbers and letters indicate primers 
(details in Table 2.1) and their PCR products respectively. (B) PCR confirmation of fbiC deletion in 
the knockout strain (C) Southern hybridization with indicated probes  (D) Cofactor F420 levels in 
the different strains analyzed via specific fluorescence output (Ex/Em λ 400/470nm) of crude cell 






Based on the metabolite profiling of PA-824 and its analogues by Ddn, it has been shown that 
bicyclic nitroimidazoles act as NO donors (Figure 4.4A) and that the extent of NO release 
correlates with the anaerobic killing of Mtb by the various analogues (Singh et al., 2008). 
Furthermore, the release of intracellular NO in mycobacteria treated with PA-824 has also been 
demonstrated (Singh et al., 2008) with diaminofluorescein (DAF-FM) that fluoresces specifically 
in the presence of NO (Kojima et al., 1998).  DAF-FM diacetate, an intracellular NO probe, is 
converted to DAF-FM by esterase enzymes present in the cells (Figure 4.4B). The release of NO 
from cells over time can be measured by monitoring the fluorescence generated as a result of the 
covalent binding of NO to DAF. In order to confirm that the BCGΔfbiC strain was incapable of 
PA-824-derived NO production, all three strains of M. bovis BCG were pre-loaded with DAF-FM 
diacetate and treated with PA-824. The results showed a time and concentration dependent 
intracellular release of NO in the WT strain but not in the BCGΔfbiC strain (Figure 4.4C) The 
BCGΔfbiC::fbiC strain was competent for PA-824 mediated in vivo NO release, reconfirming 
complementation. These results confirmed that the BCGΔfbiC strain was resistant to PA-824 and 
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Figure 4.4 Analysis of PA-824-mediated in vivo NO release.  
(A) Ddn/F420H2 mediated reduction of PA-824 and NO generation. (B) Reaction of DAF-FM with 
NO and fluorescence generation. (C) Detection of in vivo NO release in BCG-WT, BCGΔfbiC and 







 mutants show survival defect under in vitro induced nitrosative stress  
The main site of Mtb infection is the lungs, where it infects alveolar macrophages (Smith, 2003) 
subsequent survival and multiplication within macrophages is a key feature of mycobacterial 
virulence in vivo (Raupach and Kaufmann, 2001). As elaborated earlier in this chapter, 
macrophages phagocytose invading bacteria and kill them by a number of mechanisms of which 
one is the production of reactive nitrogen species or intermediates (RNS or RNI) (Boshoff and 
Barry, III, 2005). RNS generated by the host enzyme iNOS is very critical for controlling 
infection of Mtb in mice (MacMicking et al., 1995). To avert toxicity caused by these species, 
Mtb follows a dual strategy of detoxification and damage repair; section 4.7 of this thesis outlines 
a number of mechanisms that Mtb has evolved for the detoxification of reactive oxygen and 
nitrogen intermediates that aid in virulence (Ehrt and Schnappinger, 2009a). A genome wide 
transposon mutagenesis screen looking for Mtb mutants hypersensitive to killing by NO identified 
several genes required for protection against NO, one of which was fbiC (Darwin et al., 2003).  
In order to test whether MtbΔfbiC strain was hypersensitive to NO stress, all three strains (WT, 
knockout and complemented) of Mtb H37Rv were exposed to acidified (pH 5.5) sodium nitrite 
(1.5mM and 3.0 mM) for a period of 7 days. Under acidic conditions, protonation of NaNO2 
results in the generation of HNO2 which upon dissociation produces NO and other nitrogenous 
radicals. At different time points, the stressed cells were plated on 7H11 agar and incubated at 37 
°C for at least 2-3 weeks and CFUs were counted. The mutant exhibited hypersensitivity to 
nitrosative stress in comparison to the WT and growth was greatly attenuated by day 4 (Figure 
4.5A). When treated with 3.0 mM NaNO2, the F420
-
 mutant's growth was nearly 1.5 log CFUs/ml   
lesser than the WT as early as day 1 (Figure 4.5 B). However, there was no difference between 
the growth phenotype of the WT and the H37RvΔfbiC strains under acidic conditions alone 
without treatment with NaNO2. This experiment reconfirmed the phenotype observed for the Mtb 
fbiC transposon insertion mutant observed previously (Darwin et al., 2003). When the knockout 
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strains were complemented with fbiC expressed under its native promoter using the integrative 
plasmid pMV306, growth phenotype similar to the WT was restored and hypersensitivity to 
nitrosative stress was abolished.  
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- mutants show survival defect under nitrosative stress.  
Rv-WT, Rv∆fbiC and Rv∆fbiC::fbiC strains were grown in 7H9 media treated with (A) 1.5mM or    
(B) 3 mM NaNO2 under acidic conditions (pH 5.5); viable cells (CFUs) were counted by plating at 






 mutant is hypersensitive to menadione and plumbagin induced 
oxidative stress  
In order to assess the role of F420 in Mtb, the fitness of the Mtb H37Rv∆fbiC strain was evaluated 
under oxidative stress conditions generated by redox cycling agents such as menadione or 
plumbagin.  It was evident from the results that the H37Rv∆fbiC strain was hypersensitive (~1-2 
log reduction) to both menadione and plumbagin (Figure 4.6 B-F). At higher concentrations of the 
redox cycling agents, the knockout strain displayed a strong growth defect phenotype (1.5-3 log 
reduction) as early as 24 hours post treatment (Figure 4.6 C, F). In all cases however, the 
complemented strain was able to restore survival similar to WT levels. 
The phagosomal defense repertoire of an activated macrophage against a pathogen includes 
oxidative and nitrosative stress that damage captured microorganisms by modification of their 
DNA, lipids, thiols, tyrosine side chains, and active centers of metal-dependent proteins (Fang et 
al., 2004). In order to evaluate the effect of the macrophage environment on the F420 deficient 
strain, growth phenotyps were observed upon infection of the THP-1 Human acute monocytic 
leukemia cell line with all three Mtb H37Rv strains. Compared to the WT, the percentage survival 
of the H37RvΔfbiC strain was lower (growth at Day 0 of each of the respective strains being 100%) 
(Figure 4.6 G). 
Menadione treatment is known to cause significant decrease in NADH/NAD
+
 ratios owing to 
NADH-dependent quinone reduction (Boshoff et al., 2004). Treatment of the H37Rv∆fbiC strain 
with lower concentrations of menadione (10-20 µM) resulted in a significant drop in the 
NADH/NAD
+
 ratio compared to the WT and complemented strain (Figure 4.6 H). Similar 
hypersensitivity to oxidative stress and changes in NADH/NAD
+
 ratios was observed in a M. 
bovis BCG∆fbiC mutant and its complemented strain. These data suggest that F420H2 may 
compete with NADH in the reduction of menadione. In the absence of cofactor F420, 
mycobacteria therefore exhibit lower NADH/NAD
+
 ratios and become more sensitive to redox 
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cycling agents such as menadione and plumbagin. These observations led to the hypothesis of the 
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- mutants are hypersensitive to oxidative stress.  
Time course kill-kinetics of H37Rv WT, H37Rv∆fbiC and H37Rv∆fbiC::fbiC in the (A)absence or 
presence of indicated concentrations of (B,C) plumbagin and (D-F) menadione.  (G) Growth 
phenotype of all three strains in activated THP-1 cells. % survival at day 7 in comparison to day 0 
is shown. (H) NADH/NAD+ ratios of all three strains when treated with sub-inhibitory 
concentration of menadione. Experimental CFU data are shown as means ± standard deviation 





4.10.4  Ddn catalyzes F420H2 dependent reduction of quinone to quinol 
A recent study in M. smegmatis highlighted the involvement of the FGD1-F420 system in 
the reduction of quinone substrates and in combating oxidative stress (Hasan et al., 
2010;Guerra-Lopez et al., 2007). While genetic studies identified a role for the M. smegmatis 
FGD1 (therefore possibly F420H2) in the reduction of quinones, incubation of these substrates with 
F420 or F420H2 in isolation failed to result in their chemical reduction (Hasan et al., 2010) indicating 
the possible involvement of an F420H2 dependent enzyme.  
In Mtb, Ddn is the only enzyme that is known to oxidize F420H2, albeit in a reaction that is not 
part of Mtb physiology (Manjunatha et al., 2006b). Ddn’s unambiguous role in the activation of 
bicyclic 4-nitroimidazoles is well understood; however, its physiological role in Mtb is unknown. 
Attempts to evaluate nitro-compounds such as nitro-guanine and nitro-tyrosine as substrates of Ddn 
owing to the enzyme’s nitroreductase activity as part of this research work were in vain. Several 
bacterial nitroreductases that catalyze the reduction of xenobiotic nitro compounds have been 
shown to exhibit quinone reductase activity (Roldan et al., 2008). Furthermore, quinone reductases 
in several prokaryotic and eukaryotic organisms have been characterized for their role in protection 
against oxidative stress (Akhtar et al., 2006) (Beyer, 1994a;Gonzalez et al., 2005a;Hong et al., 
2008;Montano et al., 2007;Raina et al., 1999;Sollner et al., 2009;Wang and Maier, 2004a) 
 In light of all that is aforementioned, Ddn’s quinone reductase activity was initially evaluated with 
menadione and plumbagin as substrates by monitoring F420H2 oxidation spectrophotometrically. 
Absorbance spectra with varying concentrations of the substrate were monitored; time, enzyme and 
substrate dependent oxidation of F420H2 was observed with both menadione (2-methyl- 
1,4naphthaquinone) and plumbagin (5-hydroxy- 1,4naphthaquinone) (Figure 4.7A, B).  
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Figure 4.7 F420H2 dependent Ddn quinone reductase activity.  
Absorbance spectrum of varying concentrations of (A) menadione and (B) plumbagin with 100 μM 
of F420H2 after 10 and 25 minutes reaction with 1 µM Ddn respectively. 
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Time course kinetics for Ddn with menadione, the short chain isopreneid analogue of 
menaquinone, as substrate was monitored (Figure 4.8A) in order to determine kinetic constants 
from Michaelis-Menten plot (Figure 4.8A).  Ddn displayed a much higher F420H2 oxidation activity 
with menadione (kcat/Km 5.16 min
-1μM-1) when compared to PA-824 (kcat/Km 0.16 min
-1μM-1), its 
first known substrate (Table 4.2). The enzyme activity of a point mutant of Ddn, Ddn::Y65L, was 
also determined in order to ascertain that the quinone reductase activity of the enzyme was F420H2 
specific. Based on the co-crystal structure of an N-terminus deleted truncation mutant of Ddn with 
cofactor F420, Tyr65 residue of Ddn was implicated to play a role in stabilizing the F420 complex, 
therefore aligning the Re-face of the cofactor towards its substrate (Cellitti et al., 2012). 
Furthermore, mutations in Y65 resulted in loss of Ddn enzymatic activity in the PA-824 reduction 
assay (Cellitti et al., 2012). Therefore, in order to verify the F420H2 specific nature of Ddn’s 
quinone reductase activity, the Ddn::Y65L mutant was tested in the menadione reduction assay. As 
expected, the point mutant of Ddn was not able to utilize F420H2 in the reduction of menadione 
(Figure 4.8B).  
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Figure 4.8 Ddn enzyme kinetics with menadione.  
(A)Time course kinetics of menadione reduction by Ddn measured by F420H2 oxidation (A400) 
(B) Michaelis-Menten plot for menadione reduction with Ddn and Ddn::Y65L mutant (inactive for 
PA-824 reduction).  
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In order to evaluate the quinone reductase activity of Ddn using an alternative readout and to 
ensure that F420H2 oxidation was indeed a resultant of quinone reduction by the enzyme, 
absorbance at 337nm was monitored in Ddn kinetics with menadione (Hasan et al., 2010). Time, 
enzyme and menadione concentration dependent decrease in absorbance at 337 nm was observed 
(Figure 4.9A) indicating a decrease of oxidized menadione in the reaction mixtures. Furthermore, 
reaction products of menadione reduction were analyzed via LC-MS at 10, 40 and 70 minutes 
post enzyme addition (Figure 4.9B). As expected, a time dependent increase in the peak for 
menadiol was observed. The MS profiles of peaks eluted at 9.3 min and 10 min (menadiol and 
menadione respectively) are shown (Figure 4.9C).  
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Figure 4.9 F420H2 dependent Ddn menadione reduction leads to formation of dihydro-
menadione. 
 (A) Time course kinetics of menadione reduction by Ddn monitored via decrease in A337 
(absorption for oxidized menadione). The open circles correspond to respective control reactions 
without Ddn. (B) Ddn mediated menadione reduction monitored by LC-MS (C-18 column – 0.1% 
formic acid with a gradient of acetonitrile containing 0.1% formic acid) at three indicated time 
points. A300 chromatogram peaks for menadiol (9.3 min), menadione (10 min) and an unknown 
peak (*) are indicated. (C) MS profiles for menadiol (9.3 mins) and menadione (10 mins). 
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Following this, Michaelis-Menton plots for Ddn’s quinone reductase activity was determined with 
various other naphthaquinone and benzoquinone analogue substrates (structures shown in Figure 
4.10). Our data indicated that quinones were much better substrates than PA-824 for Ddn 
dependent F420H2 oxidation. Plumbagin, DMN (2, 3-dimethylnaphthaquinone) and NQ (1, 4-
napthaquinone) displayed similar activities with Ddn (kcat/Km ~ 2 min
-1μM-1); all of them were 
better substrates than PA-824 but were inferior to menadione (Table 4.2). Amongst the 
benzoquinone analogues, coenzyme Q0 (kcat/Km 0.1 min
-1μM-1) and coQ1 (0.21 min-1μM-1) were 
poor substrates of Ddn with activities comparable to that of PA-824, whereas coenzyme Q2 with 
two isopreneid moieties in its side chain showed improved activity (kcat/Km 1.73 min
-1μM-1) as a 
Ddn substrate. In general naphthoquinones were better substrates of Ddn than benzoquinones, 
consistent with the fact that the characteristic quinone in mycobacterium is menaquinone, a 
naphthoquinone with nine isoprenoid moieties in its side-chain. Therefore, one would expect the 
turnover under physiological conditions to be much higher than what is observed with menadione 
which requires further investigation. The physiological electron acceptor for Ddn mediated F420H2 




Figure 4.10 Chemical structures of quinone substrates used in this study 
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Ddn 3.44±1.27 17.7±0.12 5.16 

































(Benzoquinone or quinone) 
Ns Ns Ns 
2,3-dimethoxy-5-methyl- 
1,4-benzoquinone 
(coenzyme Q0 or Co-Q0) 




(coenzyme Q1 or Co-Q1) 
10.12±2.23 2.15±0.14 0.21 
2,3-dimethoxy-5-methyl- 
6-geranyl-1,4-benzoquinone 
(coenzyme Q2 or Co-Q2) 
3.14±0.97 5.43±0.12 1.73 
PA-824  28.6±3.55 4.7±0.24 0.16 
 
Fluorometry assay for F420H2 oxidation* 
 
Menadione Ddn 4.43 ±2.23 43.18 ±5.32 9.75 
Rv1558 21.71± 0.46 157.2 ±1.24 7.24 
Rv1261c 47.35± 4.91 21.92 ±1.08 0.463 




4.10.5 Ddn, Rv1261 and Rv1558 form a unique class of F420H2 specific quinone 
reductases.  
Ddn is a member of a large family of proteins that are scattered throughout F420-producing 
actinobacteria (Selengut and Haft, 2010). Interestingly, each of these actinobacterial species is 
known to have multiple Ddn homologues - M. avium has 12 homologues, Mtb has 4 homologues 
and Nocardia farcinica has 5. None of the Ddn homologues have been functionally characterized 
and they all have very diverse N-terminal sequences. Homologues in Mtb, Rv1261c and Rv1558 
(Figure 3.5), with 55-56% amino acid sequence similarity to Ddn, were evaluated for their 
quinone reductase activity with menadione as the substrate (Figure 4.11). Activity of Rv1588 was 
similar to that of Ddn while that of Rv1261c was significantly lower (Table 4.2). Nonetheless, 
these results established that Ddn and its homologues form a unique class of enzymes i.e. F420H2 












Figure 4.11 Ddn, Rv1261c and Rv1558 form a class of F420 dependent quinone reductases (fqr).  
Michaelis-Menten plot of menadione reduction by Ddn and its Mtb homologs, Rv1261c and 
Rv1558 All enzymes used in this assay were MBP-tagged 
 



























mutants are hypersensitive to bactericidal agents 
A recent hypothesis implies oxidative stress to be a common pathway by which all bactericidal 
agents lead to cell death (Belenky and Collins, 2011) (Hassett and Imlay, 2007) (Kohanski et al., 
2007). Treatment of M. smegmatis with bactericidal agents such as ofloxacin or INH has been 
shown to result in hydroxyl radical generation (Mukherjee et al., 2009). Owing to the 
hypersensitivity of the F420
- 
deficient strain to oxidative stress, we evaluated the effect of 
bactericidal (INH, moxifloxacin (Mfx) and Clofazimine (Clof)) and bacteriostatic (ρ-
aminosalicylic acid (PAS)) agents on growth of H37Rv∆fbiC and its complemented strain. While 
the complemented strain’s growth was comparable to that of the WT, the H37Rv∆fbiC strain 
exhibited a strong growth defect phenotype in presence of all three cidal agents (Figure 4.12 A-
F).  Similar growth defect phenotype of the F420
-
 strain to the cidal agents was observed in M. 
bovis BCG. However, no such phenotype was observed with the bacteriostatic agent PAS in the 



























































































































































































- mutants are hypersensitive to bactericidal agents. 
H37Rv WT, H37Rv∆fbiC and H37Rv∆fbiC::fbiC strains were exposed to indicated concentrations of 
(A,B) INH, (C,D) moxifloxacin and (E,F) clofazimine over a period of 7 days; viable cells were 
counted by plating at various time points as indicated. Experimental CFU data are shown as means 
± standard deviation of duplicate values. Experiment was repeated at least two times, out of 
which one is represented. 
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- mutants are not hypersensitive to PAS 
WT, ∆fbiC and ∆fbiC::fbiC strains of (A-D) M.bovis BCG and (E) Mtb H37Rv were exposed to 
indicated concentrations of ρ-aminosalicylic acid (PAS) over a period of 7 days; viable cells were 
counted by plating. Experimental CFU data are shown as means ± standard deviation of duplicate 






 mutants show survival defect under hypoxic dormancy models 
Mtb, albeit an obligate aerobic bacterium, is capable of long term survival under hypoxic 
conditions. When exposed to low oxygen tension, Mtb ceases replication but maintains viability, 
a state that the bacillus is known to enter in necrotic granulomas during infection of the lung 
(Barry, III et al., 2009).  Mtb has mechanisms that not only enable entry into hypoxia and survival 
under these conditions, but also those that play a role in return to replicating state upon reaeration 
(Rustad et al., 2008;Sherrid et al., 2010). Upon sudden exposure to oxygen, the bacillus 
encounters a whole range of reactive oxygen species and therefore combating oxidative stress is a 
crucial phenomenon for reactivation of latent TB. In order to evaluate the role cofactor F420 in a 
physiologically relevant context, the re-growth phenotypes on agar plates of all three strains were 
monitored after adaptation in a Wayne model for dormancy (Wayne and Hayes, 1996). The fbiC 
knockout strain in both H37Rv as well as M.bovis BCG showed 1-2 log reduction in growth upon 
entering NRP-2 phenotype (~day 21 onwards) (Figure 4.14 A, B). Similar growth defective 
phenotype was observed for the BCGΔfbiC strain when it was subject to anaerobic shiftdown 
(Figure 4.14 C, D), an alternative model to evaluate dormancy related phenotype.  However, in 
both the in vitro models of mycobacterial dormancy, the complemented strain was unable to 
restore the phenotype of the WT.  In order to understand why complementation was unsuccessful 
in this case (while it worked for the various aerobic conditions), qRT-PCR experiments were 
carried out to evaluate transcript levels of fbiC gene under hypoxia conditions in the various 
strains. However, these experiments failed to provide an explanation for the observed phenotype 
as the fbiC transcript levels in the complemented strain were identical those observed in the WT.  
A potential role for F420 or an F420 dependent pathway in regrowth after hypoxia induced 
dormancy and in mycobacterial persistence in hypoxic lung lesions and reactivation 
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needs to be evaluated further. This phenomenon is of remarkable interest and requires 
further probing in future studies. 
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- mutants show survival defect under hypoxic dormancy models.  
Growth profiles of WT and ΔfbiC strains of (A) Mtb H37Rv and (B) M. bovis BCG under the Wayne 
model for non-replicating persistence; viable cells were counted by plating at various time points. 
BCG-WT and BCGΔfbiC strains were subject to growth in a ‘rapid oxygen depletion (shiftdown) 
model’ in either (C) 7H9 or (D) Dubos medium; viable cells were counted by plating at various 
time points. Experimental CFU data are shown as means ± standard deviation of duplicate 





Oxygen is a necessary evil in all aerobic organisms - on the one hand it acts as an efficient terminal 
electron acceptor during oxidative phosphorylation while on the other, it has the capacity to form  
highly reactive oxygen species such as superoxide (O2
-
) and H2O2 by accepting unpaired electrons 
(Imlay, 2008). Mtb, in addition to being an aerobic bacterium, is an intracellular pathogen that at 
least initially occupies the phagosomal compartment of host macrophages where it is subject to 
oxidative and nitrosative stress and has therefore evolved diverse protective mechanisms. An 
understanding of the defense mechanisms evolved by Mtb to cope with oxidative stress is of 
significant importance in studying the pathogenesis and control of TB.  In addition to known 
protective enzymes such as catalase, superoxide dismutase, peroxidase-peroxynitrite reductase 
complex and thioredoxin-thioredoxin reductase systems, specialized mechanisms and pathways 
such as those involved in DNA repair and the proteasome operate to repair the damage caused to 
macromolecules by oxidative and nitrosative stress (Imlay, 2008; Ehrt and Schnappinger, 2009a).  
In a transposon mutagenesis study aimed to identify Mtb genes that conferred resistance against 
nitrosative stress, an insertional inactivation of fbiC rendered Mtb hypersusceptible to acidified 
nitrite establishing the very first hypothesis for the role of F420 in combating nitrosative stress 
(Darwin et al., 2003). Hypersensitivity of genetic knockouts of fbiC and fgd in M. smegmatis 
reinforced this hypothesis (Purwantini and Mukhopadhyay, 2009). In the research work presented 
in this thesis, an F420 deficient strain in Mtb H37Rv was generated by knocking out the fbiC gene 
via homologous recombination. Knocking out of the fbiC gene resulted in a cofactor F420 deficient 
mutant strain as expected. As speculated, the knockout mutant displayed phenotypes associated 
with the cofactor’s role in protection against oxidative and nitrosative stress.  
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However, the mechanism of oxidative stress response in mycobacteria involving F420-dependent 
pathways is not well understood. Intracellular G6P levels in several mycobacterial species have 
shown to be significantly higher when compared to other bacteria (Hasan et al., 2010). In addition 
to classical NADP dependent G6PDs (ZWF1 and ZWF2), mycobacteria encode an F420 dependent 
G6PD, FGD1 (Purwantini and Daniels, 1996b). In most bacteria, one of the two fates of G6P is its 
oxidation via the pentose phosphate pathway to generate NADPH, an important source of reducing 
power, which in turn combats various oxidative stress agents (Ma et al., 1998). An M. smegmatis 
mutant deficient in FGD1 is hypersensitive to oxidative stress (Hasan et al., 2010), indicating that 
the presence of an NADPH dependent G6PD alone to be insufficient, and the lack of FGD1 makes 
mycobacteria compromised in combating oxidative stress. Results obtained in this study clearly 
demonstrate that absence of cofactor F420 renders Mtb hypersensitive to oxidative stress, 
recapitulating findings obtained in previous studies carried out in M. smegmatis.  
In addition, this study highlights the Fqr enzymes (Ddn and its homologues) as a novel class of 
proteins that are involved in the F420 dependent antioxidant strategies employed by mycobacteria. 
Ddn’s ability to reduce a range of quinone substrates in an F420H2-dependent manner to their 
respective dihydroquinone forms has been demonstrated here. Notably quinones proved to be much 
better substrates of Ddn than PA-824 and several other bicyclic nitroimidazole substrates evaluated 
previously (Mukherjee and Boshoff, 2011). Rv1558 and Rv1261, two homologues of Ddn, were 
also capable of F420H2-specific menadione reduction thereby establishing Ddn and its homologues 
to be a unique class of enzymes in Mtb - F420H2 dependent quinone reductases (Fqr). 
Experimentally, Ddn has been identified as a membrane protein in Mtb (Sinha et al., 2005;Gu et 
al., 2003), with an N-terminus likely comprised of an amphipathic helix that has a highly 
hydrophobic region which may result in peripheral membrane association (Cellitti et al., 2012). 
These data and current findings of Ddn’s ability to reduce quinones point strongly towards Ddn’s 
physiological role as a membrane associated quinone reductase. In Mtb, menaquinone (2-methyl-
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1,4-napthoquinone moiety α-linked to a chain of on average nine isoprene units) is the sole quinone 
electron carrier in the respiratory chain (Collins and Jones, 1981). The physiological electron 
acceptor for Fqr-mediated F420H2 oxidation is therefore likely to be the endogenous menaquinone 
found in the membrane fraction of Mtb.  
In the case of DdnΔN29, an N-terminus truncation mutant whose structure has been solved, the 
menadione reductase activity was lost; similar to what was observed with PA-824 as a substrate 
(Cellitti et al., 2012). Nevertheless, this mutant protein retained F420 binding, indicating the 
importance of the N-terminus for full enzymatic function and its involvement in substrate binding. 
Ddn is a member of a large family of proteins distributed exclusively in F420-producing 
actinobacteria (Selengut and Haft, 2010) and multiple Ddn homologues are present in these 
organisms with diverse N-terminal sequences. Importantly, the variability of the N-terminus among 
these homologues suggests a role for this region in defining specificity of cellular functions and 
substrate specificity. The bioreductive activation of bicyclic nitroimidazoles (PA824, OPC67683 
etc)(Gurumurthy et al., 2012), reduction of menadione by Ddn (this study) and the degradation of 
aflatoxin by an M.smegmatis Ddn homologue (Graham, 2010), all seem to share a common 
mechanism in which hydride is transferred from the reduced deazaflavin F420 to the electron 
deficient ring systems of the substrates. At a quick glance, the broad substrate specificity of the Fqr 
enzymes (bicyclic nitroimidazoles, benzoquinones and naphthoquinones) may appear puzzling; 
however, literature is replete with examples of bacterial nitroreductases, known to reduce 
xenobiotic nitro compounds, exhibiting quinone reductase activity with endogenous substrates 
(Roldan et al., 2008; Ross and Siegel, 2004). 
Quinone reductases in eukaryotes and in bacteria have been well characterized for their roles in 
protection against oxidative stress (Beyer, 1994b;Gonzalez et al., 2005b;Hong et al., 2008;Wang 
and Maier, 2004b). A eukaryotic NAD(P)H quinone reductase, DT-diaphorase(Beyer, 
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1994b;Beyer et al., 1997), catalyzes the two-electron reduction of quinones, thereby preventing 
the formation of reactive semiquinones in favor of quinols. Molecular oxygen reacts rapidly with 
semiquinones to form superoxide (Muller, 1987). A homologue of the eukaryotic quinone 
reductase in the pathogenic bacteria Helicobacter pylori has been shown to be NADPH-
dependent and to play an important role in colonization of the host by providing resistance to 
oxidative stress (Wang and Maier, 2004c). ChrR, characterized as a quinone reductase in 
Pseudomonas putida has been observed to combat H2O2-induced stress by favoring the 
simultaneous two-electron reduction of quinones (Gonzalez et al., 2005a). Interestingly, in E. 
coli, which contains both ubiquinone (redox potential +113 mV) and menaquinone (redox 
potential -74 mV), superoxide generation is ascribed mainly to menaquinone likely because of its 
lower reduction potential (Korshunov and Imlay, 2006). As highlighted previously, Mtb contains 
only menaquinone.  
These results led to a model in which Fqr proteins (Ddn, Rv1261c and Rv1558) catalyze an 
F420H2-specific obligate two-electron reduction of quinones to quinol and thereby compete with 
the harmful one-electron reduction pathway and prevent the formation of cytotoxic semiquinones 
(Figure 4.15). FGD1 oxidizes G6P to 6-phosphogluconolactone while reducing cofactor F420.  In 





 mutants in mycobacteria (Hasan et al., 2010) are hypersensitive to 
oxidative stress. The G6P-FGD1 and F420H2-Fqr systems therefore play a crucial role in 
mechanisms contributing to Mtb’s resistance against oxidative stress. Superoxide is known to 
interact with nitric oxide to form highly reactive peroxynitrite (Nathan and Shiloh, 2000). As 
reported earlier (Darwin et al., 2003), the Mtb∆fbiC mutant displayed a hypersensitive phenotype 
to nitrosative stress. This is possibly linked to the increase in oxidative stress and superoxide 
levels in the mutant, in which case Mtb∆fbiC is likely be a prolific generator of a particularly 
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Figure 4.15 Proposed model for an F420 dependent anti-oxidant pathway by fqr proteins.  
Fqr proteins catalyze F420H2 specific obligate two electron reduction of quinones, thereby 
competing with the harmful one electron reduction pathway; as a result of this competition, the 
formation of cytotoxic semiquinones is avoided.  Therefore, the F420
- (incapable of F420 
biosynthesis) as well as the FGD1- (incapable of F420 reduction to F420H2) (Hasan et al., 2010) 





Consistent with earlier reports that oxidative stress represents a central pathway by which all 
bactericidal agents lead to cell death, F420
- 
mutants were observed to be hypersensitive to 
mycobactericidal agents such as INH, Mfx and Clof. In a murine mouse model, the combination of 
PA-824 with Moxifloxacin (PA-824-Mfx) or with Pyrazinamide (PA-824-PZA) was shown to be 
more efficacious than the Mfx-PZA combination. Further, the replacement of rifampicin with PA-
824 in the Rifampicin-Mfx-PZA (RMZ) regimen was shown to have significantly improved in vivo 
bactericidal activity (Nuermberger et al., 2008). Importantly, the PaMZ (PA-824, Mfx and PZA) 
regimen has recently proven to be highly efficacious in humans in a phase II clinical trial (Diacon 
et al., 2012), supporting our hypothesis of a synergistic interaction between depletion of F420H2 (by 
PA-824) and the action of bactericidal agents (Mfx in this case). In the presence of bicyclic 
nitroimidazoles such as PA-824, Ddn would sequester cellular F420H2 for the drug bioactivation due 
to the excess cellular drug concentration relative to endogenous menaquinone levels, thus rendering 
mycobacterial cells sensitive to oxidative stress caused by other bactericidal agents. Bicyclic 
nitroimidazoles like PA-824 and OPC67683 possibly operate like a double edged sword as they 
sequester away cellular F420H2 and also release intracellular nitric oxide. Further, we would 
envisage clinical PA-824 or OPC-67683 resistant mutants (FGD- and F420-) would have greater 
sensitivity to oxidative stress and to other bactericidal drugs. This supports combination therapies 
of these drugs and PA-824 to lessen resistance. 
The growth defect phenotype of the fbiC mutant observed in hypoxic dormancy models in this 
study supports a role for F420 either in anaerobic respiration and energy metabolism or in 
combating oxidative stress encountered during reactivation on the agar plate. In a microarray 
study (Rustad et al., 2008), the fbiC gene was significantly upregulated (7.4-fold) in the 
hypoxically growing dosR mutant (7 days exposure to 0.2% oxygen) in comparison to the 
aerobically growing dosR mutant, suggesting a dosR independent role for cofactor F420 in 
adapting to hypoxia. In addition, the fbiC gene was significantly upregulated (7.5-fold) in the 
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dosR mutant in comparison to WT H37Rv, both grown under hypoxia (Honaker et al., 2009). 
These data suggest that while fbiC transcription may be independent of dosR in that its 
upregulation during hypoxia occurs even in the dosR mutant; its role seems to be of increased 
significance in the absence of this regulator. Global transcription analyses have also identified 
genes (Reaeration Response) that characterize the adaptive response of Mtb upon exposure to 
oxygen and return to favorable growth conditions. Within the Reaeration Response, there is an 
enrichment of genes upregulated in response to various other stresses suggesting that Mtb senses 
and responds to stress during reaeration. Ddn shows a significant upregulation (4.5-fold) upon 24 
hours of reaeration of H37Rv cells grown under hypoxia (0.2% oxygen) for 7 days (Sherrid et al., 
2010) possibly suggesting a protective role of the Ddn against sudden oxidative burst 
accompanying re-aeration. During aerosol transmission from active TB patients, Mtb is exposed 
to much higher oxygen concentrations than what it may encounter even in open lung cavities; 
growth defect of Rv∆fbiC mutant during re-aeration may therefore have an impact on its 
transmissibility too.  
A membrane bound F420H2: quinone oxidoreductase complex has previously been isolated from 
the anaerobic sulphate-reducing archaeon Archaeoglobus fulgidus (Kunow et al., 1994a). The 
complex catalyzed the reduction of various naphthaquinone and benzoquinone analogues in an 
F420H2 specific and dependent manner. The physiological electron acceptor of the complex was 
thought to be menaquinone and the complex itself was implicated in the energy conserving 
electron transport chain. As part of this thesis work, antibodies were raised against the Mtb Ddn 
protein and western blotting was performed in an attempt to determine its localization in Mtb 
cellular fractions. However, owing to the quality of the antibodies, these experiments did not 
yield conclusive results. In order to evaluate if F420 and the Fqrs indeed had a role to play in Mtb’s 
electron transport chain, membrane vesicles from M. smegmatis and M. bovis BCG were isolated 
and F420H2 was evaluated as an electron donor in an ATP generation assay (see section 2.24 for 
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experimental design). While positive results were obtained for ATP generation with NADH as the 
electron donor, reactions with F420H2 as the electron donor failed to generate ATP (Appendix 3). 
Nevertheless, these observations do not rule out F420’s role in respiration – this particular aspect 
of F420 function in Mtb needs to be further explored. Owing to its redox properties and its role in 
anaerobic respiration in archaebacteria, a role for F420 has been proposed in the protonmotive 
force generation in an anaerobic ETC (Boshoff and Barry, III, 2005).  
Taken together, the results from the research work described in this chapter suggest a significant 
role for F420 and its dependent mechanisms in Mtb survival and pathogenesis. Mtb and M. leprae, 
both pathogenic mycobacteria, have retained the F420 biosynthetic machinery. Both the pathogenic 
species are dysfunctional in several oxidative stress response mechanisms, yet they can survive 
and persist in macrophages rich in reactive oxygen species. F420H2 and its associated quinone 
reductases such as Ddn could therefore play an important role in the defense of pathogenic 
mycobacteria; the Fqrs described here are a new class of proteins that protect Mtb against 
oxidative stress and bactericidal agents. It is possible that the FGD1-F420-Fqr system in Mtb 
serves as a virulence factor, inhibition of which could reduce fitness and enhance the activity of 







The current pipeline of new therapeutics for TB is quite robust and it demands an efficient 
evaluation of individual agents and combinations. Rational design of optimal multidrug regimens 
will have to take into account several factors such as clinical efficacy, drug interaction effects, 
pharmacokinetics, toxicity, drug metabolism, and the development of resistance. Importantly, 
intelligent strategies for drug staging, which would capitalize existing knowledge of mechanisms 
of action and activities of the various drugs against the spectrum of bacterial subpopulations, are 
required in order to improve outcomes with current drugs. Two bicyclic nitroimidazole 
compounds – PA-824 and OPC-67683— are currently in clinical evaluation as anti-tubercular 
drugs. Current Phase II clinical trials, in addition to generating information regarding the clinical 
utility of PA-824 and OPC-67683, may determine the future directions of drug development for 
anti-tubercular nitroimidazoles (Mukherjee and Boshoff, 2011).  
PA-824 and OPC-67683 are prodrugs that appear to undergo similar reduction reactions     
(Matsumoto et al., 2006) (Singh et al., 2008). The F420-dependent reduction of PA-824 by Ddn 
has been shown to produce a mixture of three stable metabolites as well as a release of reactive 
nitrogen species. Of the three metabolites, the levels of a des-nitro species correlate best with NO 
release and anaerobic bactericidal activity. The data presented in this study provide biochemical 
and structural insights into the Ddn-catalyzed activation of bicyclic 4-nitroimidazole prodrugs, a 
process key to the function of this important class of antitubercular clinical candidates. The 
biochemical characterization of Ddn described here with PA-824 and other analogs, and the 
methods developed, will prove useful in future attempts to characterize additional members of the 
Ddn enzyme family. In addition, since Ddn appears to be capable of rigorous structure-based 
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specificity, characterizing this protein for its binding to the various nitroimidazole analogs will 
prove to be beneficial to optimize a backup clinical candidate for PA-824. The novel Nitric Oxide 
Analyzer (NOA)-based tool developed here to monitor in vitro Ddn enzyme kinetics offers an 
exciting way forward in the screening and evaluation of nitroimidazole drug candidates for their 
anaerobicidal activity based on NO generation.  
F420, a hydride carrier deazaflavin cofactor, is known for its role in the ‘activation’ of the bicyclic 
nitroimidazoles. However, due to limited knowledge about its role in Mtb physiology and 
pathogenesis, the implications of F420H2 being sequestered for PA-824 activation is not 
understood. Further, given F420’s redox properties and its role in anaerobic respiration of archaea, 
the role of the cofactor in Mtb persistence has been hypothesized for several years now. An 
understanding of the nature and characteristics of ‘persister’ organisms and dormancy is 
fundamental to developing a reasonable strategy for shortening the duration of current TB 
treatment. Upon understanding the physiological function and significance of F420, its 
involvement in PA-824 mechanism of activation/action may potentially become more complex 
and fascinating. 
All mycobacterial species studied to date have F420 biosynthetic genes including M. leprae. The 
maintenance of such complex biosynthetic pathways, even in M. leprae which has undergone 
substantial gene decay (Cole et al., 2001b), strongly suggests that F420 plays a vital role in the 
biology of mycobacteria. The midpoint potential of F420 is lower (-360 mV) than that of the 
classical hydrogen carrier NAD(P)
+
 (-320 mV). In methanogens such as Methanosarcina mazei, a 
membrane-bound electron-transport system consisting of a F420H2 dehydrogenase with striking 
similarities to the respiratory type I NADH dehydrogenase is used to generate a protonmotive 
force from reduced F420 and intermediates of the methane-generation pathway
 
and in 
Archaeoglobus fulgidus, an F420H2: quinone oxidoreductase is equivalent to the respiratory type I 
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NADH dehydrogenase (Deppenmeier et al., 1990). In mycobacteria, the role of F420 is not fully 
understood. Mtb encodes four glucose-6-phosphate dehydrogenases — two of which require 
NADPH as the electron donor (ZWF1, ZWF2), whereas fgd1 and fgd2 encode F420-requiring 
dehydrogenases (Cole et al., 2001). In M. leprae, zwf1 and zwf2 are pseudogenes, but fgd1 has 
been maintained. 
As the title suggests, the findings of this thesis add several steps forward in the direction of 
understanding cofactor F420 dependent mechanisms in Mtb pathogenesis. The results obtained 
here establish the role of F420 in resistance to nitrosative stress and highlight a novel F420 
dependent anti-oxidant mechanism in Mtb. Furthermore, Ddn and its homologues have been 
identified as F420H2 dependent quinone reductases with a potential role in combating oxidative 
stress imposed by redox cycling agents. The complex mechanisms by which Mtb combats 
reactive oxygen species and develops resistance to host induced oxidative stress play a key role in 
TB pathogenesis and the findings of this thesis provide new insights into the functions 
responsible for the viability of highly stressed Mtb cells. In addition, the identification of a novel 
F420H2 dependent quinone reductase class of enzymes whose physiological substrate could be 
menaquinone reinstates the hypothesis that that F420H2 may have a role in the low-redox potential 
electron-transfer reactions that would be associated with anaerobic survival. Further, preliminary 
experiments that revealed F420 deficient mutants to be crippled under hypoxic conditions are 
shown here suggesting a possible role for an F420 dependent mechanism in Mtb’s survival under 
hypoxic conditions or during its reactivation. If demonstrated, F420 biosynthesis could be an 
attractive latency target against Mtb. In summary, F420 seems to play a role in aspects of 
metabolism which are considered critical for the pathogenesis of this organism by virtue of its 
role in protection against nitrosative and oxidative stress as well as survival during non-
replicating persistence.  
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Other than FGD1’s role as an F420 dependent G6PD, little else is currently known about the 
biological role of the other enzymes in actinobacteria nominated to be F420 dependent. The LLM-
family protein Rv2951c however bears exception as it has shown to be a key ketoreductase in the 
biosynthesis of the mycobacterial diacyl phthiocerol virulence factors (Onwueme et al., 2005) 
(Simeone et al., 2007) opening up possibilities for cofactor F420 dependent reactions in 
mycobacterial PDIM biosynthesis.  
Table 5.1 summarises the potential functions of F420 dependent enzymes based on results obtained 













 Genetic knockout mutant in H37Rv 
impaired for biosynthesis of F420  
 H37Rv knockout mutant hypersensitive to 
nitrosative stress and oxidative stress  
 Transposon mutant in H37Rv 
hypersensitive to nitrosative stress 
 Knockout mutant in M. smegmatis 
sensitive to redox cycling agents 
 Knockout mutant in H37Rv displays 
growth defect under hypoxia 
 Knockout mutant in M. bovis BCG shows 
altered PDIM profile 
 Transcripts upregulated in hypoxia grown 
dosR mutant compared to WT 
 Transcripts upregulated in dosR mutant 
under hypoxia in comparison to dosR 






Darwin et al. (2003) 
 






Honaker et al. (2009) 
 
Rustad et al., (2008) 
Rv3547 Ddn, 
Potential Fqr 
 Responsible for PA-824 activation 
 Catalyzes F420H2 specific quinone 
reduction 
 Upregulated under reaeration conditions 
 Found in membrane fractions 
Manjunatha et al. 
(2006a) 
This study 
Sherrid et al. (2010) 
Gu et al.(2003), Sinha et 
al.(2005) 
Rv0407 FGD1  Responsible for F420 reduction to F420H2 
 Knockout mutant in M. smegmatis 
hypersensitive to menadione/plumbagin  
 Knockout mutant in M. smegmatis 
hypersensitive to nitrosative stress 
 Knockout mutant in M. smegmatis 
incapable of menadione/plumbagin 
chemical reduction 
Purwantini et al. (1996) 





Hasan et al. (2010) 




Rv1261c Potential Fqr  Catalyzes F420H2 specific quinone 
reduction 
This study 
Rv2951c Potential F420 
dependent 
ketoreductase 
 Overexpression of M.marinum homologue 
in M. ulcerans and M. kansasii results in 
the reduction of keto-PDIM to hydroxy 
PDIM 
Onwueme et al.(2007) 
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The clinical management of Mtb in infected patients is a challenging problem because of the six-
month duration of chemotherapy with multiple drugs. This prolonged treatment is essentially 
attributed to lack of good activity of the currently available drugs against latent bacilli. The 
effective means to tackle TB is targetting persistent bacilli for drug development. We anticipate 
that by understanding the role F420
 
in non-replicating mycobacterial cells and its role in protecting 
Mtb against various stresses would advance our knowledge of the biology of latent TB and 
change the way we think about molecular pathways that are critical for the pathogenesis of Mtb. 
The PaMZ (PA-824, Mfx and PZA) regimen that has recently demonstrated high efficacy in 
humans in a phase II clinical trial (Diacon et al., 2012) renders support to the hypothesis 
presented here of potentiation of bactericidal activity (Mfx in the case of PaMZ) upon depletion 
of F420H2 (by PA-824).There certainly seems to be adequate data that suggest that it may be 
advantage in targeting the distinctive biosynthesis of the F420 cofactor either as a means of 
developing new anti-mycobacterial drugs for combination therapy or for potentiating the action of 
bactericidal drugs.  
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7.1 Appendix 1. Synthesis of CGI-17341 isomers  
The synthesis of the (R) and (S) isomers of CGI-17341 was carried out stereo-specifically 
modifying the procedure for racemic synthesis as described previously (Nagarajan et al., 1989).  
Briefly, 2,4-dinitroimidazole (Sudarsanam VNK et al., 1982) was condensed with either (R) or 
(S) 1,2-epoxybutane to give the corresponding alcohols.  The alcohols were then cyclized using 
NaH to yield the final products. 
 (S)-1-(2,4-dinitro-1H-imidazol-1-yl)butan-2-ol (CSD-250): The title compound was prepared in 
the same manner as for the R isomer using (R)-1,2-epoxybutane.  The yield after column 
chromatography (run once) was 1.19 g (5.17 mmol, 82 %). LCMS (ESI) M+H= 230.9.  
1
H NMR 
matched the values for CSD-252. 
(R)-1-(2,4-dinitro-1H-imidazol-1-yl)butan-2-ol (CSD-252):  2,4-dinitroimidazole (1.00g, 6.33 
mmol) and (S)-1,2-epoxybutane (0.83 ml, 9.54 mmol) were combined in ethanol (0.6 ml) and 
heated in a sealed tube at 70 °C overnight.  The reaction mixture was cooled to ambient 
temperature and the solvents were removed in vacuo.  The reaction mixture was purified twice by 
column chromatography (CHCl3:CH3OH, 10: 0.6) to give 0.47 g (2.04 mmol, 32 %)of pure 
material. 
1
H NMR (300 MHz, CDCl3) δ: 1.08 (t, 3H, CH3), 1.48-1.78 (m, 2H, CH2), 3.93-4.01 (m, 
1H, CH), 4.24 (dd, 1H, J1=13.8, J2=9.3 Hz), 4.81 (dd, 1H, J1=13.8, J2=2.4 Hz), 8.00 (1H, Ar-H). 
(R)-2-ethyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole ((R)-CGI-17341): (S)-1-(2,4-dinitro-1H-
imidazol-1-yl)butan-2-ol (CSD-250) (0.79 g, 3.43 mmol) was combined with NaH (60 % 
dispersion in oil, 158 mg, 4.12 mmol) in anhydrous THF (20 ml) under argon at 0˚C.  Once the 
NaH addition was complete, the reaction mixture was brought to ambient temperature and stirred 
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for 4 h.  The reaction was quenched with water and the solvent was removed in vacuo.  The 
mixture was extracted between water and EtOAc, and the organic portion was dried over MgSO4.  
The mixture was filtered and evaporated to give a pale solid (0.40 g).  The solid was 
recrystallized from EtOAc to give 87 mg (0.48 mmol, 14 %) of the desired product.  
1
H NMR 
(300 MHz, CDCl3) δ: 1.10 (t, 3H, CH3), 1.88-2.06 (m, 2H, CH2), 3.93 (dd, 1H, J1=10.2, J2=7.5 
Hz), 4.36 (dd, 1H, J1=10.2. J2=8.4 Hz), 5.23-5.32 (m, 1H, CH), 7.53 (1H, Ar-H). 
(S)-2-ethyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole ((S)-CGI-17341): (R)-1-(2,4-dinitro-1H-
imidazol-1-yl)butan-2-ol (CSD-252) (0.42 g, 1.82 mmol) was combined with NaH (60 % 
dispersion in oil, 84 mg, 2.2 mmol) in anhydrous THF (10.4 ml) under argon at 0˚C.  Once the 
NaH addition was complete, the reaction mixture was brought to ambient temperature and stirred 
for 4 h.  The reaction was quenched with water and the solvent was removed in vacuo.  The 
mixture was extracted between water and EtOAc, and the organic portion was dried over MgSO4.  
The mixture was filtered and evaporated to give a pale solid (0.26 g).  The solid was 
recrystallized from EtOAc to give 0.12 g (0.66 mmol, 36 %) of the desired product.  
1
H NMR 
(300 MHz, CDCl3) δ: 1.10 (t, 3H, CH3), 1.88-2.06 (m, 2H, CH2), 3.93 (dd, 1H, J1=10.2, J2=7.5 





7.2 Appendix 2. Synthesis of (R) and (S) phenyl analogues of 
nitroimidazo-oxazoles  
(R)-2-(2-chloro-4-nitro-1H-imidazol-1-yl)-1-phenylethanol (CSD-297):  2-Chloro-4-
nitroimidazole (1.00 g, 6.78 mmol), (S)-(-)-styrene oxide (1.22 g, 10.17 mmol), and K2CO3 (0.13 
g, 0.95 mmol) were combined at ambient temperature in ethanol (9 mL).  The reaction mixture 
was heated at 70-75 °C overnight in a sealed tube.  TLC showed two spots and no remaining 
starting material.  The mixture was reduced, re-dissolved in CHCl3 and passed through a Celite 
bed.  The eluent was evaporated and purified via column chromatography (Hex: EtOAc, 3:1 to 
3:2.25) to give 0.45 g (1.70 mmol, 25 %) of the desired product as a solid.  A second column 
recovered 0.17 g (0.63 mmol) additional desired product, bringing the total yield to 34 %.  LCMS 
(ESI) M+H= 268.1.  
1
H NMR (300 MHz, CDCl3) δ:  2.81 (bs, 1H), 4.14 (dd, 1H, J1=14.4 Hz, 
J2=7.8 Hz), 4.26 (dd, 1H, J1=14.4 Hz, J2=3.3 Hz), 5.07 (1H, dd, J1=7.8 Hz, J2=3.3 Hz), 7.30-7.41 
(m, 5H), 7.88 (s, 1H). 
(S)-2-(2-chloro-4-nitro-1H-imidazol-1-yl)-1-phenylethanol (CSD-296):  The desired compound 
was prepared as for the (R)-isomer using (R)-(+)-styrene.  The yield after column chromatography 
was 0.52 g (1.95 mmol, 29%).  LCMS (ESI) M+H=268.1. 
1
H NMR (300 MHz, CDCl3) δ:  2.40 
(bs, 1H), 4.16 (dd, 1H, J1=14.1 Hz, J2=7.2 Hz), 4.27 (dd, 1H, J1=14.1 Hz, J2=3.6 Hz), 5.06 (1H, 
dd, J1=6.9 Hz, J2=3.0 Hz), 7.30-7.42 (m, 5H), 7.89 (s, 1H). 
(S)-1-(2-(tert-butyldimethylsilyloxy)-2-phenylethyl)-2-chloro-4-nitro-1H-imidazole (CSD-302):  
At 0 °C, TBDMS-triflate (0.37 ml, 1.61 mmol) was added to a stirring solution of (S)-2-(2-
chloro-4-nitro-1H-imidazol-1-yl)-1-phenylethanol (CSD-296) (0.266 g, 0.99 mmol) in CH2Cl2 
(10 ml) and 2,6-lutidine (0.217 ml, 1.86 mmol).  The reaction mixture was allowed to stir for 3.5 
h, when TLC showed no remaining starting material.  Aqueous NaHCO3 (10%) was added to 
quench the reaction.  The mixture was extracted between CH2Cl2 and water.  The organic 
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portions were combined, washed with 1N HCl, and dried over MgSO4.  The mixture was filtered 
and evaporated to give 0.323 g (0.85 mmol, 86 %) of a crystalline solid that was used in the next 
reaction without further purification.  LCMS (ESI) M+H=382.1 and M+Na=404.0. 
1
H NMR (300 
MHz, CDCl3) δ:  -0.20 (s, 3H), -0.13 (s, 3H), 0.85 (s, 9H), 4.06 (dd, 1H, J1=14.4 Hz, J2= 8.1 Hz), 
4.17 (dd, 1H, J1=14.1 Hz, J2=3.6 Hz), 4.93 (dd, 1H, J1=8.1 Hz, J2=3.9 Hz), 7.27-7.40 (m, 5H), 
7.74 (s, 1H). 
(S)-6-nitro-2-phenyl-2,3-dihydroimidazo[2,1-b]oxazole ((R)-Phenyl Oxazole):  At 0
o
C and under 
an argon atmosphere, NaH (60% oil dispersion, 48 mg) was added to (R)-2-(2-chloro-4-nitro-1H-
imidazol-1-yl)-1-phenylethanol (CSD-297) (0.16 g, 0.60 mmol) in 5 ml dry THF.  The reaction 
mixture became orange and opaque upon addition.  After 90 minutes, the reaction was quenched 
by the addition of MeOH.  Roughly one-third of the product was purified via preparative TLC to 
give 15 mg of the desired compound.  HRMS for C11H9N3O3 was calculated 232.0722 and found 
to be 232.0741.  
1
H NMR (300 MHz, CDCl3) δ:  4.22 (dd, 1H, J1=10.2, J2=8.1 Hz), 4.67 (dd, 1H, 
J1=10.5, J2=8.7 Hz), 6.25 (t, 1H, CH), 7.36-7.49 (m, 5H, Ar-H), 7.59 (s, 1H, Ar-H). 
(R)-6-nitro-2-phenyl-2,3-dihydroimidazo[2,1-b]oxazole ((S) Phenyl Oxazole):  At ambient 
temperature and under a nitrogen atmosphere, TBAF (1M in THF, 1.35 ml, 1.35 mmol) was 
added to (S)-1-(2-(tert-butyldimethylsilyloxy)-2-phenylethyl)-2-chloro-4-nitro-1H-imidazole 
(CSD-302) (0.17 g, 0.45 mmol) in 20 ml anhydrous THF. The reaction mixture changed from 
colorless to yellowish brown.  After 1h, the reaction was stopped by the addition of water and 
was evaporated to dryness.  The mixture was purified by preparative TLC (EtOAc: Hex, 2:3) to 
give 26 mg (25 %) of the target compound.  Purification also yielded 39 mg (32.4 %) of the des-
TBDMS alcohol as an undesired side product. HRMS for C11H9N3O3 calculated 232.0728 and 
found to be 232.0722. 
1
H NMR (300 MHz, CDCl3) δ: 4.22 (dd, 1H, J1=10.5, J2=7.8 Hz), 4.68 
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